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In order to function properly, a cell needs to control the distribution, abundance, 
and activity of all its proteins. Not only is it important to increase protein expression upon 
an external stimulus but also removal and downregulation play a key role in cellular          
homeostasis. The disruption of peptide bonds in order to break down a protein is called                  
hydrolysis and is facilitated by enzymes termed proteases. As this reaction is usually        
conducted in an aqueous environment, it was surprising to discover a group of proteases 
that were able to perform this enzymatic reaction within the plane of the membrane. After 
their discovery, these intramembrane-cleaving proteases (IMPs) have attracted focus, as 
their processing mechanism seemed to be involved in many regulatory pathways.  
The IMPs are grouped according to their active site amino acid. Based on this,              
presenilins, signal peptide peptidase (SPP), and SPP-like proteases (SPPL) are classified as 
aspartyl-IMPs that share the same active site motif GxGD. In humans, the SPP/SPPL family 
comprises five members: SPP, SPPL2a, b, c, and SPPL3. In particular, SPPL2a has                    
demonstrated to be of physiological relevance, as it plays an important role in the immune 
response of the human body. In contrast to the family of SPPL proteases, presenilins 1 
and 2, which form the catalytically active subunit of γ-secretase, have already been well 
studied. Mutations in presenilins have gained attention as they contribute to the 
pathomechanism of Alzheimer's disease. Thus, presenilin mutations induce particularly                 
aggressive forms of the disease as they change the processing of their substrates. The                    
characteristic cleavage mechanism, the regulated intramembrane proteolysis (RIP), is 
common for many IMPs. RIP is a well-controlled process that can be separated into three 
steps: shedding of the ectodomain (ECD), recognition of the shortened substrate and        
subsequent processing. So far, little is known about common features of SPPL2 substrates 
that enable recognition and processing of the substrates in the context of RIP. Therefore, 
this study aims to provide insights into the individual steps of RIP to establish common 
requirements for recognition and processing by SPPL2a and SPPL2b. 
 The first part of the study focuses on the removal of the large substrate ECDs, 
which is referred to as shedding. Processing of a protein by IMPs often requires a               





more evidence has emerged that ECD shedding is not necessarily a mandatory prerequi-
site for all substrates to be recognized and processed by IMPs. This study reveals that 
SPPL2a is able to process tumour necrosis factor alpha (TNFα) without prior shedding and 
that this non-canonical shedding can be modulated by mutations in different domains of 
the protein. These mutations most likely affect the secondary structure of the protein, 
making it better or less assessable for cleavage by SPPL2a or SPPL2b. 
So far, no consensus sequence or recognition motif has been identified, which 
would allow predictions of SPPL2 substrates. Therefore, in the second part of the study, 
the recognition and initial cleavage of substrates in the context of RIP was investigated by 
taking advantage of the British dementia protein (Bri) 3, an established non-substrate of 
SPPL2. While Bri2 is a substrate, its close homologue Bri3 is not processed by SPPL2. 
Based on this, it was investigated whether sequence specificity or certain domains of           
substrates are responsible for recognition by SPPL2. By substituting domains of TNFα with 
the corresponding domains of Bri3, it was shown, that the intracellular domain (ICD) but 
even more the juxtamembrane domain (JMD) enable recognition and initial cleavage. 
Within these domains, charged residues are most likely to facilitate this mechanism.  
In the third part of the study, the mechanism of further substrate processing by 
the SPPL2 proteases was investigated in more detail. Sequential cleavage of the                 
substrate’s transmembrane domain (TMD) is characteristic for intramembrane cleavage 
by presenilins and SPPL2b and, as shown in this study, also SPPL2a, even though less 
prominent. In contrast to presenilins that cleave many of their substrates sequentially,              
consecutive cleavage by SPPL2a/b seemed to be rather unique to TNFα. While a post-        
translational modification of TNFα ICD with palmitic acid enabled consecutive cleavage, 
mutations in the TMD were able to accelerate or reduce this cleavage. Cleavage by SPPL2a 
and SPPL2b occurred at the same positions within TNFα and in contrast to presenilins 
were never changed upon mutations.  
In conclusion, this study provides a detailed investigation of the cleavage                     
mechanism of SPPL2a and SPPL2b and focuses on commonalities and differences of both 
proteases. Within this context, not only a new type of substrate processing by SPPL2a is 




Um ihre Funktionen aufrecht erhalten zu können, muss eine Zelle die Verteilung, 
Menge und Aktivität ihrer Proteine kontrollieren. Für die Aufrechterhaltung der Homöo-
stase ist es nicht nur wichtig, die Expression der Proteine anzupassen, wenn sich die        
Bedingungen ändern, sondern auch die bereits vorhandenen Proteine, wenn nötig wieder 
abzubauen. Der Abbau erfolgt durch die Spaltung der Peptidbindungen in Anwesenheit 
von Wasser durch spezialisierte Enzyme, den sogenannten Proteasen. Diese Hydrolyse 
findet meist in wässrigen Lösungen statt, daher überraschte die Entdeckung einer Gruppe 
von Proteasen, die diese Reaktion in der hydrophoben Umgebung einer Zellmembran 
durchführen können. Als Grundlage vieler regulatorischer Prozesse ist die Erforschung 
der Intramembranproteasen (IMPs) heute wichtiger denn je. 
Die Kategorisierung der IMPs erfolgt auf Grund der katalytischen Aminosäure im 
aktiven Zentrum des Enzyms. Preseniline, Signal Peptid Peptidasen (SPP) und SPP-        ähn-
liche (SPPL) Proteasen werden auf Grund des gemeinsamen GxGD Motivs als Aspartyl-
IMPs klassifiziert. Im Menschen besteht die Familie der SPP/SPPL Proteasen aus fünf                    
Mitgliedern: SPP, SPPL2a, b, c und SPPL3. Physiologische Bedeutung hat dabei besonders 
SPPL2a, da es eine wichtige Rolle bei der Immunantwort des menschlichen Körpers spielt. 
Bereits gut erforscht sind, im Gegensatz zu der Familie der SPPL Proteasen, die Preseniline 
1 und 2, die die katalytisch aktive Untereinheit der γ-Sekretase bilden. Kommt es zu                        
Mutationen in Presenilinen, tragen diese zum Pathomechanismus der Alzheimer Krank-
heit bei und führen dann zu besonders aggressiven Formen dieser Erkrankung. Diese   
Mutationen verändern dabei die Prozessivität der Enzyme, die normalerweise nach dem 
Prinzip der regulierten Intramembranproteolyse (RIP) agieren. Bei diesem charakteristi-
schen Mechanismus lassen sich drei Schritte für die meisten IMPs erkennen. Zunächst 
erfolgt die Abspaltung der Ektodomäne (ECD) des Substrates, danach die Erkennung des 
nun gekürzten Proteins und als letzter Schritt erfolgt die eigentliche Prozessierung in der 
Membran durch die IMPs.  
Der erste Teil der Arbeit widmet sich dem Prozess der Abspaltung der ECD, dem 
sogenannten Shedding. In der Regel wird ein Substrat durch eineunabhängige Protease 
gesheddet. Dieser Vorgang, zum Beispiel durch die Metalloproteasen der ADAM Familie 





durch SPPL2. Diese Arbeit zeigt jedoch, dass SPPL2a den Tumor Nekrose Faktor alpha 
(TNFα) ohne vorangeganges Shedding direkt schneiden kann. Dieses nicht-kanonische 
Shedding wird durch Mutationen in unterschiedlichen Domänen TNFα entweder verstärkt 
oder abgeschwächt, da sie vermutlich die Sekundärstruktur in einer Art und Weise beein-
flussten, die die Schnittstellen mehr oder weniger zugänglich für SPPL2a machen.  
Nach dem heutigen Erkenntnisstand konnte bis jetzt kein spezifisches Spaltungs- 
oder Erkennungsmotiv identifiziert werden, dass eine Vorhersage von SPPL2-Substraten 
ermöglicht. Um diese Lücke zu schließen, wurde im zweiten Teil der Studie mit Hilfe des 
bereits etablierten Nicht-Substrates, Britisches Demenz Protein 3 (Bri3), untersucht, wie 
ein Protein von SPPL2 als Substrat erkannt wird. Während Bri2 ein Substrat für SPPL2 ist, 
wird das homologe Bri3 dagegen weder erkannt noch geschnitten. Daher wurde der Frage 
nachgegangen, ob sequenzspezifische Eigenschaften oder ganze Domänen für die Erken-
nung eines Proteins durch SPPL2 verantwortlich sind. Dazu wurden einzelne Domänen/ 
Sequenzen aus TNFα durch entsprechende Bereiche aus Bri3 ersetzt. Das Ergebnis dieses 
Verfahrens zeigt, dass die intrazelluläre Domäne (ICD) und mehr noch die Juxtamembran-
domäne (JMD) die Erkennung des Substrates beeinflussen. Innerhalb dieser Domänen 
sind vermutlich geladene Aminosäuren für eine korrekte und effiziente Spaltung des             
Substrates verantwortlich.  
Im Fokus des dritten Abschnitts dieser Arbeit steht der Prozessierungs-                     
mechanismus der SPPL2 Proteasen. Charakteristisch für SPPL2b und Preseniline ist die 
sequentielle Spaltung der Transmembrandomäne (TMD) des Substrats. Diese                       
sequenzielle Spaltung konnte, wenn auch weniger ausgeprägt, ebenfalls für SPPL2a          
beobachtet werden. Im Gegensatz zu Presenilinen, die all ihre Substrate sequenziell 
schneiden, scheint die konsekutive Spaltung durch SPPL2 substratspezifisch zu sein und 
wurde bisher nur für TNFα beobachtet. Während die posttranslationale Modifizierung des 
TNFα ICDs mit Palmitinsäure eine Voraussetzung für die konsekutive Spaltung von TNFα 
zu sein scheint, konnten Mutationen in der TMD diese beschleunigen oder reduzieren. 
Die Spaltung von TNFα durch SPPL2a oder SPPL2b erfolgt an den gleichen Positionen        






Die Ergebnisse dieser Untersuchung geben einen detaillierteren Einblick in den 
Schnittmechanismus von SPPL2a und SPPL2b und heben Gemeinsamkeiten und Unter-
schiede hervor. In diesem Zusammenhang wurde nicht nur eine neue Art der Substrat-
prozessierung durch SPPL2a beschrieben, sondern auch das Verständnis der                     












To orchestrate perfect collaboration of body cells, communication is key. The trans-
mission of signals between cells is mediated via direct cell-cell contacts when cells are 
close to each other. Yet in case of larger distances, information is transmitted via soluble 
signals. Hence, signalling proteins need to be localised to the cell surface for direct contact 
or the release of soluble signalling peptides from the surface protein. Not only the correct 
localisation but also the correct quantity off proteins is necessary for adequate signal 
transmission to recipient cells. Upon binding of the soluble or membrane-bound peptide 
to a receptor, the signal is conveyed into the recipient cell, activating or down- regulating 
signalling pathways to maintain the perfect homeostasis of the recipient cell. If the home-
ostasis collapses and communication fails, diseases develop, and if permanent, the                   
condition becomes chronic. In many cases, this situation is difficult to restore without 
compromising the body’s integrity. To ensure correct signalling, expression and degra-
dation are tightly regulated, balancing the abundance of cell surface proteins. Throughout 
all kingdoms of life, and in every cell removal and degradation of membrane proteins is 
an essential process. The cleavage of peptide bonds within the membrane, termed             
intramembrane proteolysis, in order to remove residual membrane proteins, was long 
thought to be highly unlikely. However, a specialised group of enzymes has developed to 





1.1. PROTEASES AND PROTEOLYSIS 
Proteolysis describes an irreversible procedure where peptide bonds are dissolved 
in the presence of water. This cleavage is facilitated by proteases that account around 
60% of all enzymes. According to the international protease network, 2% of the genome 
encode for almost 500 proteases in a human body (http://www.protease.net.au). They 
regulate fate, localisation, and activity of many proteins, by modulating protein–protein 





molecular signals. All physiological processes from cell growth to differentiation, in- and 
outside signalling to apoptosis involve proteases. Thus, proteases are indispensable in all 
living organisms and misregulation accounts for multiple diseases (Bond, 2019). As a         
result in 2016, an estimated 5-10% of all pharmaceutical targets pursued for drug                  
development were proteases (Drag and Salvesen, 2010). Thus, the role of proteases and 
their mechanism in substrate selection and processing needs thorough investigation to 
ensure efficient drug development and successful treatment of the diseases.  
 Generally, proteases bind and cleave proteins in aqueous solutions such as the 
cytoplasm or the extracellular space. Even though hydrolysis of a peptide bond is an        
energetically favourable reaction, the resolution of a stable biological polymer is                 
extremely slow (Langosch et al., 2015). Peptide bonds withstand high temperatures and 
acid concentrations within their environment. However, they are broken up easily in the 
presence of a specific protease. Proteolytic cleavage of surface proteins is an irreversible 
but important posttranslational modification (PTM), which usually results in the release of 
a soluble peptide and a membrane-retained fragment. This procedure is referred to as 
ectodomain (ECD) shedding and enables either release of a signalling competent peptide 
or activates the membrane-residing protein (Lichtenthaler et al., 2018). The intracellular 
fragment resulting from this cleavage can have signalling capacities as well or is degraded 
by independent proteases.  
Classification of proteases is dependent on the chemical group that is responsible 
for catalytic activity in the active centre. If this amino acid is exchanged, the proteases lose 
their catalytic activity (Urban, 2013). According to this classification, six groups of               
proteases can be distinguished: cysteine, serine, threonine, glutamyl-, aspartyl- and       
metalloproteases. Cysteine proteases such as the caspases are involved in almost every 
aspect of life from plants to humans and thus are targeted in a wide range of human 
disorders (Gurumallesh et al., 2019). Their active site contains a cysteine and histidine that 
need reducing agents to develop proper functioning. Serine proteases make up one third 
of all known proteases (Di Cera, 2009, Kraut, 1977). Trypsin is a serine protease that is 
used frequently on cell cultures to release attached cells from the petri dish. It cleaves              
specifically after a lysine or arginine residue. Threonine proteases are largely responsible 
for intracellular protein turnover as one of the most prominent members is the                 





removes proteins, which are tagged for degradation with a series of ubiquitin molecules 
(Budenholzer et al., 2017). Glutamyl- and aspartylproteases are characterised by two      
glutamic/ aspartic acids at the catalytic site and are therefore acidic proteases working 
most efficiently at a low pH (Gurumallesh et al., 2019). Pepsin in the gastric fluid, as well 
as the β-site APP cleaving enzyme 1 (BACE1), which cleaves the amyloid precursor protein 
(APP), are both aspartylproteases. 
Metalloproteases require a divalent metal ion to exhibit proteolytic activity. About 
30 families are so far identified one of which is a disintegrin and metalloprotease (ADAM) 
family. Besides ADAMs, matrix metalloproteases (MMPs) regulate branching morpho- 
genesis, angiogenesis, wound healing, and extracellular matrix degradation (Edwards et 
al., 2008).  
 
 
1.1.1. MEMBRANE-BOUND PROTEASES – THE ADAM FAMILY 
The ADAM family contains 21 members of which 13 display catalytic activity 
(Edwards et al., 2008). Some of them are expressed in somatic tissues while most others 
have a more restricted tissue range (Cho, 2012). As this family is so large, it is not                
surprising, that they are involved in almost every biological process from sperm-egg           
interaction, cell fate determination, cell migration, muscle development to the activation 
of several immunological pathways. Their engagement in diseases such as autoimmune           
diseases, infection, inflammation, cardiovascular    
diseases, cancer and neurodegeneration is crucial. 
Protective roles in the pathogenesis of Alzheimer’s 
disease, but also amplification of malignant tumour 
growth have been reported (Duffy et al., 2009). Thus, 
their broad expression and participation in many    
signalling pathways make it almost impossible to    
develop suitable inhibitors or modulators for             
experimental or clinical use. 
Figure 1.1 Structural elements of ADAM17. 
ADAM is a type I transmembrane (TM) protein 
with a C-shaped ECD. The ECD contains the       
active site of the protease domain and further-
more a disintegrin-like domain, a membrane-





ADAMs are type 1 transmembrane (TM) proteins with a signal sequence at their N-
terminus, which directs them to the secretory pathway (Zunke and Rose-John, 2017). The 
pro-domain acts as an intramolecular chaperone to ensure correct protein folding via          
cysteine-rich sequences and is cleaved off during the transit through the Golgi network. 
The C-shaped ECD of a functional ADAM consists of three domains: the metalloproteinase        
domain, the disintegrin-like domain and the cysteine-rich domain. A membrane-proximal  
domain (MPD) is characteristic only for ADAM10 and ADAM17 (Figure 1.1). The cytoplas-
mic domain of ADAM17 interacts with proteins involved in intracellular signalling and    
trafficking, such as iRhom and FRMD8 (Figure 1.2). iRhoms are inactive rhomboid             
proteases (see below Section 1.1.2.2) that bind to the cytoplasmic tail of immature 
ADAM17 to guide it to the cell surface, where they are sorted to lipid-rafts. The FERM       
domain-containing protein (FRMD8) stabilises the complex at the cell surface. Both iRhom 
and FRMD8 not only prevent the lysosomal degradation of this complex but also                 
contribute to the activation and substrate-specificity by phosphorylation of iRhom (Kunzel 
et al., 2018).  
Regulation of the protease activity differs between members of the ADAM family. 
Some are constitutively active such as ADAM10, whereas some need additional activation. 
Physiological activity of ADAM17 is regulated via phosphorylation. Phorbol esters such as 
PMA activate phosphokinase C (PKC) that phosphorylates ADAM17 (Figure 1.2). Inhibition 
of ADAMs is endogenously facilitated by tissue-specific inhibitors of metalloproteinases 
(TIMPs) that bind non-covalently to the cytoplasmic tail. In mammals, four different TIMPs 
Figure 1.2 Maturation and 
transport of ADAM17. In 
the ER iRhom, FRMD8 and 
proADAM17 form a complex. 
iRhom ensures stability and 
correct trafficking of the 
complex from the Golgi net-
work to the cell surface. 
Within the Golgi, the Furin-
mediated cleavage of a signal 
peptide allows the matura-
tion of ADAM17. On the cell 
surface, iRhom and ADAM17 
are activated via phosphory-
lation by phorbol-12-
myristat-13-actetat (PMA), 
Toll-like receptors (TLR), G-
protein-coupled receptors 
(GPCR) or the PDK1 kinase. 
The activated complex is able 





inhibit ADAM functions, whereas the preferences of binding and inhibitor capacity vary 
between family members and tissues (Nagase et al., 2006). 
ADAMs are an essential upstream regulator for many important signalling path-
ways in vertebrates. By cleaving their substrates, they partake in the activation of growth 
factors, chemokines, and other important soluble mediators that influence signalling by 
binding to the corresponding receptor on a recipient cell. To date, more than 90 different 
substrates have been described for ADAM17 (Dusterhoft et al., 2019), which makes it the 
most prominent member of the family. Even though many ADAMs seem to have a specific 
set of substrates, they can act promiscuously, which means if one ADAM is inhibited           
another member of the family can resume the cleavage. In humans, ADAM17 (also TNFα 
converting enzyme, TACE) is essential for releasing soluble TNFα (sTNFα) from the                   
membrane-resident TNFα (TNFα FL). sTNFα controls immune and inflammatory                     
responses via activation of its corresponding receptor (Tseng et al., 2018) (see below           
Section 1.3.1). Further prominent substrates of ADAM17 but also ADAM10 include ligands 
of the epidermal growth factor receptor (EGFR) as well as the Notch receptor and APP 
(Pruessmeyer and Ludwig, 2009). Shedding of these substrates releases a signalling               
competent peptide into the extracellular space/ lumen and primes many proteins for their 
subsequent processing by intramembrane-cleaving proteases (IMPs). 
 
 
1.1.2. INTRAMEMBRANE-CLEAVAING PROTEASES 
Soluble and membrane-associated proteases such as ADAMs cleave their              
substrates in the aqueous solution in- or outside of the cell making water easily assessable 
for the proteolysis. However, the cleavage becomes much more challenging in the context 
of a hydrophobic membrane. Nevertheless, such as conventional proteases, IMPs are 
grouped by their catalytic residues. At present four families that promote intramembrane 
proteolysis are known: metallo-, serine, glytamyl- and aspartyl-IMPs (Beard et al., 2019, 
Kuhnle et al., 2019). A cysteine IMP has not been described so far.  
The different groups of IMPs are located throughout the cell (Figure 1.3). Many are 





the cell surface and the lysosomal/ endosomal compartment, IMPs partake important 
roles in signalling and protein degradation.  
 
Figure 1.3 Localisation of intramembrane proteases (IMPs) in the cell. Several IMPs are expressed in the ER and Golgi          
network, as these are central compartments in protein maturation and modification. In compartments such as mito-                 
chondria, lysosomes and endosomes more specific IMPs are expressed. It is up to speculate whether SPPL2a and RHBDL3 
have a broader substrate spectrum, as their function might be general degradation in the lysosomal compartments. 
Whereas most of the IMPs are stationary, iRhom appears throughout the entire secretory pathway. It does not display 
catalytic activity but rather guides other proteins (such as ADAM17) to the correct subcellular location.  
 
1.1.2.1. METALLOINTRAMEMBRANE PROTEASES 
The first IMP to be identified was site-2 protease (S2P). It induces a negative feed-
back loop in the sterol regulatory element-binding protein (SREBP) pathway (Chen and 
Zhang, 2010). Changes in the cellular demand for cholesterol are signalled via alterations 
of the lipid composition in the endoplasmic reticulum (ER) membrane. In response to that, 
SREBPs are shuttled to the Golgi apparatus. Here, the serine protease site-1 protease 
(S1P) cleaves SREBP within the luminal loop spanning the two TM helices. This cleavage 
also considered a shedding event, leaves behind two single membrane-spanning frag-
ments of which the N-terminal one is cleaved by S2P at a Leu-Cys bond within the             
membrane (Duncan et al., 1998). The fragment that is released to the cytosol travels to 





(Rawson, 2013). In the absence of exogenous lipid, 
cells lacking S2P cannot survive. Besides SREBPs, S2P 
also cleaves several stress response transcription       
factors (Sun et al., 2016).  
The crystal structure of an archaeal S2P               
indicates six TM segments (Figure 1.4). Just as soluble 
metalloproteases, S2P requires a zinc ion for its            
proteolytic activity, which is coordinated by a HExxH        
motif in transmembrane domain (TMD) 2. A 
GxxxN/G/S motif in TMD 4 is speculated to be involved 
in substrate binding (Feng et al., 2007).  
 
1.1.2.2. SERINE INTRAMEMBRANE PROTEASES 
The serine IMPs are represented by the rhomboid proteases, which were originally 
identified in Drosophila. This group of proteases is highly conserved throughout species 
and plays an important role in epidermal growth factor receptor (EGFR) signalling. The 
release of growth factor ligands into the extracellular space is crucial to initiate EGFR        
signalling (Kandel and Neal, 2020).  
The five mammalian rhomboids (RHBDL1-4, PARL) are expressed in different           
locations throughout the cell indicating a specific function and set of substrates within 
each localisation (Figure 1.3). PARL is the only IMP that localises to the mitochondrial 
membrane where it cleaves important substrates related to the mitochondrial homeo-
stasis. Decreased abundancy of PARL is associated with reduced mitochondrial mass and 
activity and hence, PARL polymorphisms identified in humans are linked to mitochondrial 
dysfunctions in diabetes type 2 (Hatunic et al., 2009). Furthermore, dysregulation of          
mitophagy by altered cleavage of the substrate PINK1 by PARL has been implicated in 
Parkinson’s disease (Shi et al., 2011). However, the exact role of PARL in mitochondrial and 
cellular death has yet to be unravelled.  
Rhomboid proteases recognise their substrates based on a combination of        
structural features and recognition motifs (Lysyk et al., 2020). They require a certain         
degree of flexibility within the TM helix to cleave their substrates. Unique to this group of 
Figure 1.4 Model of the metallointramem-
brane protease, S2P. S2P displays six TMDs, 
so both N- and C-terminus are facing the cyto-
sol. The active centre is formed by a HExxH 
motif in TMD 2 together with a DG motif in 
TMD 4. The histidine and aspartic acid hold a 





IMPs is that they do not require any preceding processing step such as substrate           
shedding. Nevertheless, the exact cleavage mechanism is currently under debate. One of 
the two models suggests structural rearrangements within the protease to facilitate         
binding and cleavage at the same position within the enzyme. The other model suggests 
less structural changes and an initial binding step at an exosite with subsequent transport 
to the active site for cleavage (Lysyk et al., 2020). However, as some of the rhomboid              
proteases remain orphan, the identification of new substrates is required to give better 
insights into the cleavage mechanism.  
The family of rhomboid proteases comprises additional members that do not        
display catalytic activities. These rhomboid pseudoproteases include amongst others      
derlin1 and inactive rhomboids iRhom1 and iRhom2 (Figure 1.5). Even though they share 
the catalytic dyad GxSG with the catalytically active members of the family, they have        
acquired a proline in the x-position, which is believed to abolish enzymatic activity (Zettl 
et al., 2011). Interestingly, while catalytically active IMPs can be inactivated by mutation of 
the amino acids in their active centre, it is not known whether a pseudoprotease can be 
turned into an active protease by removal of the proline. Nevertheless, even without      
catalytic activity, they fulfil crucial tasks within the cell, as they are able to bind proteins in 
the secretory pathway and control their fate by regulating the trafficking or inducing       
degradation. As essential co-factors, they were found to be regulators of EGFR and TNFα 
signalling (Lemberg and Adrain, 2016).  
 
Figure 1.5 Structural overview of serine intramembrane proteases (IMPs). The rhomboids display a topology with six 
to seven TMDs. Structural elements have been reported that dip into the membrane without really spanning it completely. 
Not all rhomboids are catalytically active. iRhoms and derlin1 do not display cleavage activity. Nevertheless, they have          
important functions as adaptor molecules to enable correct trafficking or cleavage by other proteases. 
 
Rhomboid proteases display relatively low sequence similarity and differ within 





the bacterial rhomboid protease GlpG revealed a conserved catalytic His-Ser dyad             
between the TMD 4 and TMD 6 required for substrate cleavage (Figure 1.5). Initially,         
rhomboids were thought to cleave exclusively type I TM proteins; however, several              
exceptions from that rule have been described recently (Bergbold and Lemberg, 2013). 
This strengthens the hypothesis that rhomboids are in fact recognising sequence           
specificities paired with certain conformational requirements.  
 
1.1.2.3. GLUTAMYL-INTRAMEMBRANE PROTEASES 
In 2013, the crystal structure of Ras converting enzyme (Rce1) revealed that the 
enzyme previously classified as metallo-IMP comprises a glutamate embedded in a Glu-
His-His-Asn motif in its catalytic centre. Therefore, it was re-classified as glutamyl-IMP thus 
establishing a new group of IMPs (Manolaridis et al., 2013). Rce1 is expressed in the ER 
and inner nuclear membrane of cells in multiple tissues (Kuhnle et al., 2019) and the              
structure of an archaeal homologue revealed eight TM segments, even though other         
topologies have been suggested (Figure 1.6) (Hampton et al., 2018). Although Rce1 shares 
structural features with the other IMPs, it differs fundamentally in its mechanism. Unlike 
the other IMPs, Rce1 does not cleave the substrate within its TMD but rather cleaves the 
Caax motif (C: cysteine; a: aliphatic amino acid; x: random amino acid) at the C-terminal 
end of the substrate (Manolaridis et al., 2013). GTPases, nuclear laminins, protein kinases 
and phosphatases comprise a Caax motif and are involved in diverse biological functions 
such as development, ageing, and parasitic growth. Their implication in cancer has pushed 
the understanding of the modifications by Rce1 into the focus of current research 
(Hampton et al., 2018). 
Figure 1.6 Structural overview of mamma-
lian and yeast glutamylintramembrane 
protease Rce1. An eight TMD containing to-
pology is proposed for this group of IMPs in 
mammals. However, in yeast and bacteria the 
topology is not yet clear. Several TMDs and 








1.1.2.4. ASPARTYL-INTRAMEMBRANE PROTEASES 
The fourth group of IMPs, the aspartyl-IMPs, contains signal peptide peptidase 
(SPP) and four related SPP-like proteases (SPPLs), as well as two presenilins. Remarkably, 
despite low sequence homology between presenilins and SPP(L)s, they all share a              
signature YD and GxGD catalytic motif and a C-terminal PAL motif, which are unique to 
this protease family. Mutations of either of the aspartates result in catalytically inactive 
forms of the proteases (Krawitz et al., 2005). Even though the aspartyl-IMPs share the 
conserved signature motifs and some topological features, detailed analysis revealed     
differences in substrate selection, processing and turnover rate.  
 
1.1.2.4.1. PRESENILINS AND γ-SECRETASE 
Presenilins manifested their importance in the 1990s when mutations in their 
genes were linked to early-onset, familiar forms of Alzheimer’s disease (Holcomb et al., 
1998). They act as the proteolytic subunit of a multiprotein complex, the γ-secretase, and      
undergo endoproteolysis for activation. The γ–secretase complex embraces a catalytic 
centre with one of the homologous presenilins (PS1 or PS2) and co-factors nicastrin,       
presenilin enhancer (PEN) 1 or 2, and anterior pharynx defective 1 (APH1) (Figure 1.7). All 
parts of the complex are required to generate a functional γ-secretase complex (Kaether 
et al., 2006). 
 
Figure 1.7 γ-secretase is a complex consisting of four proteins. The catalytically active subunit of this complex comprises 
presenilins (PS). They are aspartyl-IMPs containing the characteristic GxGD and YD motif. The N-terminus is facing the         
cytosol and the large loop between TM 6 and 7 is auto-catalytically cleaved. Besides PS, nicastrin, presenilin enhancer (PEN) 
1 and 2, and pharynx defective 1 (APH1) are part of this complex. Nicastrin has a large ECD with several glycosylation sites. 
It is debated whether it functions as gatekeeper or is responsible for substrate selection and binding. The function of all 






PS1 and PS2 harbour the active site aspartyl-residues and the PAL motif, which 
contributes to the active site conformation of the γ‐secretase complex (Wang et al., 2006). 
Both presenilins are able to mediate substrate cleavage, suggesting a functional redun-
dancy (Wolfe and Haass, 2001). Nicastrin is discussed as a substrate receptor or gate-
keeper and PEN1/2 as stabilizing factor keeping the auto-proteolytically generated prese-
nilin fragments in close contact. No function besides stabilisation of the complex has so 
far been assigned to APH1 (Pardossi-Piquard et al., 2009).  
The cleavage process of one of the most prominent γ-secretase substrates, APP, 
differs throughout the human body. In the periphery, it undergoes non-amyloidogenic 
processing by an α-secretase (ADAM10/17), which results in a membrane-bound                      
C-terminal fragment (CTF) that is 83 amino acids (C83) in length (Figure 1.8). C83 is                  
subsequently recognised and cleaved by γ-secretase, generating an APP intracellular               
domain (AICD) and extracellularly released peptides (p3). The p3 peptides do not form 
aggregates; therefore, they are considered non-neurotoxic (Kojro and Fahrenholz, 2005).  
 
Figure 1.8 Processing of the amyloid precursor protein (APP). APP can be processed by two different sheddases, BACE1 
or α-secretase, generating two different membrane-bound fragments, C99 or C83. Both of them are recognised and pro-
cessed by γ-secretase. However, the cleavage of C99 generates Aβ fragments that are released and prone to aggregation. 
These aggregates are neurotoxic and suspected to be a major cause of Alzheimer’s disease. The cleavage of C83 by γ-





However, on the cell surface of neurons in the brain, APP is mostly cleaved by the 
membrane-bound aspartyl-protease BACE1, generating a peptide of 99 amino acids (C99). 
The membrane-resident C99 is consecutively cleaved by γ-secretase, which releases an 
AICD that can potentially translocate to the nucleus to induce gene expression (Matsuda 
and Senda, 2019). The fragments that are released into the extracellular space, the so-
called Aβ peptides vary in length and are prone to aggregation (Orlando et al., 2020).               
Currently, more than 350 mutations in PS1/2 are identified as the cause of aberrant Aβ             
production (http://www.alzforum.org/mutations). The mutations affect precision and 
cleavage efficiency of γ-secretase. Along with current knowledge, the Aβ aggregates are 
the major cause of Alzheimer’s disease; however, it is debated whether the phosphoryla-
tion of tau protein, AICD signalling and abnormal axonal transport add up onto the           
disease progression or if they contribute to the onset of the disease in a similar manner 
as Aβ (Hardy, 2003).  
 
1.1.2.4.2. SPP(L) FAMILY 
SPP/SPPLs are highly conserved members of the aspartyl-IMP family and have 
been described in eukaryotes, fungi and protozoa (Voss et al., 2013). A data bank search 
identified five members of the SPP/SPPL family in humans, SPP, SPPL2a,b,c and SPPL3 
(Fluhrer et al., 2009). The SPP members are differentially distributed within the secretory 
pathway (Figure 1.3), a fact that may reflect their preference for substrates located within 
the respective compartments. Until now, many degradative functions have been                 
described for SPPLs. However, latest research shows the participation of the proteases in          
signalling pathways in- and outside of the cell (Mentrup et al., 2020, Papadopoulou et al., 
2019, Voss et al., 2013). 
In contrast to presenilins, catalytic SPP/SPPL activity does not require endo-         
proteolytic activation or additional components. Nevertheless, they share the topology of 
nine TM segments, with the most striking difference in the opposite orientation of the 
catalytic domains within the plane of the membrane (Figure 1.9). While the N-termini of 
presenilins face the cytosol, SPP/SPPL N-termini face the extracellular space. Because    





it is speculated that the opposite orientation of SPP/SPPLs is the reason for cleaving                   
exclusively type II oriented TM proteins (Friedmann et al., 2004). 
 
 
Figure 1.9 Topology of all mammalian members of the SPP/ SPPL family. All members share the nine TMD topology 
and the characteristic motifs, GxGD, YD and QPALLY. The family members differ especially in the length of the N- and C-
termini and glycosylation status. In contrast to presenilins, the N-termini are facing the extracellular space. SPPL2a, b and 
c contain a signal sequence at the N-terminus.  
 
Although SPP/SPPL proteases lack obvious sequence homologies, they all share 
the characteristic active site G(L/I/F)GD motif within TMD 7 and the (Y/F)D motif located in 
TMD 6 (Figure 1.9) (Martin et al., 2009). Besides the active site motifs, SPP/SPPL family 
members share a conserved QPALLY motif in TMD 9, which is likely to interact with the 
catalytic centre of GxGD-type proteases (Fluhrer et al., 2008). A direct contribution of this 
motif to the formation of the catalytic centre is supported by the finding that a transition 
state analogue inhibitor fails to bind to SPP and PS upon mutagenesis of the PAL sequence 
(Wang et al., 2006). It is currently unknown how the QPALLY motif affects SPPL activity; 
however, close proximity of all three conserved domains in the native enzyme forming 
the catalytic centre is assumed for aspartyl-IMPs (Torres-Arancivia et al., 2010). The lack 
of specific antibodies, inhibitors or in vitro assays for SPP/SPPL proteases makes these 
proteases difficult to study. A commonly used active site inhibitor for SPPL2 is (Z-LL)2-      
ketone (2,2′-(2-Oxo-1,3-propanediyl)bis[N-[(phenylmethoxy) carbonyl]-L-leucyl-L-leucine-





(Weihofen et al., 2002, Voss et al., 2014). To complicate the research on SPPLs further, it 
seems that some of the family members have such fundamental functions that growth 
and development of cells or mice are strongly affected upon depletion of the protease 
(Papadopoulou, unpublished data).  
 
1.1.2.4.2.1. SPP 
SPP was the first member of the family to be discovered (Lemberg and Martoglio, 
2004). Even though SPP does not need any co-factors for proteolytic function, it has been 
shown that it mostly functions as a homodimer (Voss et al., 2013) and recruits other           
proteins such as derlin1 (see above Section 1.1.2.2) or the EC3 ubiquitin ligase TCR8 (Chen 
et al., 2014b). These proteins allow recognition and cleavage of additional proteins that 
otherwise are not part of the SPP substrate collection (Chen et al., 2014b).  
A specific signalling sequence, the signal peptide, is guiding proteins destined for 
the ER to their correct location where this sequence is cleaved off upon arrival. Thereafter, 
the remaining signal peptides that comprise a type II orientation can undergo intra-    
membrane proteolysis by SPP, which is maintained in the ER by a retention motif (KKxx) 
at its C-terminus. Requirements for intramembrane cleavage by SPP are helix-destabilis-
ing residues within the substrate’s TMD. Positively charged residues in juxtamembrane         
domain (JMD) have an inhibitory effect on the cleavage efficiency (Lemberg and Martoglio, 
2002). The cleavage of signal peptides by SPP results in their liberation from the ER      
membrane (Mentrup et al., 2017). SPP processes a broad variety of these signal peptides 
such as prolactin, major histocompatibility complex (MHC) class I molecules human         
lymphocyte antigen (HLA)-E and calreticulin (Lemberg and Martoglio, 2002). Release of the 
epitope-containing signal peptides from the ER membrane toward the cytosol plays a   
central role in the activation of a cellular immune response. This cleavage is essential for 
the generation of HLA-E epitopes that upon surface presentation protect cells against              
natural killer (NK) cell-mediated elimination (Bland et al., 2003). In addition to eukaryotic              
substrates, SPP plays a central role in the processing of viral peptides such as human    
immunodeficiency virus (HIV) gp130 and hepatitis virus C core protein (Mentrup et al., 
2017). As SPP has such a central role in cell homeostasis, an implication in breast, lung 





expression correlates with progression and malignancy of tumours (Hsu et al., 2019). 
However, it has not been investigated whether this is cause or causality of the cancer. 
 
1.1.2.4.2.2. SPPL2A/B 
The members of SPPL2 subfamily all share a large, glycosylated N-terminus (Figure 
1.9). Regarding their sequence, SPPL2a and SPPL2b are 50% identical and 70% homo-        
logous (Golde et al., 2009). Even though closely related, SPPL2a and SPPL2b show            
substantial differences considering their localisation. SPPL2a is expressed in all tissues 
with the lowest abundancy in brain while SPPL2b is more restricted in its expression and 
mostly found in the brain and with lower abundancy in the lymphatic system (Mentrup et 
al., 2020). On a subcellular level, SPPL2b is located at the cell surface, while SPPL2a resides 
in lysosomes/ late endosomes due to a C-terminal tyrosine-based sorting signal (Behnke 
et al., 2011). Even though differences in subcellular localisation restrict the number of    
potential substrates within the organism, it has been shown that the set of substrates 
overlaps partially in vitro (Martin et al., 2009). TNFα, British dementia protein 2 (Bri2), 
CD74, Clec7a, Clec8a, type III neuregulin 1 and foamy virus envelope protein (FVenv) are 
cleaved by both proteases. FasL and TMEM106b are exclusively cleaved by SPPL2a and 
the transferrin receptor 1 (TFR1) only by SPPL2b (Voss et al., 2013, Brady et al., 2014, Fleck 
et al., 2016, Mentrup et al., 2019). For most of the substrates, the fate and function of the 
cleavage products is a central unresolved question. First evidence suggests that the     
cleavage mechanism differs depending on the substrate. Whether this is a characteristic 
controlled by the protease or the substrate is not known. 
The physiological relevance of SPPL2a becomes apparent in patients with a single 
nucleotide polymorphism (SNP) in the SPPL2a gene. In psoriasis patients, an SPPL2a SNP 
increases epidermal SPPL2a expression (Liu et al., 2008). It is speculated that this increase 
leads to an enhanced local release of TNFα ICD that induces IL-12 expression (Arican et 
al., 2005, Friedmann et al., 2006). Besides other interleukins, levels of TNFα and IL-12            
correlate with disease severity.  
Contrary to an increased expression, SPPL2a-deficiency in humans has been linked 
to augmented susceptibility to mycobacterial infections (Kong et al., 2018). This             
mechanism is mostly conveyed via misregulated CD74 cleavage as CD74 NTF accumulates 





Interestingly, the accumulation mostly induces depletion of DCs, which results in a          
subsequent reduction of chemokine release. The lack of chemokines leads to an impaired          
activation of immune cells that are needed to orchestrate the depletion of mycobacteria. 
Therefore, patients suffer from infections of low-virulent mycobacteria. The loss of SPPL2a 
function also decreased TNFα expression in CD4 T cells; however, overall levels of sTNFα 
were normal.  
Furthermore, SPPL2a has been described as a potential risk factor in Alzheimer’s     
disease (Bis et al., 2018, Novikova et al., 2019).  The correlations and causal effects of 
SPPL2a expression in Alzheimer’s disease have not yet been identified. A possible            
connection of SPPL2a as a potential risk factor for Alzheimer’s disease and immune           
deficiencies lies within its location on chromosome 15q21.2. Patients with a disruption of 
this gene locus display amongst the accumulation of CD74 (Schneppenheim et al., 2014) 
idiopathic neurological condition with severe disabilities (Moreno-De-Luca et al., 2011).  
A physiological function of SPPL2b has yet to be identified.  
 
1.1.2.4.2.3. SPPL2C 
Just until as recent as 2019, SPPL2c was marked a pseudoprotease. However,       
proteomic screens identified several soluble N-ethylmaleimide-sensitive factor                     
attachment (SNARE) proteins as substrates for SPPL2c. The vesicle fusion proteins           
syntaxin 5, 8 and 18 are cleaved by SPPL2c, therefore cellular transport is impaired in the 
presence of active SPPL2c (Papadopoulou et al., 2019). The monoglycosylated SPPL2c      
resides in the ER of elongated spermatids and exists in a long and C-terminally truncated 
version. When isolated it exceeds its calculated size suggesting that it is also part of a 
larger complex (Mentrup et al., 2020). So far, the composition of this complex remains 
unknown. 
Increased expression of SPPL2c in cells leads to the accumulation of proteins in the 
ER and disassembly of the Golgi apparatus (Papadopoulou et al., 2019). Due to this strong      
impact on cellular homeostasis, the expression of SPPL2c is limited to differentiating male 
germ cells that are destined to undergo major intracellular rearrangements during       
spermatogenesis. In the absence of SPPL2c, mature spermatozoa differ in morphology 
and motility. However, this controls fertility only to a minor extent and only when            





2019, Papadopoulou et al., 2019). This surprising effect hints towards an additional effect 
of SPPL2c in female mice, even though no expression was found in the reproductive       
system so far. 
Despite SPPL2c and SPP sharing the same intracellular localisation, they only         
overlap partially in substrate selection, indicating unique biological functions for each             
protease. The recognition of substrates appears to be highly protease-specific even 
though SPP, SPPL2a, b and c seem to prefer substrates with short ECDs.  
 
1.1.2.4.2.4. SPPL3 
SPPL3 is the smallest member of the SPPL family, as its N-terminus is short and not 
glycosylated. Presence of murine SPPL3 has been demonstrated in NK and T cells in brain, 
lung, spleen and embryonic fibroblasts (Voss et al., 2013). A constitutive deficiency in      
cultured cell lines and mice strongly increases lethality, impeding the research on this 
protease but demonstrating its importance within the organism. Nevertheless, the           
important role of SPPL3 expression in NK cells is emphasised by the observation that 
SPPL3-deficient mice lack mature, therefore functioning NK cells (Hamblet et al., 2016). 
Whether this maturation defect is directly correlating with cleavage of a specific SPPL3 
substrate or whether it is a secondary effect is not yet clear.  
On a subcellular level, SPPL3 resides in the Golgi apparatus where numerous         
glycosyltransferases and glycosidases add glycans to proteins on their way through the 
secretory pathway. SPPL3 cleaves off the catalytic domain of such glycosyltransferases 
and glycosidases, therefore, decreasing the glycosylation of many proteins in the Golgi     
apparatus. Thus, increased SPPL3 expression leads to hypoglycosylation, while reduction 
results in hyperglycosylation, which makes SPPL3 expression an important switch that      
allows adaptation to environmental factors (Voss et al., 2014). 
Unlike the other SPPL family members, SPPL3 displays no favour towards proteins 
with short ECDs. This property distinguishes the protease from the other aspartyl-IMPs 
and resembles the class of rhomboid proteases. In addition, SPPL3 selects substrates not 
purely based on structural elements but rather prefers methionine and tyrosine in the P1 
cleavage position (Kuhn et al., 2015). However, it remains to be elucidated whether this is 





1.2. REGULATED INTRAMEMBRANE PROTEOLYSIS 
The process of regulated intramembrane proteolysis (RIP) has been a subject of 
intensive research during the last decades. Generally, RIP can be divided into three steps 
(Figure 1.10). The first step is the cleavage of the ECD by an accompanying sheddase. This 
shedding is required to allow the second step of RIP, the recognition and binding of         
substrates by an IMP. During the third step, the substrate is cleaved within the TMD in the 
plane of the membrane. This intramembrane cleavage has been described for many          
substrates and is required either for the generation of an intracellular signalling peptide 
or the removal of membrane-retained fragments (Fluhrer et al., 2008). In the following 







1.2.1. RIP STEP 1 - SHEDDING 
According to Lichtenthaler et al. shedding is defined as the removal of a large part 
of the ECD releasing it into the extracellular space or lumen of an organelle (Lichtenthaler 
et al., 2018). Shedding is an irreversible modification of the protein and can alter the     
structure and function of the substrate, thus, it controls the abundance and activation 
status of many membrane proteins. Cleavage occurs 10-35 amino acids distant from the 
membrane, in the JMD of the substrate (Figure 1.11). These usually membrane-bound 
Figure 1.10 The three basic 
steps of regulated intramem-
brane proteolysis (RIP) of a 
type II TM protein. After an           
initial shedding of the full-length 
(FL) protein, which releases a 
soluble ectodomain (sECD), the 
membrane-bound N/C-terminal 
fragment (NTF/ CTF) is recog-
nized by an IMP. The IMP cleaves 
the NTF/ CTF, which releases a 
small (C-) peptide to the extra-
cellular space and an intracellu-





sheddases are referred to as canonical or full-time sheddases. Some of these sheddases 
act redundantly on many substrates such as BACE1, others have only a limited substrate 
selection (Lichtenthaler et al., 2018). Besides membrane-bound sheddases, more and 
more soluble proteases such as the MMPs have been reported to facilitate canonical 
shedding as well. This type of shedding does not only describe the release of an ECD but 
rather the cleavage of a loop spanning two TM helices (Figure 1.11). 
 
Figure 1.11 Different types of shedding. In the conventional way of shedding, a single span TM protein is cleaved close to 
the membrane, which releases the majority of the ECD. Furthermore, a protein, which spans the membrane twice, can be 
cleaved in the loop connecting both TMDs. This generates two single span TM proteins, which can both be subjected to 
further intramembrane proteolysis. This is termed conventional shedding. However, recently intramembrane proteases 
(IMPs) have been described to be able to cleave TM proteins either directly or with the help of adaptor proteins. This is 
termed non-canonical shedding.  
 
Even though, RIP might imply that an initial shedding is required to allow                    
subsequent substrate binding to and cleavage by IMPs, there are some exceptions to the 
rule. Rhomboid proteases and SPPL3 are able to cleave full-length (FL) proteins directly 
without any preceding shedding event (Figure 1.11). These intramembrane sheddases are 
referred to as non-canonical sheddases. The newest addition to this group is SPP. With 
the help of the catalytically inactive rhomboid derlin1, SPP is able to process Xbp1u FL 





substrate making the TMD accessible for SPP intramembrane cleavage (Figure 1.11) (Chen 
et al., 2014a). 
Other modifications of the three-step process are represented by Bri2 that is       
generated in a pro-form. This pro-form is cleaved by Furin in the Golgi compartment,          
preventing premature cleavage before the substrate has reached its final destination (Kim 
et al., 1999). Pro-protein convertases like Furin are soluble serine proteases. They are not 
considered sheddases as they do not cleave in close proximity to the membrane neither 
do they remove the majority of the ECD. However, it is difficult to assign clear functional 
definitions as to whether a protease becomes a sheddase and always needs to be             
discussed individually (Lichtenthaler et al., 2018). 
 
Figure 1.12 Known shedding sites in SPPL2 substrates. Even though soluble fragments are detectable for almost all 
substrates, the identification of the exact shedding site is more complicated. TNFα is shedded mainly by ADAM17 at 
A76/V77. FasL is shedded by ADAM10 at position K129/Q130 and transferrin 1 (TFR1) is shedded at R100/L101. In hepato-
cytes, TFR1 is shedded by PC7. Whether PC7 is the main sheddase also in other organs has not been investigated so far. 
Cleavage by a sheddase generates a soluble peptide and a membrane-retained stub, the N/C-terminal fragment (NTF/ CTF). 
 
Many membrane-bound sheddases are assumed to work as monomers or dimers. 
This is not surprising as many substrates also form dimers or trimers on the cell surface. 
However, growing evidence suggests that some sheddases assemble into larger               
complexes. In case of ADAM17, iRhom and FRMD8 are required for trafficking and           
supposedly responsible for substrate interaction and selection (Section 1.1.1). ADAM10 
can interact with γ-secretase during the cleavage of APP (Chen et al., 2015). Hence, it might 
be possible that many sheddases use adaptor proteins; however, not all of them are            
stable and just form quickly upon substrate binding or during trafficking. Even though 





pathway, the exact cleavage sites have only been identified for very few, among them only 
three SPPL2 substrates (Figure 1.12). 
 
 
1.2.2. RIP STEP 2 - SUBSTRATE RECOGNITION 
Whereas several proteases (and also sheddases) display sequence-specific       
cleavage preferences, it seems more complicated for many IMPs. It appears as if the        
primary sequence within the TMD or adjacent domains is not the main criteria for           
substrate recognition and turnover (Martin et al., 2009). Since ECD shedding is a              
mandatory prerequisite for numerous IMP substrates, a short ECD was established as one 
of the substrate criteria. Within the γ-secretase complex, nicastrin is considered a gate-
keeper aggravating the binding of proteins with large ECDs (De Strooper, 2005). Whether 
a certain domain of SPPL2 proteases conducts gatekeeper functions is the topic of ongo-
ing research. However, it is unlikely that a short ECD is the only requirement for IMPs                 
accepting proteins for cleavage as the non-substrate Bri3 is still not processed by SPPL2 
proteases even if the ECD is removed (Martin et al., 2008).  
 
Figure 1.13 Exosite model. Substrate binding and substrate processing happen in different places within the intra-                     
membrane protease (IMP). As full-length proteins are not processed by many IMPs, it is speculated whether shedding           
induces structural rearrangements in the protein. Thus, the substrate can be recognised either within the IMP or by co-
factors (nicastrin in γ-secretase) and is subsequently transported to the active site where the cleavage occurs. As this is 






Growing interest is focusing on a new model of substrate recognition for IMPs 
where recognition depends on structural properties of protease and enzyme. This model 
proposes that substrate binding and cleavage happen in different locations within the 
enzyme. Hence, the cleavage site of the substrate might not necessarily be the same as 
the recognition site. Within the protease, so-called exosites facilitate binding/ selection of 
substrates before the substrates are relocated within the enzyme to the active site where 




1.2.3. RIP STEP 3 - SUBSTRATE CLEAVAGE 
Once the substrate has undergone shedding and subsequent recognition by the 
protease, it is cleaved in the TMD within the lipid bilayer. Most proteases cleave their     
substrates in one specific position. This results in the immediate release of two fragments. 
However, for γ-secretase and SPPL2b, a sequential cleavage that occurs roughly every 
third amino acid has been described (Fluhrer et al., 2008, Fluhrer et al., 2006, Fukumori et 
al., 2010, Matsumura et al., 2014, Olsson et al., 2014). Mutations in γ-secretase shift the 
start of the product line of APP cleavage, which results in an altered product line and, thus, 
in larger, amyloidogenic peptides (Figure 1.14). 
 A similar effect has been observed for Notch, proposing that consecutive cleavage 
is a general mechanism of γ-secretase (LaVoie and Selkoe, 2003). The consecutive cleavage 
mechanism of SPPL2b has been shown for TNFα where after recognition, initial cleavage 
releases a C-peptide while the remaining ICD is cleaved sequentially (Figure 1.14) (Fluhrer 
et al., 2006). Mutations in the GxGD motif slow down the consecutive cleavage of SPPL2b, 
resulting in longer TNFα N-terminal cleavage products (Fluhrer et al., 2008). So far, it has 








Figure 1.14 Consecutive cleavage mechanism of SPPL2b and γ-secretase. SPPL2b recognises TNFα NTF. After an initial 
cleavage, which releases the C-peptide, the remaining TNFα intracellular domain (TICD) is cleaved roughly every third amino 
acid, releasing TICDs of different lengths into the cytosol. As membrane-orientation of γ-secretase is flipped, it cleaves type 
I proteins such as APP. After shedding by β–secretase, a C-terminal fragment remains in the membrane that is termed 
according to its length (C99). The consecutive cleavage of C99 releases an APP ICD (AICD) into the cytosol and N-terminal 
fragments into the extracellular space (Aβ). The consecutive cleavage in APP has multiple starting positions resulting in 








1.3. SPPL2 SUBSTRATES 
So far, only a few substrates for SPPL2 have been identified but the spectrum is         
continuously growing. In the following section, current knowledge about all SPPL2          
substrates will be summarised. As many of them are involved in complex immune                  
reactions and are investigated in the context of many diseases, the summary is far from 
being complete. 
 
1.3.1. TNFα – THE MASTER REGULATOR OF INFLAMMATION 
Over 60 years ago, TNFα was identified as a factor that induces haemorrhagic        
necrosis of tumours in mice upon LPS stimulation (Carswell et al., 1975, O'Malley et al., 
1962). Since its discovery, over 40 proteins with similar properties have been grouped into 
the TNF/TNFR superfamily that is continuously growing. Besides TNFα, the TNF/TNFR         
superfamily includes prominent members such as lymphotoxin, Fas/FasL, TRAIL, 
CD40/CD40L and RANK/RANKL. Nowadays, TNFα is not considered a tumour necrosis      
factor but rather a pleiotropic cytokine that is produced by neutrophils and cells of        
monocytic lineage such as macrophages, astrocytes, microglia, Langerhans cells and     
Kupffer cells (Flynn et al., 1995, Pfeffer et al., 1993).  
TNFα is, amongst others, the first and most abundant cytokine released after                
infection or trauma, stimulating the expression of other inflammatory mediators and       
recruiting immune cells to the place of injury (Kalliolias and Ivashkiv, 2016). It perpetuates 
inflammation and apoptosis; thus, is considered an upstream regulator of the immune 
response and its expression needs precise regulation. TNFα expression is induced by       
activation of Toll-like receptors and release of interferon gamma (IFNγ) (Parameswaran, 
2010). Once upregulated and expressed on the cell surface, TNFα is shedded by ADAM17 
to release its ECD that can bind to one of the two TNFα receptors (TNFR1, TNFR2). The 
removal of the membrane-retained N-terminal stub is facilitated through cleavage by 
SPPL2a or SPPL2b (Fluhrer et al., 2006). The cytosolic domain that is released by SPPL2 
cleavage can travel to the nucleus and activate expression of interleukin (IL-) 12 






Figure 1.15 TNFα conducts various cellular responses. TNFα is shedded on the cell surface by ADAM17. The trimerised 
soluble ECD binds to the TNFα receptor 1 (TNFR1). Upon stimulation, the receptor can induce either a death or a survival 
response. Membrane-bound TNFα is able to bind directly to TNFR2. This induces a survival response. However, neither 
response is healthy if not regulated correctly. 
 
In addition to apoptotic functions, TNFα also induces an extensive array of             
protective and renewing properties. The at first glance contradicting functions of TNFα 
are mediated via signalling through the two distinct receptors. While cell death is mostly           
induced via pathways activated by TNFR1, survival is mediated via TNFR2 (Figure 1.15) 
(Tartaglia et al., 1991). TNFR1 is ubiquitously expressed and its activation induces a large 
number of inflammatory responses that are usually attributed to TNFα signalling (Tseng 
et al., 2018). Upon ligand binding, TNFR1 initiates apoptosis and necroptosis that lead to 
tissue degeneration. However, induction of TNFR1 signalling can also facilitate cell           
proliferation, migration and differentiation (Parameswaran, 2010). The regulation of these 
conflicting processes depends on the formation of different molecular complexes that 
diverge in their kinetic and special distribution within the receiving cell (Workman and 





cells (Tartaglia et al., 1991). It lacks the intracellular death domains and therefore mediates 
homeostatic effects such as survival, proliferation and tissue regeneration via the MAPK 
and ERK pathway (Kalliolias and Ivashkiv, 2016). Even though these are two very different 
functions, both receptors can contribute to the fuelling of inflammation by inducing cell 
death in abnormal cells and stimulating proliferation in immune cells (Figure 1.15).             
Furthermore, they are able to induce negative feedback loops to downregulate the              
inflammatory response. 
Interestingly, even though a central player of the immune response, TNFα                
deficiency in mice is not lethal. Amongst other defects, these animals display a high         
susceptibility to infectious diseases but are resistant to sepsis (Marino et al., 1997).                      
Interestingly, no TNFα variations on protein level have so far been described. In contrast, 
variations in the promoter region of the TNFA gene have been reported extensively (El-
Tahan et al., 2016, Yi et al., 2018). These SNPs affect the susceptibility for certain auto-
immune disorders, infectious diseases and sleep disorders (Hohjoh and Tokunaga, 2001). 
The SNPs modify transcription factor binding, which leads to altered expression of TNFα 
protein. Due to its central role in the question of death vs. survival, the inhibition of TNFα 
activity has been a focus of drug development. Anti-TNFα antibodies are extremely           
successful in the treatment of chronic inflammatory diseases. Etanercept – a recombinant 
human soluble fusion protein of TNFR2 coupled to Fc domain of IgG – improves the clinical 
course of rheumatoid arthritis (RA) and psoriasis (Strand et al., 2012). Infliximab (anti-
TNFα human-murine chimeric IgG1 monoclonal antibody) and Adalimumab (human anti-
human TNF antibody produced by phage display) are used in patients with inflammatory 
bowel diseases (Ordás et al., 2012). These antibodies that inhibit the interaction with TNFR 
by antagonizing the receptor or neutralize sTNFα are the gold standard for treatment of 
TNFα-related diseases and among the most sold drugs worldwide (Parameswaran, 2010). 
 
 
1.3.2. FASL (CD95L) – THE APOPTOTIC CYTOKINE 
The Fas ligand (FasL, or CD95L) is another cytokine of the TNF superfamily (TNFSF6) 
that binds primarily to its receptor Fas but is also able to bind to TNFR (Linkermann et al., 





T cells and NK cells but also in T cell development and peripheral tolerance. These cells 
eliminate harmful cells such as cancer or virus-infected cells and obliterate autoreactive 
lymphocytes, or activated lymphocytes during an infection (Levoin et al., 2020). 
As TNFα and FasL belong to the same family of cytokines, they share many          
structural and functional features. On the cell surface, FasL can directly bind to the             
receptor on a recipient cell inducing signalling events in the receptor-expressing cell. If 
shedded by ADAM10, the sFasL fails to induce cell death upon binding to the receptor. 
Thus, ADAM10 negatively regulates FasL-induced cell death and the processing of the FL 
protein ends its cytotoxic function (Guardiola-Serrano et al., 2010, Schulte et al., 2007). 
The remaining NTF is removed from the membrane by SPPL2a (Kirkin et al., 2007).              
Activation of Fas-mediated cell death occurs similarly to TNFα-mediated apoptosis via 
caspases. Besides cell death initiation, FasL also induces cell survival pathways or non-
death functions such as cytokine production or differentiation (Rossin et al., 2019). In      
certain cancers, e.g. NK cell lymphomas, ovarian or breast cancer and autoimmune         
disease sFasL peptides accumulate in the bloodstream (Fouque et al., 2014).  
 
 
1.3.3. BRI2 (ITM2B) – THE DEMENTIA PROTEIN 
The family of the British dementia proteins consists of three members, Bri1, Bri2 
and Bri3. Bri2 has gained attention when it was found to be mutated in patients with       
familiar British/ Danish dementia (FBD/ FDD) (Kim et al., 1999). Given their role in                
dementia, it is not surprising that Bri2 but also Bri3 reside in the brain. Bri1 expression is 
however restricted to chondrocytes suggesting no engagement in dementia development 
(Del Campo and Teunissen, 2014).  
The three proteins are highly homologous in sequence and structure. The large 
ECD contains the BRICHOS domain, which is involved in targeting the secretory pathway 
and chaperoning the formation of β-sheets (Del Campo and Teunissen, 2014, Tsachaki et 
al., 2008). In Bri2, a GxxxG motif, as well as a cysteine (C89) close to the extracellular plane 
of the membrane, are involved in dimer formation (Figure 1.16).  
Even though very similar, the Bri proteins diverge significantly regarding their        





Furin, which releases a rather small pro-peptide (~25 amino acids), Bri1 and Bri3 are                      
subsequently not shedded and therefore not subjected to RIP. Even truncated versions of 
Bri3 that bypass shedding are not a substrate of SPPL2 (Martin et al., 2009). In contrast, 
Bri2 is a RIP substrate of SPPL2b and shedded by ADAM10 after Furin-mediated cleavage 
(Figure 1.16) (Martin et al., 2008). Even though the cleavages happen sequentially, in vitro 
experiments showed that the cleavage of ADAM10 and SPPL2 can occur without prior 
removal of the pro-peptide (Del Campo and Teunissen, 2014). Exact cleavage sites of 
ADAM10 in Bri2 have yet to be determined. The membrane-remaining fragment of Bri2 is 
subject to cleavage by SPPL2a or SPPL2b, which release a C-peptide and an ICD with           
unknown fate. A consecutive cleavage of the Bri2 TMD such as for TNFα has not been 
observed so far.  
 
Figure 1.16 Structural overview of Bri2 and its cleavage in the extracellular space by Furin and ADAM10. Bri2 com-
prises a large ECD with a BRICHOS domain, a domain, which binds to APP and inhibits its turnover by γ-secretase, and 
several cysteins involved in folding. The full-length (FL) protein is first cleaved by Furin between R243 and E244 (Bri2 FC). It 
is not known whether the released fragment has any physiological role. However, in FBD/FDD patients a mutation causes 
this fragment to become longer thereby forming toxic aggregates. The majority of the Bri2 ECD is released by the cleavage 
of ADAM10. The exact cleavage site of ADAM10 has yet to be identified.  
 
In patients with FBD/ FDD, the BRI2 gene exhibits a point mutation affecting the 
stop codon and thus adding 10/ 11 amino acids to the Furin-released fragment. This 
longer ABri peptide tends to form amyloidogenic aggregates in the brain causing severe 
forms of dementia with patients exhibiting progressive dementia, cerebellar ataxia and 
spasticity (Del Campo and Teunissen, 2014). Additionally, patients develop extensive      
cerebral amyloid angiopathy, neurofibrillar tangles and an increased microglial response 





(cataracts) manifest at an average age of onset of 48 years and most patients die within 
10 years after disease onset (Mead et al., 2000). Developing suitable mouse models to 
investigate the physiological processes has turned out to be difficult. Even though Bri2 or 
an amyloidogenic Bri2 precursor protein are expressed in mice, they do not exhibit the 
clinical and pathological characteristics of the disease (Pickford et al., 2006). Cognitive    
deficits are either not present or cannot be measured due to abnormal movements and 
severe kyphosis (Del Campo and Teunissen, 2014).  
Besides the involvement of Bri2 in dementia, the physiological function of the     
protein has yet to be determined. An idea about its function was derived from                        
observations of increased Bri2 in brain injuries suggesting an implication in plasticity of           
neuronal processes (Choi et al., 2004). Bri2 might also act as a tumour-suppressor gene 
(Tsachaki et al., 2008) and has potentially protective functions in Alzheimer’s disease. By 
masking the docking site of α- and β-secretases or interacting with C99 but not C83, Bri2 
is discussed to reduce Aβ deposition (Matsuda and Senda, 2019). Even though the                
interaction is mediated by a short specific juxtamembrane region, which is unique to Bri2       
(Figure 1.16), Bri3 has been attributed with similar APP-binding capacity that is however 
mechanistically different from Bri2 (Matsuda et al., 2009). Moreover, reports hint towards 
an involvement in TNF-induced cell death and neuronal differentiation (Gong et al., 2008, 
Wu et al., 2003). A physiological function for Bri1 has been established in chondrocyte                 
differentiation; however, nothing is known about its cleavage mechanism so far (Boeuf et 
al., 2009).  
 
 
1.3.4. CD74 (INVARIANT CHAIN) – THE REGULATOR OF IMMUNITY 
CD74 was identified as a chaperone for the MHC class II while trafficking from the 
ER to endosomal compartments (Dijkstra and Yamaguchi, 2019). MHC class II presents 
peptides on the surface of antigen-presenting cells that are then recognised by the T cell 
receptor on T helper or regulatory T cells. Peptides are buried in a groove pocket that is 
specific for the presented peptide and ensures efficient and long-lasting (up to weeks) 
presentation (Yin et al., 2012). Since the groove displays a high affinity to misfolded          





endosomes, CD74 is degraded by several proteases one of which is SPPL2a (Figure 1.17) 
(Huttl et al., 2015). Misregulation of the CD74 degradation leads to maturation defects in 
B cells and DCs and increased susceptibility to infections. These results have been mostly 
established in SPPL2a-deficient mouse lines. However, a few patients deficient for SPPL2a 
have been described that mimic the effects observed in mice (Kong et al., 2018, 
Schneppenheim et al., 2014). 
 
Recent studies show that CD74 is able to chaperone other proteins besides MHC 
class II and even displays non-chaperone functions on the cell surface. CD74 can serve as 
receptor on the surface of non-immune and epithelial cells inducing ERK, PI3K-Akt and 
NFκB pathways (Figure 1.17) (Schroder, 2016). One of the most prominent ligands is the 
secreted macrophage migration inhibitory factor (MIF). MIF is ubiquitously expressed and 
its secretion is rapidly upregulated during the early stages of inflammation. Thus, high 
levels of CD74 can be found in injury, inflammation and cancer defining it as another key 
player in the context of inflammation. Interestingly, failure of anti-TNFα therapy in              
inflammatory bowel disease are connected to CD74 polymorphisms (Farr et al., 2020). 
Whether processing of CD74 on the cell surface follows the same mechanism as in endo-
somes is under investigation.  
 
Figure 1.17 CD74 chaperones 
MHC II on the way through 
the secretory pathway and 
has receptor functions on 
the cell surface. To protect 
the high-affinity groove of the 
MHC II receptor from im-
proper binding of peptides, 
CD74 binds to it. CD74 is then 
degraded by cathepsins and 
SPPL2a in endosomes. 
Afterwards, foreign peptides 
are loaded into the groove and 
thus, presented to immune 
cells on the surface of the        
antigen-presenting cell. CD74 
is also expressed on the cell 
surface where it can bind           
ligands such as the macro-
phage inhibitory factor (MIF). 






1.3.5. TMEM106B – A DEMENTIA RISK FACTOR 
TMEM106b was identified as a risk factor for frontotemporal lobar degeneration 
(FTLD) and amyotrophic lateral sclerosis (ALS) (Nicholson and Rademakers, 2016). In a 
large cohort of FTLD patients, several SNPs were determined to boost the pathology          
besides progranulin and C9orf72 (chromosome 9 open reading frame 72) mutations (Feng 
et al., 2020). 
The TMEM106 family consists of three members: A, B and C. TMEM106b is                
expressed in endosomes/ lysosomes of neurons, glial and endothelial cells. Even though 
it is known that TMEM106b undergoes RIP on the surface of the lysosomes, a specific 
sheddase has not yet been identified (Brady et al., 2014). The remaining NTF is processed 
by SPPL2a that generates an ICD, which is rapidly degraded. With so little known about 
the cleavage process, it is not surprising that the significance of physiological or mis-       
regulated RIP of TMEM106b is uncertain. First observations from in vitro experiments 
show that TMEM106b is involved in controlling lysosome size, acidification and function 
(Nicholson and Rademakers, 2016). The overexpression of TMEM106b leads to larger, less 
functional lysosomes, which are reduced in total numbers. Further observations, e.g., that 
TMEM106b is important for myelination are only descriptive and do not explain the exact 
mechanism of how TMEM106b exerts its molecular function (Feng et al., 2020).  
 
 
1.3.6. TRANSFERRIN RECEPTOR 1 (CD71) – THE REGULATOR OF IRON UPTAKE 
The transferrin receptor 1 (TFR1) is a homodimeric protein that is ubiquitously      
expressed in most cell membranes (Naito et al., 2020) even though expression levels are 
generally low except for differentiating cells and immature erythrocytes (Testi et al., 2019). 
Upregulation upon certain stimuli controls the expression levels of TFR1 and subsequent 
iron uptake. TFR1 regulates the uptake of plasma iron-carriers e.g., transferrin or ferretin 
that upon interaction are internalised and iron is released into the cell by endocytosis. 
The receptor is recycled to the surface (Figure 1.18) (Naito et al., 2020).  
Deficiency in the receptor leads to severe heart diseases as it is detrimental in 





2015). Due to its primary role in iron uptake, storage and release, exceptionally tight          
regulation is needed to sustain an optimal balance. Several intracellular protein inter-       
actions fine-tune the binding affinity and trafficking of the receptor (Testi et al., 2019). In 
the liver, TFR1 is shedded by the metalloprotease PC7 (Figure 1.12) and the soluble           
peptide is used as a diagnostic marker for anaemia caused by iron deficiency (Guillemot 
et al., 2013). Whether it exerts any physiological functions is not yet clear. The membrane-
retained TFR1 stub is subsequently processed by SPPL2b. Even though it has been shown 
that SPPL2a is able to cleave TFR1, it does not account for the majority of the degrada-





1.3.7. CLEC7A (DECTIN-1)/ CLEC8A (LOX-1) – THE NEW SUBSTRATES 
Clec7a and Clec8a are C-type lectin receptors (CLRs) that recognize sugars (e.g.,      
zymosan) in the cell wall of bacteria, plants and fungi. The over 1 000 CLRs are grouped 
into 17 families based on their function and/ or structure and most of them play a crucial 
role in immunity and homeostasis (Tone et al., 2019).  
Clec8a is mostly expressed in low amounts on endothelial cells but is rapidly up-
regulated upon stimulation by inflammatory cytokines and oxidised low-density lipo-     
protein (LDL). Once bound, the ligand is internalised, activating intracellular signalling as 
well as the production of cytokines, upregulation of adhesion molecules, apoptosis and 
Figure 1.18 The transferrin 
receptor 1 (TFR1) enables 
iron uptake. Ferretin-bound 
iron binds to the TFR1. After 
internalisation of the complex, 
the iron is released into the 
cell. TFR1 and ferretin are re-
cycled to the cell surface. This 
process can be governed by 
RIP, therefore reducing the 
amount of cell surface TFR1 
and subsequent iron uptake. 
Only a small portion of TFR1 is 
degraded in the lysosomal    
system (grey, dashed arrow), 
the majority is subjected to RIP 





NFκB signalling (Tone et al., 2019). Shedding of Clec8a is mediated by ADAM10 releasing 
a soluble fragment that is detectable in serum. The levels correlate with cardiovascular     
diseases and stroke; thus, they are used as diagnostic markers. The NTF is further              
processed by SPPL2a or SPPL2b (Mentrup et al., 2019). Whether the FL protein or the NTF 
mediate intracellular signalling is not yet clear.  
Clec7a is expressed on myeloid cells but also in B cells and some subsets of T cells 
(Tone et al., 2019). In humans, two isoforms are expressed of which one is lacking the stalk 
region. Besides the activation via β-glucans, endogenous ligands exist such as galacto-
sylated immunoglobulins and galectins (Gross et al., 2006). Activation of the receptor        
induces phagocytosis, autophagy, DC maturation, inflammasome activation, a respiratory 
burst and the production of cytokines and chemokines (Sun and Zhao, 2007). Therefore, 
polymorphisms of Clec7a are associated with reduced host defence and increased risk of 
fungal diseases (Kalia et al., 2018). The processing of Clec7a by SPPL2a is a fairly new       
observation (Schlosser, unpublished data) and not yet well understood.  
 
 
1.3.8. NEUREGULIN1 AND FVENV - UNCONVENTIONAL SUBSTRATES 
So far, most of the substrates identified for SPPL2 are type II TM proteins, with two 
exceptions. NRG1 and FVenv protein are type III TM proteins, which span the membrane 
twice. When shedded, two single TM proteins remain one of which is in type II orientation 
(Figure 1.11). This fragment is then cleaved by SPPL2 (NRG1) or SPPL3 (FVenv).  
NRG1 is indispensable for neuronal and cardiac development as it is most          
abundant in brain and heart tissue (Hu et al., 2016). Misregulation of NRG1 cleavage is 
associated with Alzheimer’s disease and schizophrenia (Hu et al., 2016, Willem, 2016). The 
neuregulin gene is one of the largest genes in the human genome. Its expression and 
regulation are highly complex involving different transcriptional isoforms and several 
splice variants. All isoforms contain an EGF-like domain that can be secreted or directly 
bind to its receptor. The activation of the receptor induces MAPK and PI3K-AKT pathways 
(Baliga et al., 1999). Unless the soluble form is directly synthesised as a functional isoform, 
NRG1 needs ADAM10/17 and BACE1 shedding twice to release the EGF-like domain to the 





1.19). The type I TM fragment contains a short luminal domain and therefore is directly               
processed further by γ-secretase. The type II TM protein exhibits a larger ECD and is           
shedded again by an unknown protease, which generates an NTF’ that is processed by 
SPPL2a or SPPL2b (Fleck et al., 2016). The cleavage occurs in the C-terminal region of the 
TMD, but the function of ICD and C-peptide are unknown. As they lack conserved domains 
this cleavage might only fulfil a degradational purpose.  
 
Figure 1.19 Processing of neuregulin 1 (NRG1) is a multi-step process. NRG1 spans the membrane twice. It is cut twice 
in the luminal domain by ADAM17 or BACE1. This cleavage releases the soluble EGF domain (sEGF). The C-terminal mem-
brane resident fragment (CTF) is cleaved by γ-secretase. The NTF is shortened by an unknown protease, which generates 
the NTF’. This fragment is cleaved by SPPL2a or SPPL2b releasing a C-peptide to the extracellular space and an N-ICD to the 
cytosol.  
 
The foamy virus (FV) belongs to a subfamily of retroviruses that infect non-human 
primates. The persistent but mostly non-pathogenic infection is transmitted by primates 
biting or licking each other but is generally restricted to epithelial cells in the mouth and 
pharynx (Buseyne et al., 2018). So far, only a small cohort of African hunters have been 
investigated in the context of a clinical study displaying signs of anaemia and differences 
in blood count after infection (Buseyne et al., 2018). So far, no mechanism is identified 
linking the FV to the clinical symptoms.  
The FVenv protein is a type III TM protein with both C- and N-terminus facing the 
cytosol. Its interaction with the viral capsid makes it most likely that it is involved in the 
release from the host cell. Furin or a Furin-like proprotein convertase sheds the protein 
in the extracellular loop twice enabling subsequent SPPL3 cleavage. Even though FVenv is 
canonically shedded, SPPL3 is able to process the protein without prior shedding. Besides 
SPPL3, SPPL2a and b are also able to process FVenv, but only after the preceding shedding 





The table below summarises the current knowledge of SPPL2 substrates in the 
context of RIP. Most of the substrates are characterised incompletely, information about 
cleavage sites of sheddases and SPPL2 are still missing. Some substrates like FasL and 
CD74 have been studied in more detail because of their central role in disease                        
development.  
The question, whether SPPL2a and SPPL2b are generally able to cleave the same 
substrates is also not entirely answered, even though in vitro experiments indicate at least 
partially overlapping substrate acceptance by both proteases. However, taking into            
account that enzyme and possible substrate may differ in subcellular localisation in vivo 
studies are necessary to proof physiological relevance. Thus, the definition of what is a 


































































































































































































































































































































































































































































































































































































    


























    
































































































































































































1.4. SUBSTRATE MODIFICATION  
PTMs are believed to induce or enhance function, increase stability or provide   
guidance of proteins to certain subcellular locations. The modifications occur throughout 
the entire secretory pathway and can involve multiple steps and several types of                   
modifications. Proteins can be modified by proteolytic removal of peptides (Section 1.1 
and 1.2.1) or by addition of lipids or glycans. While removal of peptides and addition of 
glycans are irreversible and depend on the homeostatic status of the cell, the addition of 
certain lipids is a highly dynamic process. The questions of how, when and where a           
protein is modified is unique to each protein.  
All SPPL2 substrates are glycosylated (Table 1.1); however, the function of this 
modification is rarely investigated. Differently glycosylated proteins can alter surface      
stability, signalling capacity and localisation therefore affecting the cell homeostasis. In 
TMEM106b, the correct localisation to endosomes/ lysosomes is maintained by                   
glycosylation in five positions in the luminal domain and its loss leads to retention in the 
ER (Nicholson and Rademakers, 2016). A similar function has been reported for the glyco-
sylation of Bri2, which is needed for the correct localisation on the cell surface; however, 
it seems not to be crucial for protein processing (Tsachaki et al., 2011). In contrast,              
elimination of FasL glycosylation does not seem to affect the protein at all (Levoin et al., 
2020). Therefore, it remains to be investigated how and to what extent glycosylation          
affects the SPPL2 substrates in more detail. 
Attachment of lipids is another common PTM that can alter protein localisation, 
stability and even function. Depending on the fatty acid that is attached to the protein, 
the process is called myristoylation (C14), farnesylation (C15) or palmitoylation (C16).      
When a palmitate is transferred to the functional group of a cysteine residue via a thio-
ester linkage this process is referred to as S-palmitoylation. S-palmitoylation is the only 
reversible protein lipidation. Thus, this process occurs within seconds and lasts up to            
several hours (Ko and Dixon, 2018). Protein acyltransferases (PATs) catalyse S-pal-
mitoylation and are multi-pass TM proteins with a conserved zinc-finger Asp-His-His-Cys 
(zDHHC) motif that is important for catalytic activity (Figure 1.20) (Zmuda and 
Chamberlain, 2020). Most of the PAT family members are found in the Golgi apparatus; 





expressed in the brain, explaining the large number of palmitoylated synaptic proteins 
(40%) (Globa and Bamji, 2017). Substrate selection of zDHHC PATs remains elusive as no 
consensus sequence for palmitoylation is known so far (Ko and Dixon, 2018). Often, more 
than one PAT is able to palmitoylate a substrate; however, not every cysteine within a 
protein becomes palmitoylated.  
Whereas the PAT family consists of 23 members, only a few depalmitoylating         
enzymes have been described so far. Removal of the palmitate is facilitated by acylprotein 
thioesterases (APTs), a group of serine hydrolases and palmitoyl protein thioesterases 
(PPT) that have emerged as depalmitoylating enzymes (Figure 1.20) (Koster and Yoshii, 
2019, Won et al., 2018). In addition, a group of αβ hydrolase domain (ABHD) containing 
proteins have been described to enable depalmitoylation of cancer-related and SNARE-
like proteins (Lin and Conibear, 2015). 
 
Figure 1.20 Protein acyltransferases (PAT) palmitoylate proteins, whereas acylprotein thioesterases (APT) depal-
mitoylate proteins. PATs are autopalmitoylated at the DHHC motif before they transfer the palmitate to the thiol group 
of the target protein. The palmitoylation guides the protein to lipid rafts. Palmitoylation is removed by APTs. 
 
To investigate the effects of lipidation two categories of palmitoylation inhibitors 
exist, lipid-based and non-lipid compounds. Even though lipid-based inhibitors such as    
2-bromopalmitate (2-BP), tunicamycin and cerulenin analogues have been used to inhibit 
palmitoylation in vitro, their mechanism of action is poorly understood and lacks              
substrate specificity. It has been suggested that 2-BP inhibits palmitate incorporation                 
unspecifically as it is converted into 2-BP-CoA inside the cell (Davda et al., 2013). Never-
theless, besides inhibiting palmitoylation, all lipid-based inhibitors have shown to                 





not be direct (Draper and Smith, 2009). In an attempt to bypass the tremendous effects 
on cell homeostasis when interfering with the lipid state, non-lipid compounds were             
designed to inhibit specifically palmitoylation of certain proteins. They do not act as              
palmitoyl-CoA competitors but rather target the protein-binding site. Based on this and 
the fact that they do not interrupt fatty acid synthesis, these inhibitors are tested as anti-
cancer drugs (Ko and Dixon, 2018, Zheng et al., 2013).  
Many SPPL2 substrates undergo lipidation (Table 1.1). Palmitoylation has been 
shown for TNFα (Utsumi et al., 2001), FasL (Guardiola-Serrano et al., 2010), CD74 
(Schroder, 2016), and TFR1 (Zahn et al., 2013). The physiological role of this modification 
is pending for most of the substrates, as effects of palmitoylation are difficult to                     
investigate. Results on FasL and CD74 strengthen the assumption that palmitoylation of 
SPPL2 substrates is critically involved in surface stability. However, while TFR1                       
palmitoylation enhances endocytosis (Drecourt et al., 2018), palmitoylation of CD74                 
increases cell surface stability (Huttl et al., 2015). Furthermore, effects on localisation to 
lipid rafts and proper function are assumed. The regulation of the palmitoylation/ depal-
mitoylation cycle is complex and that depends on many factors such as availability of fatty 










2. AIM OF THE STUDY 
Aspartyl-intramembrane cleaving proteases emerged as important regulatory 
players in health and disease, thus the understanding of their function is of great                 
importance. Their participation in the process of RIP requires several steps to complete 
substrate processing successfully. However, many details about substrate selection and 
the detailed processing mechanism remain elusive. The goal of this thesis is to increase 
understanding of the function and cleavage mechanism of SPPL2a and SPPL2b. So far, 
most information available on the cleavage mechanism of SPPL2 proteases is only based 
on analysis of SPPL2b and SPPL2a data is incomplete. Here, both proteases will be          
compared to judge whether substrate recognition and cleavage are actually as similar as             
suggested.  
To this end, domains in TNFα that allow recognition by SPPL2a or SPPL2b will be 
identified and specific features of these domains will be analysed. It will be investigated 
how the proteases distinguish substrates from non-substrates and if the subsequent       
processing mechanism differs between substrates. Previous reports have shown that a 
short luminal substrate domain seems to be an important requirement for SPPL2                  
cleavage; therefore, the JMD but also the effect of the TMD and ICD on recognition and 
processing will be investigated in detail, to answer whether the proteases detect sequence 
specificities or structural properties. Furthermore, the study aims to explore the question 
of whether SPPL2a and SPPL2b apply a common recognition/ processing mechanism to 
all substrates or whether the cleavage mechanism is substrate specific. The resulting data 
on the substrate selection and processing mechanism will be used to predict new              
potential substrates to expand the knowledge on SPPL2a and SPPL2b proteases further. 
  








3. MATERIAL AND METHODS  
3.1. MATERIALS 
3.1.1. INSTRUMENTS, CONSUMABLES, REAGENTS, SOFTWARE 
Table 3.1 Instruments and consumables  
Instrument Company 
Accu Jet pro Brand 
Agarose electrophorese Peq Lab 
Cawomat 2000IP X-ray developer Cawo 
Centrifuges Heraeus Pico, Heraeus Frisco 17, 21,  
Megafuge 40 R 
FACS Melody BD 
Gel Electrophorese/  
Western Blotting equipment 
Biorad 
ImageQuant LAS-4000  FUJIFILM 
Incubator Heraeus, Thermo Fisher 
Laminar Flow Hood Thermo Scientific 
NanoPhotometer Implen 
Thermomixer C Eppendorf 
Reaction tubes/ pipette tips Sarstedt 
Research plus pipettes Eppendorf 
RX-N X-ray films FUJIFILM 
4800 MALDI TOF/TOF Analyzer Applied Biosystems 
7500 Fast Real-Time PCR System Applied Biosystems 
 
Table 3.2 Software 
Software Company 
CLC Main Workbench, Version 6.9.1 CLC bio 
Prism 8 Version 8.4.1 GraphPad Software,LLC 
Data Explorer TM Version 4.4 Applied Biosystems 
Illustrator/ Photoshop 2021 25.0.0 Adobe 
Multi Gauge V3.0 FUJIFILM 
PyMOL Molecular Graphics System, Version 2.0  Schrödinger, LLC 
 
 




Table 3.3 Chemicals used in this study 
Chemical Company 
1 kb Plus DNA ladder Invitrogen 
2-bromopalmitate Sigma Aldrich 
α-cyano-4-hydroxycinnamic acid matrix Sigma Aldrich 
Acetic Acid Merck 
Acetonitrile Sigma Aldrich 
Acrylamide/ Bis 40% 29:1 Biorad 
Acrylamid/ Bis 40% 37.5:1 Invitrogen 
Agarose Invitrogen 
APS (10 %) Merck 
















Hydroxylamid Sigma Aldrich 
Tropix® I-Block Applied Biosystems 
Isopropanol Merck 
KCH3COO Sigma Aldrich 
KH2PO4 * H2O Merck 
Mg(CH3COO)2 Fluka 
NaN3 Merck 




N-octyleglycopyranoside Sigma Aldrich 
NP-40 USB 19628 




Orange G Sigma Aldrich 
Pierce TM ECL Western Blotting Substrate & Plus Thermo Fisher 
Protease inhibitor cocktail Sigma Aldrich 
SDS Serva 
See Blue Plus 2 Standard Invitrogen 
Sucrose Sigma Aldrich 
TEMED Roth 
Trifluoroacetic acid (TFA) Roth 
Tris Biomol 
Tricine PanReac AppliChem 
Triton X100 Merck 
Tween20 Merck 
Westar Antares Cyanogen 
β-mercaptoethanol Sigma Aldrich 
 
3.1.2. PLASMIDS AND CONSTRUCTS 
Table 3.4 Plasmids 
Plasmid Company 
pcDNA3.1 Hygro(+) Invitrogen 
pCMV-Cas9-GFP Sigma Aldrich 
 




Construct name Tag 
 C-terminal 
Flag TNFα FL S34L V5 
Flag TNFα FL S34P V5 
Flag TNFα FL S37L V5 
Flag TNFα FL S37P V5 
Flag TNFα FL G43L V5 
Flag TNFα FL G43P V5 
Flag TNFα FL C49L V5 
Flag TNFα FL C49P V5 
Flag TNFα FL H52L V5 
Flag TNFα FL H52P V5 
Flag TNFα FL AGA42-44L V5 
V5 TNFα NTF S34P Flag AP 
V5 TNFα NTF S37P Flag AP 




V5 TNFα NTF G43P Flag AP 
V5 TNFα NTF C49P Flag AP 
V5 TNFα NTF H52P Flag AP 
Flag TNFα FL EED61,62,66QQN V5 
Flag TNFα FL EED61,62,66QQA V5 
Flag TNFα FL EED61,62,66AAA V5 
Flag TNFα FL FlagTEV V5 
Flag 3TT FL  V5 
Flag 33T FL V5 
Flag T3T FL V5 
Flag 3T3 FL V5 
Flag TT3 FL V5 
Flag T33 FL V5 
Flag 3TT NTF  V5 
Flag 33T NTF V5 
Flag T3T NTF V5 
Flag 3T3 NTF V5 
Flag TT3 NTF V5 
Flag T33 NTF V5 
V5 3TT NTF  FlagAP 
V5 33T NTF FlagAP 
V5 T3T NTF FlagAP 
V5 3T3 NTF FlagAP 
V5 TT3 NTF FlagAP 
V5 T33 NTF FlagAP 
Flag 3T3 FL S66P V5 
Flag 3T3 FL G73P V5 
Flag TNFα FL juxBri3_1 V5 
Flag TNFα FL juxBri3_2 V5 
Flag TNFα FL juxBri3_3 V5 
Flag TNFα NTF juxBri3_1 V5 
Flag TNFα NTF juxBri3_2 V5 
Flag TNFα NTF juxBri3_3 V5 
V5 TNFα NTF juxBri3_1 FlagAP 
V5 TNFα NTF juxBri3_2 FlagAP 
V5 TNFα NTF juxBri3_3 FlagAP 
Flag SACA3 V5 
Flag ENTPD6 V5 
Flag GOLM1 V5 
Flag TNFSF15 V5 








All constructs were cloned into a pcDNA3.1 Hygro (+) vector via the HindIII and XhoI 
cleavage sites.  
Bri proteins contain an additional pro-peptide, which is removed by Furin-             
mediated cleavage. As this cleavage does not affect further processing the pro-peptide 




Table 3.6 Kits 
Kit Company 
Novex™ AcTEV™ Protease Thermo Fisher Schientific 
Clean up kit NucleoSpin® Macherey Nagel 
NucleoBond Xtra Midi kit Macherey Nagel 
 
3.1.4. CELL LINES AND CELL CULTURE 
Table 3.7 Cell lines 
Cell line name Genetic alteration Antibiotic 
resistance 
Source 
T-RexTM-293 (TR) pcDNATM6/TR Blasticidin Invitrogen 
TR SPPL2a wt HA pcDNATM6/TR 




(Martin et al., 2008) 
TR SPPL2b wt HA pcDNATM6/TR 




(Martin et al., 2008) 







(Spitz et al., 2020) 
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Current study  
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Flag NKG2D V5 
Flag Bri2 FL V5 
Flag Bri2 G60L V5 
Flag Bri2 G60P V5 




Table 3.8 Reagents  
Name Company 
Blasticidin Life Technologies 
DEMEM GlutaMAX TMI Life Technologies 
Doxycycline Carl Roth 
Fetal Bovine Serum (FBS) Sigma Aldrich 
GI254023X Sigma Aldrich 
L-Glutamine (L-Gln) Life Technologies 
Lipofectamine TM 2000 Thermo Fisher 
OptiMEM® I + GlutaMAX TM I Life Technologies 
Penicillin/ Streptomycin (P/S) Life Technologies 
Phorbol 12-myristate 13-acetate (PMA) Enzo lifesciences 
Poly-L-lysine Sigma Aldrich 
Trypsin (0.05 %) –EDTA (1 x) Life Technologies 




BMS-561395 Kindly provided by Haass Lab 
 
Table 3.9 Composition of cell culture media 
Name Composition 
Antibiotic free medium + Doxycycline (ABF+Dox)  DMEM GlutaMAX 
10 % (v/v) FCS 
1 µg/ ml Doxcycline 
Basic medium DMEM GlutaMAX 
10 % (v/v) FCS 
1 % (v/v) P/S 
1 % L-Gln 
Blasticidin Medium (B) Basic medium 
5 µg/ ml Blasticidin 
Blastcidin/ Zeocin medium (B/Z) Basic medium 
5 µg/ ml Blasticidin 










Table 3.10 Primary antibodies. WB: western blot, FC: flow cytometry, IP: immunoprecipitation. 
Antigen Host/ Type Source Clone Method Dilution 
FlagM2 Mouse Merck M2 WB 1 :  1 000 
V5-mono Mouse, mlgG2A Life Technologies R960-25 WB 
FC 
1 :  2 000 
1 :  400 
Calnexin Rabbit, pAB Enzo Life Sciences  WB 1 :  1 000 
Anti-TNFα Rabbit, pAB Abcam ab9739 WB 1 :  1 000 
V5-mono Mouse Haass Lab 29H IP 1 :  50 
V5 poly Rabbit, pAB Millipore AB3792 IP 1 - 1 :  10 
 
Table 3.11 Secondary antibodies. WB: western blot, FC: flow cytometry. 
Target organism Host Coupling Source Method Dilution 
Mouse Goat HRP Promega WB 1 :  10 000 
Rat Goat HRP Millipore WB 1 :  10 000 
Rabbit Goat HRP Promega WB 1 :  20 000 
Mouse Donkey Alexa488 Thermo Fisher FC 1 :  2 000 
 
3.1.6. BUFFERS 
Table 3.12 List of buffers used for analysis. 
Name Composition 
Acrylamide Solution 29.5 %  48 g Acrylamid 
1.5 g Bisacrylamid 
ad. 100ml H2O 
Anode buffer  1 M Tris-HCL pH 8,9 
Basic buffer 40 mM Tris pH 7.8 
40 mM KCH3COO 
1.6 mM Mg(CH3COO)2 
100 mM sucrose 
0.8 mM DTT 
1:500 PI mix 
Binding buffer 100mM HEPES 
1mM EDTA 
1% SDS 
Cathode buffer 0.1 M Tris HCl   
0.1 M Tricine   
0.1 % SDS 




CaCl2 buffer 50 mM CaCl2 
10 mM Tris pH 8,0 
CaCl2 Glycerin buffer (fresh) 7.5 ml CaCl2 buffer 
2.5 ml Glycerin sterile 
FACS buffer 1 x PBS 
0.5 % BSA 
0.01 % NaN3 
gDNA Lysis Buffer 10 mM Tris-HCl pH 7.5 
10 mM 0.5M EDTA 
10 mM NaCl 
0.5 % sarcosyl (N-lauryl sarcosine) 
10 mg/ ml Proteinase K (before use) 
ad. 1 L H2O 
gDNA precipitation buffer  0.15 M NaCl 
ad. 10 ml 98 % EtOH 
Hypotonic buffer 10 mM Tris pH 7.6 
1 mM EDTA 
1 mM EGTA, pH 7.6 
PI mix 1:500 
I-Block 2 % (w/v) Tropix I-BlockTM  
0.1 % (v/v) Tween 20 in PBS 
LB agar plates LB medium 
15 g/ L agar 
autoclaved at 120°C at 1.2 bar 20 min 
100 mg/ ml ampicillin  
LB medium 1 % (w/v) bactotrypton 
0.5 % (w/v) yeast extract 
1 % (w/v) NaCl 
Lower Tris 1.5 M Tris 
0.4 % (w/v) SDS, pH 8.8 
Mass Spec washing buffer (20 x) 2.8 M NaCl 
2 % N-octyleglycopyranoside 
200 mM Tris-HCl pH 8 
100 mM EDTA 
PBS pH 7.4 140 mM NaCl 
10 mM Na2HPO4 
1.75 mM KH2PO4 








Running buffer 25 mM Tris 
200 mM Glycine 
0.1 % (w/v) SDS 
Sample buffer (5 x) 50 % (v/v) glycerol 
7.5 % (w/v) SDS 
7.5 % (w/v) DTT 
bromophenol blue (traces) 
dissolved in 4 x upper Tris buffer 
SDS Gel buffer 3 M Tris-HCl  
0,3 % SDS 
Solution 1 50 mM Glucose 
25 mM Tris pH 8 
10 mM EDTA pH 8 
Solution 2 (fresh) 0.2 M NaOH 
1 % SDS 
ad. 6 ml H2O 
Solution 3 3 M Acetic potassium 
11.5 % acetic acid 
SPP Stock buffer 50 mM Tris pH 7.8 
50 mM KCH3COO 
2 mM Mg(CH3COO)2 
125 mM sucrose 
1 mM DTT 
STEN-lysis buffer 400 ml STEN buffer 
1 % Triton X-100 
1 % NP-40 
0.2 % BSA 
STEN buffer  50 mM Tris pH 7.5 
150 mM NaCl 
2 mM EDTA 
0.2 % NP-40 
TBE buffer (10 x) 50 mM Tris pH 7.5 
150 mM NaCl 
2 mM EDTA 
1 % NP-40 
PI mix 1:500 
TBS-T pH 7.6 50 mM Tris 
150 mM NaCl 
0.05 % (v/v) Tween 20 
TE buffer 10 mM Tris HCl pH 8 
1 mM EDTA 




Transfer buffer 25 mM Tris 
200 mM glycine 
Upper Tris (4 x) pH 6.8 0.5 M Tris 
0.8 % (w/v) SDS 
 
3.1.7. ACRYLAMID GELS 
Table 3.13 Acrylamide gel composition for 12 % SDS gel 
 Separating gel (12 %) Stacking Gel 
H2O 1.8 ml 1,625 ml 
Acrylamide/ Bis 37, 5:1 1.2 ml 0.25 ml 
Lower Tris 1 ml - 
Upper Tris - 0.625 ml 
TEMED 7.5 µl 7.5 µl 
APS (10 %) 7.5 µl 7.5 µl 
 
Table 3.14 Acrylamide gel composition for a Schägger gel 
 Separating gel Spacing gel Stacking gel 
Acrylamide solution 2 ml 0.75 ml 0.25 ml 
Tris-tricine gelbuffer 1.75 ml 1.25 ml 0.75 ml 
H2O - 1.75 ml 2.1 ml 
32 % (v/v) glycerol 1.5 ml - - 
TEMED 32.5 µl 35 µl 25 µl 
APS (10 %) 3.25 µl 4 µl 5 µl 
 
Table 3.15 Acrylamide gel composition for DNA analysis 
 Running Gel (8 %) 
H2O 8.4 ml 
Acrylamide/ Bis 29:1 2.4 ml 
10 x TBE 1.2 ml 
TEMED 10 µl 
APS (10 %) 200 µl 
 
3.1.8. MOUSE SAMPLES 
Samples of bone marrow-derived dendritic cells (BMDCs) of wildtype (wt) and 
SPPL2a-deficient mice were kindly provided by Dr. Bernd Schröder in Dresden 




(Schneppenheim et al., 2014). BMDCs were isolated and treated with LPS and the ADAM 






3.2.1. MOLECULAR CLONING 
3.2.1.1. STANDARD PCR, QUICKCHANGE, GBLOCK 
cDNA constructs were designed using the CLC software. Either mutations were       
inserted via PCR or cDNA was purchased at IDT (https://eu.idtdna.com/pages). Tags were 
added on both N- and C-terminus as shown in  
Table 3.5 (Flag: DYKDDDDK(AP) or V5: GKPIPNPLLGLDST). To change tags or to fuse 
larger cDNA fragments an optimised PCR protocol was used (Table 3.16). This protocol 
was also used to amplify the cDNA received from IDT. The composition of the PCR mix is 
listed in Table 3.17. 
 
Table 3.17 Optimised PCR Program 
Cycle Temp. Time 
1 95°C 2 min 
2 95°C 1 min 
3 42°C 1 min 
4 72°C 2 min 
5  Go to 2, Repeat 20 x 
6 94°C 1 min 
7 42°C 1 min 
8 72°C 2 min 
9  Go to 6, Repeat 30 x 
10 72°C 7 min 
11 4°C Hold 
 
To introduce point mutations the Quick-Change PCR was used (Table 3.18). Primers 
were designed using the online webtool of Agilent Technologies (http://www.genomics. 
Table 3.16 PCR mix for standard PCR 
cDNA (10 - 50 ng) 1 µl 
Primer fwd (25nM) 1 µl 
Primer rv (25nM) 1 µl 
dNTP 2 µl 
5x Go Taq polymerase buffer 
(Promega) 
10 µl 
Go Taq polymerase 
(Promega) 
1 µl 
H2O ad. 50 µl 
 




agilent.com/primerDesignProgram.jsp) and purchased at Sigma Aldrich. The composition 
of the Quick-Change PCR mix is listed in Table 3.19.  
 
Table 3.19 Program for Quick Change PCR 
Cycle Temp. Time 
1 95°C 1 min 
2 95°C 30 s 
3 55°C 30 s 
4 68°C 2 min/ 1 kb 
5  Go to 2, Repeat 16 x 
6 68°C 20 min 
7 4°C Hold 
 
 
PCR products were analysed on 1.5% TBE buffered agarose gels containing 
0.2µg/µl GelRed. For analysis samples were mixed 1:10 with DNA sample buffer. A 1 kb 
Plus DNA ladder was used to estimate the size of the PCR products. Correctly sized bands 
were cut under UV light and extracted from the agarose using the NucleoSpin Gel and 
PCR clean-up kit. 
 
3.2.1.2. RESTRICTION 
The PCR products or gBlocks were subcloned into the HindIII and XhoI sites of a 
pcDNA3.1 Hygro(+) vector. Restriction was performed for 2 h at 37°C. Restriction endo-
nucleases were obtained from Thermo Fisher or New England Biolabs and used according 
to the manufacturer’s instructions. Restriction products were cleared from enzymes using 
the NucleoSpin Gel and PCR clean-up kit.  
 
Table 3.20 Restriction mix per sample 
PCR product 20 µl 
Restriction enyme 1 (HindIII) 1 µl 
Restriction enzyme 2 (Xho I) 1 µl 
Buffer (buffer red) 3 µl 
H2O ad. 30 µl 
 
Table 3.18 PCR mix for Quick Change PCR 
Template cDNA (10 ng) 1µl 
Primer fwd (125 ng) 1µl 
Primer rv (125 ng) 1µl 
dNTP 2 µl 
10x buffer  
(Agilent technologies) 
5 µl 
Pfu Turbo polymerase 
(Agilent technologies) 
1 µl 
H2O ad. 50 µl 
 





The digested PCR products were ligated into the pcDNA3.1 Hygro(+) vector for 4 h 
at RT or overnight at 4°C. The composition of the ligation mix is shown in Table 3.21. 
 
Table 3.21 Ligation mix 
Cleaved vector 2 µl 
Insert 15 µl 
T4 ligase buffer 10x 2 µl 
T4 ligase 1 µl 
 
3.2.1.4. TRANSFORMATION INTO COMPETENT CELLS 
For transformation, competent E.coli DH5α cells were generated. To this end, E.coli 
were cultured overnight in 3 ml of LB media. This pre-culture was transferred into 800 ml 
fresh LB media and incubated at 37°C until an OD600 of 0.5 was reached. The suspension 
was centrifuged at 1 500 g for 10 min and pellets were resuspended in CaCl2 buffer. The 
bacteria were incubated for 30 min on ice and centrifuged again at 1 500 g for 10 min at 
4°C. The pellet was resuspended in CaCl2-Glycerin buffer and stored at -80°C until use.  
PCR-generated cDNA constructs were transformed into the competent cells via 
heat shock. 50 µl of competent cells were thawed 10 min on ice and then 10 µl of the cDNA-
containing plasmid was added. The samples were incubated for 10 min on ice, 2 min at 
42°C and 2 min on ice again. 1 mL of sterile LB media was added before the samples were 
incubated for an hour at 37°C and subsequently plated on LB agar plates containing        
ampicillin. The plates were incubated at 37°C overnight to select for ampicillin resistant 
clones. 
 
3.2.1.5. PLASMID PREPARATION 
Ampicillin resistant clones were selected and transferred into 4 ml LB media with 
ampicillin and incubated overnight at 37°C. The bacteria were centrifuged at 1 500 g for 
10 min and the pellet was resuspended in 100 µl Solution 1. 200 µl Solution 2 and 150 µl 
Solution 3 were added. In between, the samples were softly shaken. Then, samples were 
centrifuged at 17 000 g for 10 min at 4°C. The supernatant was collected in a new reaction 
tube and 1 ml 98 % EtOH was added. Samples were again centrifuged as before. After    




centrifugation, the supernatant was removed and the pellets were washed with 500 µl 
70 % EtOH. After another centrifugation step, the pellets were dried and resuspended in 
20µl H2O with 10 % RNase. Insertion of cDNA was verified by restriction endonuclease   
digestion and agarose gel electrophorese. Photometric analysis of DNA concentration was 
performed using a UV-Vis Nano-Photometer (Table 3.1). 
 
3.2.1.6. SEQUENCING 
All constructs were sequence-verified prior to experimental use. DNA was                
sequenced by GATC Biotech (Konstanz, DE). For the Sanger sequencing, either standard 
GATC or self-designed primers were used. Sequence analysis was performed using the 
CLC Main Workbench (Table 3.2). 
 
 
3.2.2. CELL CULTURE 
Cell culture procedures were performed under laminar flow hoods. Cells were     
cultivated in the according media (Table 3.9) in water-jacket incubators with a humidified 
atmosphere containing 5 % (v/v)  CO2. Cells were passaged every 3 - 4 days by Trypsin-EDTA 
digest. Therefore, cells were washed with PBS to remove all traces of serum. Trypsin-EDTA 
was added for 5 min, detached cells were collected in a reaction tube and centrifuged at 
1 200 g for 5 min. The pellet was resuspended in 4 - 5 ml of the according culture media 
and plated into a new petri dish.  
When plated for experiments, cells were seeded onto Poly-L-lysine coated plates. 
Plates were coated for at least 45 min with 100 µg/ ml Poly-L-lysine, followed by one wash 
with PBS and one wash with H2O. Cell culture media used during experiments did not 
contain any antibiotics. 
 
3.2.2.1. TRANSFECTION 
HEK293 cells stably expressing ectopic SPPL2a or SPPL2b have been described    
earlier (Martin et al., 2008). To induce expression of the respective SPPL2 protease, cells 
were incubated with 1 µg/ ml doxycycline added to an otherwise antibiotic free medium, 




at least 24 h before transient transfection of SPPL2 substrates. Transient transfection of 
cells was carried out using Lipofectamine 2000 and OpitMEM according to the manu-       
facturer’s instructions. Cells were transfected with 2µg of the according cDNA at a density 
of 60 - 80 %.  
 
3.2.2.2. INHIBITOR/ ACTIVATOR TREATMENT 
To inhibit SPPL2 activity cells were treated with a final concentration of 30-50 µM 
(Z-LL)2-ketone. Treatment with 5 µM of GI + 1 µM of BMS-561395 or 50 µM TAPI was           
applied to inhibit ADAM10/17 enzymatic activity. Inhibitors were added directly after     
transient transfection of the cells. Treatment lasted up to 24 h after transfection. DMSO 
was added to the untreated control cells in equal volumes as the respective inhibitor. To 
activate ADAM17 activity, cells were treated 4 h before collection with 1 µM PMA.  
 
3.2.2.3. GENERATION OF SPPL2A/B KNOCKOUT HEK293 USING CRISPR/ CAS9 
Depletion of SPPL2a and/ or SPPL2b was performed according to the protocol of 
Ran et al. in T-RexTM 293 HEK (TR) cells (Ran et al., 2013). Commercially available guide 
RNAs (Sigma Aldrich) were used for targeting the SPPL2a or SPPL2b gene. For SPPL2a, a 
human GFP-tagged guide RNA binding to exon 1 was used. Studies of SPPL2a-deficient 
patients showed that disruption of exon 1 depletes protein expression completely 
(Schneppenheim et al., 2014). SPPL2b GFP-tagged guide RNA was chosen to bind to exon 
4 to target all different splice variants. SPPL2a/b double knockout was achieved by trans-
fecting validated TR SPPL2b knockout clones with SPPL2a guide RNA. 
24 h after transfection, GFP expression was controlled using a LSM 710 Zeiss          
Observer Z.1 confocal microscope. 48 h after transfection cells were submitted to FACS 
based single cell sorting and sorted for the GFP signal. The sorting was carried out at the 
sorting facility of the Institute for Cardiovascular Prevention (IPEK, Munich, DE) with a BD 
FACSAria™III. The cells were sorted into flat bottom 96-well plates. After two weeks,           
colonies were progressively transferred into larger plates. Clones were subsequently 
washed with PBS, centrifuged at 1 200 g and frozen at -80°C until further use. 
 
 




3.2.2.4. VALIDATION OF KNOCKOUT BY PCR AND WESTERN BLOTTING 
Knockout of SPPL2a was validated on protein level using Western Blot (WB)          
analysis. Only clones with undetectable levels of SPPL2a were subjected to genomic DNA 
(gDNA) analysis. Knockout of SPPL2b could not be validated via WB due to inefficient         
antibody detection, so all clones were analysed using PCR. 
gDNA was extracted by adding 500 µl of gDNA Lysis buffer to the cells and              
subsequent incubation at -80°C for 1 h. Then, 1.5 ml gDNA precipitation buffer was added 
and samples were incubated for 30 min at RT. Samples were centrifuged at 17 000 g for 
15 min at 4°C and washed with 1 ml 70 % ethanol. After an additional centrifugation step, 
the pellet was dried and resuspended in 100 µl of TE buffer. 1 µl of DNA was subjected to 
PCR amplification. As a control, gDNA from non-modified TR cells was used.  
In order to ensure specific amplification, nested PCR was performed with two sets 
of primers for each gRNA. The first primer pair amplified a region of 700 - 1 000 bp, while 
the second primer pair amplified a region of 200-400 bp within the first region (Table 3.22). 
PCR samples from the second PCR were run on an 1.5 % agarose gel in TBE. After               
confirming a single band on the agarose gel, samples were denatured and reannealed 
either with themselves or in combination with the wt DNA isolated from control HEK293 
cells. Composition of the PCR mix and PCR program are listed in Table 3.23 and Table 3.24 
respectively. 
 
Table 3.22 Primers used for nested PCR 
1st SPPL2a 
Primer fw: AGTGAGCAACTATCGAGAAG 
Primer rv: AGCCGGAAAGCGACA  
2nd SPPL2a 
Primer fw: GCGAGGAGTAGGGGAAG 
Primer rv: GGGTTTCCGCATCTTACG  
1st SPPL2b 
Primer fw: AGAGTGCCATCCCTGTC 
Primer rv: GAGGCAGGCGTCAGA 
2nd SPPL2b 
Primer fw: GCGAATGGGCACAGAG 











After reannealing, 4 µl DNA loading buffer were added to 15 µl of sample and 
loaded on a DNA acrylamide gel (Table 3.15). The gels were run for 4-5 h in 1 x TBE at 30 V 
and subsequently stained with 0.2 µg/ml GelRed for 30 min in TBE. 1 kb Plus DNA ladder 
was used to assess the length of the DNA fragment under UV light.  
Clones with homozygous dsDNA showed only one band, whereas mismatched 
DNA ran as multiple bands. Clones that differed in their band pattern from the wt control 
but were homozygous were selected for sequencing (Section 3.2.1.6). For each single 
knockout and for the SPPL2a/ b double knockout one clone with an early stop codon was 




3.2.3. BIOCHEMICAL METHODS 
3.2.3.1. PROTEIN EXTRACTION FROM CELLS (MEMBRANES/ LYSATE) 
Depending on the location of the proteins, two different methods of extraction 
were used. The first method extracted and enriched for proteins in the cellular mem-
branes. For this, cells were washed with PBS and harvested on ice before mixing and lysis 
for 10 min in ice-cold hypoton buffer supplemented with protease inhibitor mix (1:500) 
followed by a homogenising using a 23 G needle. Membranes were isolated by two          
centrifugation steps, first for 5 min at 16 000 g to remove cell debris and second for 45 min 
at 17 000 g to pellet the membranes. The pellet was resuspended in basic buffer and      
samples were incubated at 37°C for indicated times to allow proteolysis. Subsequently 
proteins were precipitated with chloroform/ methanol (2:1) and, most commonly, re-       
suspended in 20 µl 2 x sample buffer.  
Table 3.23 Denature/ reannealing PCR program 
Temperature Time 
95°C 2 min 
-2°C/ s to 85°C - 
-0.1°C/ s to 25°C - 
16°C hold 
 
Table 3.24 Denaturing and reannealing sample composition 
Self-reannealing Reannealing with WT 
2 µl 2nd PCR product 1.5 µl 2nd PCR product  
+ 1.5 µl TR wt PCR 
2 µl T7 buffer 2 µl T7 buffer 
16 µl H2O 15 µl H2O 
 
 




The second method was used to isolate proteins and peptides from total cell           
lysates. Cells were shortly mixed and lysed for 20 min in ice-cold STEN lysis buffer. Cell 
debris was removed by centrifugation for 20 min at 16 000 g. Anti-Flag®M2 affinity gel 
(Sigma Aldrich) was used to precipitate all soluble protein fragments. After overnight         
incubation on a shaker, beads were washed 3 x with STEN buffer. 10 µl 5 x sample buffer 
was added and all probes were incubated 10 min at 95°C before subjection to gel electro-
phoresis.  
For detection of palmitoylated proteins cell membrane were isolated as described 
above until the second centrifugation step. Then the pellet was resuspended in quenching 
buffer and incubated for 2 min at 40°C to block free thiol groups. Afterwards samples were 
precipitated with CHCl3/ MeOH as described above. After centrifugation, the pellet was 
resuspended in 400 µl binding buffer and split into two. One half was treated with 0.5 M 
NH2OH to remove the palmitic acid from the protein and the other half was treated with 
0.5 M Tris-HCl. 15 µl Thiopropyl-Sepharose®6B was added and samples were incubated 
overnight at 4°C. After 5 min centrifugation at 1 200 g at 4°C the supernatant was trans-
ferred into a new tube and residual protein was immunoprecipitated with anti-Flag®M2 
agarose affinity gel. Immunoprecipitated samples were washed 3 x with 1 x STEN. 10 µl 5 x 
sample buffer was added and probes were incubated 10 min at 95°C before gel electro-
phoresis. 
 
3.2.3.2. ISOLATION OF PEPTIDES FROM MEDIA 
Proteins that were secreted into the conditioned cell culture media were immuno-
precipitated using the V5 polyclonal antibody with protein A sepharose beads, the V5        
monoclonal antibody (Table 3.10) with protein G sepharose beads or anti-Flag®M2          
agarose affinity gel. After overnight incubation, samples were washed 3 x with STEN 
buffer, 10 µl 5 x sample buffer was added and probes were incubated for 10 min at 95°C.  
For samples that released high amounts of peptide into the media, 5 x SB buffer 
was directly added 1:5 to the conditioned media. The samples were denatured at 95°C for 
10 min before gel electrophoresis. 
 
 




3.2.3.3. ELECTROPHORESIS/ IMMUNOBLOTTING 
For separation of proteins smaller than 16 kDa a modified Tris-tricine gel was used 
(Table 3.14) (Fluhrer et al., 2006). Larger proteins were separated on 12 % Tris-glycine gel 
(Table 3.13). The gels were run at 70 V until the samples were concentrated at the border 
of stacking and separating gel and then run at 120 V. The See Blue Plus Protein ladder was 
used for estimating the molecular weight of the proteins.  
Samples were blotted on isopropanol activated polyvinylidene fluoride (PVDF) 
membranes or – for cleavage products tagged with a V5-tag and smaller than 6 kDa - on 
nitrocellulose membranes by wet transfer for 1 h at 400 mAmp/ chamber. Blocking of     
unspecific antibody binding was performed by using Tropix® I BlockTM solution for 1 h at 
RT. The membranes were incubated with primary antibodies (Table 3.10) overnight at 4°C 
and washed 3 x with TBS-T before incubation for 1 h at RT with secondary HRP coupled 
antibodies (Table 3.11). After additional three washing steps, proteins were incubated with 
Pierce™ ECL Western Blotting Substrate or Westar Antares for increased sensitivity. The 
chemiluminescence was detected on X-ray films (Table 3.1). To digitalize the films, they 
were scanned with an Epson Perfection V700 Photo scanner. The brightness was adjusted 
using Photoshop. For quantification of the protein signal, the chemiluminescence was    
detected with a CCD camera-based imaging system (Table 3.1) and analysed using the 
Multi Gauge software (Table 3.2).  
 
3.2.3.4. FLOW CYTOMETRY 
To detect proteins on the cell surface, samples were subjected to flow cytometry. 
Cells were washed with PBS and harvested on ice. The cell count was adjusted to 1-5 x 106 
cell/ ml in FACS buffer. 100 µl of cell suspension were transferred into a new reaction tube 
and centrifuged at 400 g for 5 min. The cell pellet was resuspended in PBS supplemented 
with 3 % FCS and V5 monoclonal antibody (Table 3.10). Controls of untransfected cells and 
transfected cells without primary antibody staining were included in the analysis. The 
samples were incubated for 30 min at RT or on ice. Afterwards samples were washed 3 x 
with PBS and stained with anti-mouse Alexa 488 (Table 3.11). Samples were again                
incubated for 30 min on ice or RT in the dark and afterwards washed 3 x with PBS before 
flow cytometry. Viable cells were gated for side scatter (SSC-A) vs. front scatter (FSC-A). 
These cells were then gated for single cells by side scatter-width (SSC-W) vs. side scatter-




height (SSC-H) and front scatter-width (FSC-W) vs. front scatter-height (FSC-H). GFP          
positive cells were gated from this population. 
 
3.2.3.5. MASS SPECTROMETRY WITH MALDI-TOF 
To identify the exact length of peptides that resulted from protease cleavage,     
samples were analysed with matrix-assisted laser desorption/ionisation – time of flight 
(MALDI-TOF) mass spectrometry. Secreted peptides from media were precipitated as      
described above (Section 3.2.3.2). Membrane proteins were isolated as described in        
section 3.2.3.1 and solubilized in SPP stock buffer supplemented with 2 % of DDM and 
incubated 30 min on ice before centrifugation at 16 000 g at 4°C. Solubilized peptides were 
immunoprecipitated using anti-Flag®M2 agarose affinity gel. All samples were washed 3 x 
with mass spec washing buffer and de-salted by two washes with dH2O.  
For the analysis of peptides generated from Flag TNFα FlagTEV V5, the fragments 
were immunoprecipitated with anti-Flag®M2 agarose affinity gel overnight and sub-        
sequently eluted from the beads with 100 mM glycine pH 2.5. Cleavage at the TEV site was 
facilitated with a commercially available kit according to the manufacture’s instructions 
(Table 3.6). Resulting peptides were precipitated with the anti-Flag®M2 agarose affinity 
gel for 1 h at RT followed by 3 washes with mass spec washing buffer and 2 washes with 
dH2O. 
Samples were subjected to analysis by mass spectrometry using a α-cyano-4-         
hydroxycinnamic acid matrix mixed 1:1 with acetonitrile and 0,6 % TFA. Three times 0,4 µl 
of sample were spotted on a 384-spot plate (Applied Biosystems) and left to dry at RT. 
Mass spectra were recorded in the linear mode and analysed with the Data Explorer         
Software (Table 3.2). Intensities were normalised to the internal maximum.  
 
 
3.2.4. STATISTICAL ANALYSIS 
Quantifications and differences in surface expression were statistically analysed 
with GraphPad (Table 3.2). If not stated differently, at least three biological replicates were 
performed for the statistical analysis. To enable comparison of increased vs. decreased 




samples, measured values were transformed to log2 and the wt samples was set to 0. For 
the comparison of two groups, an unpaired, two-tailed student’s t-test was applied if 
groups comprised equal sample numbers and a Welch’s test in case of unequal group 
size. For comparison of more than two groups, a two-way ANOVA test was used.                           
Significance is indicated in the respective figure legend. 
  








4.1. GENERATION OF SPPL2A/B-DEFICIENT CELL LINES 
In order to investigate the proteolytic mechanism of human SPPL2a and SPPL2b, 
the proteases were ectopically expressed in T-RexTM-293 (HEK293) cells (Fluhrer et al., 
2008). As control, single and double SPPL2a/b-deficient cell lines were generated using 
the CRISPR/ Cas9 genome-editing technique. With commercially available guide RNAs 
(gRNA), the SPPL2a and SPPL2b genes were targeted, which resulted in several homo-
zygous clones. Due to the deletion of several nucleotides, frameshift mutations occurred. 
However, not all of them induced a premature stop codon. An SPPL2a clone with a              
deletion of 4 bp generating a stop codon at position 20 was chosen for further analysis 
(Figure 4.1). In this clone no SPPL2a protein was detectable (Figure 4.2B). To target all 
splice variants of SPPL2b a gRNA was chosen that induced a frameshift by deleting 11 bp 
generating a stop codon at position 135 (Figure 4.1). Protein levels of SPPL2b could not be 
tested, as no antibodies detecting endogenous SPPL2b in HEK293 cells are available. 
 
Figure 4.1 Genomic sequences of SPPL2a and SPPL2b-deficient cell lines. SPPL2 guide RNA (gRNA) generated frameshift 
mutations leading to a premature stop codon. The SPPL2a protein was translated up to amino acid 20, and SPPL2b protein 
up to amino acid 135 (Spitz et al., 2020). 
 
In addition to single knockout clones, a cell line deficient for SPPL2a and SPPL2b 
was generated. To this end, the previously established SPPL2b-deficient clone was trans-
fected with SPPL2a gRNA. This resulted in the deletion of 17 bp and a premature stop 
codon at position 40 of the SPPL2a protein (Figure 4.2A). The double deficient clone was 






Figure 4.2 Characterisation of the SPPL2a/b-deficient cell line. (A) To generate an SPPL2a/b-deficient cell line, SPPL2a 
guide RNA was applied to SPPL2b-deficient cells. SPPL2a guide RNA generated a frameshift resulting in a premature stop 
codon at amino acid 40. (B) Expression of SPPL2a in CRISPR/Cas9 treated cell lines. Endogenous (en.) SPPL2a levels were 
not affected in SPPL2b knockout cells, while no SPPL2a was detectable in the single SPPL2a and the double SPPL2a/b-






4.2.1. SPPL2A ACTS AS A NON-CANONICAL SHEDDASE 
Among the above-mentioned substrates, TNFα has the most prominent functions 
throughout the human body and is well characterised. When TNFα is transported to the 
cell surface, it is usually shedded by ADAM10 or ADAM17 to release the majority of its ECD 
(McGeehan et al., 1994). T-Rex™-293 (HEK293) cells with endogenous expression of 
ADAM17, SPPL2a and/ or SPPL2b were transiently transfected with C-terminally V5-tagged 
TNFα. The ECD released upon shedding is detected at about 22kDa (sTNFα) (Figure 1.3). 
However, a second, slightly larger fragment was isolated along with the ADAM-cleaved 
ECD (sTNFα) in cells with endogenous SPPL2a expression (sTNFα(L2)). As ADAM10/17     
levels were not changed it seems that TNFα is shedded by another protease. Based on 
the fact that the larger fragment was not detectable in SPPL2a-deficient cells irrespectively 
of SPPL2b expression, it seems that SPPL2a is able to cleave TNFα full-length (FL) directly 
without a preceding shedding by ADAM17. According to the definition of shedding          











To further support the hypothesis of TNFα non-canonical shedding by SPPL2a and 
to exclude that sTNFα(L2) production by SPPL2b was not just missed due to low endo-
genous SPPL2b expression, SPPL2a or SPPL2b were ectopically expressed in HEK293 cells 
that additionally express endogenous SPPL2a or SPPL2b. While ectopic SPPL2a                      
expression significantly increased sTNFα(L2) secretion compared to control cells, ectopic 
expression of SPPL2b did not (Figure 4.4). This supports that SPPL2a is capable of non-
canonical shedding, while SPPL2b hardly accepts TNFα FL as substrate. 
 
Figure 4.4 sTNFα(L2) secretion is increased upon ectopic SPPL2a expression (ex.). Soluble TNFα(L2) was directly             
analysed from conditioned media, quantified relative to sTNFα from Western Blots (WB) by densitometric analysis and 
normalized to untreated controls, n=3. Data are represented as mean +/- SD. Statistical significance was calculated applying 
an unpaired, two-sided Student‘s t-test. *: p<0.05. The WB shows one representative experiment. TNFα FL was used as 
transfection control (Spitz et al., 2020). 
 
Whereas ectopic expression of SPPL2a enhanced non-canonical shedding of TNFα, 
treatment with (Z-LL)2-ketone, an SPP/ SPPL specific inhibitor, significantly reduced              
generation of sTNFα(L2). Canonical shedding by ADAM was unaffected by this treatment 
(Figure 4.5). Even though ADAM17 is considered the major sheddase for TNFα, other        
ADAMs are able to partake in the release of the ECD (Zheng et al., 2004). Therefore, cells 
were treated with ADAM10 and ADAM17-specific inhibitors (AI), which resulted in a             
significant reduction of sTNFα, while sTNFα(L2) remained unchanged compared to the 
Figure 4.3 Non-canonical TNFα shedding by endogenous SPPL2a.                
Soluble TNFα ECDs were isolated from conditioned media of HEK293 cell 
lines expressing endogenous (en.) levels of SPPL2a, SPPL2b, both or none 
(ko). The V5-mono antibody was used for visualisation. Detection of TNFα 
full-length (FL) in the membranes served as transfection control. 
sTNFα(L2): TNFα ECD secreted by SPPL2-mediated shedding; sTNFα: 





respective non-treated cells (Figure 4.5). Treatment with the ADAM activator, phorbol 12-
myristate 13-acetate (PMA) stimulates ADAM17 activity and thus, increased canonical 
shedding and sTNFα secretion, but not sTNFα(L2) release (Figure 4.5). This demonstrated 
that sTNFα(L2) secretion is independent of sTNFα secretion, suggesting that ADAM10/17 
and SPPL2a are not competing for cleavage of TNFα. 
 
Figure 4.5 Canonical and non-canonical shedding of TNFα are two independent processes. TNFα ECDs from condi-
tioned media of the indicated HEK293 cell lines were isolated and detected with the V5-mono antibody. Cells were treated 
with either 50µM Z-LL2-ketone (+ (ZLL)2) to inhibit SPPL2 catalytic activity, with 5µM GI 254023X and 1µM BMS-561395 (+ AI) 
to inhibit ADAM proteases or 1µM phorbol 12-myristate 13-acetate (PMA) to activate ADAM17 cleavage. Controls were 
treated with DMSO (-). The expression of TNFα FL was used as transfection control. Quantification of sTNFα(L2) was calcu-
lated relative to intracellular TNFα FL by densitometric analysis from WB and normalized to untreated controls; n=3. Data 
are represented as mean +/- SD. Statistical significance was calculated applying a two-way ANOVA, *: p<0.05. (Experiments 
depicted in this figure were conducted by Christine Schlosser.) (Spitz et al., 2020) 
 
 
4.2.2. IDENTIFICATION OF SPPL2A CLEAVAGE SITES IN TNFα  
A previous study has identified SPPL2b cleavage sites in TNFα in the context of RIP 
(Fluhrer et al., 2006). To investigate whether SPPL2a cleavage sites differ from that of 
SPPL2b, SPPL2a-mediated cleavage of truncated TNFα was analysed by MALDI-TOF mass 
spectrometry. To detect C-peptides that are released by SPPL2 proteases in context of 
RIP, a short TNFα protein that carried a C-terminal Flag-tag stabilized by alanine and         
proline (TNFα NTF-FlagAP) was used. Analysis of TNFα C-peptides released by SPPL2b 
cleavage confirmed the previously described major cleavage sites at L50 and H52 (Figure 
4.6). Moreover, two smaller C-peptides were identified resulting from cleavages at V55 
and R60. Surprisingly, these cleavages occurred in the JMD, outside of the membrane. Due 





study. Essentially, SPPL2a secreted the same peptides, although the shorter C-peptide 
species were less abundant (Figure 4.6). Untransfected cells were included to control for 
background signals. Table 4.1 lists the exact masses of the measured and calculated      
peptides.  
 
Figure 4.6 C-terminal cleavage sites in TNFα NTF. Mass spectrometric analysis of TNFα C-peptides generated by SPPL2a 
or SPPL2b, respectively. Numbers indicate the position of the most N-terminal amino acid of the respective cleavage prod-
uct. Media of untransfected controls were included to decipher unspecific peaks. Cleavage sites are indicated in the TNFα 
sequence with arrows. The TMD is indicated in grey and the FlagAP-tag in green (Spitz et al., 2020). 
 
Table 4.1 Masses of TNFα C-peptides measured by MALDI-TOF compared to calculated masses. Measured values are                 





Measured mass (in Da) 
 
SPPL2a SPPL2b 
60 3045 3044 3041 
55 3540 3539 3537 
52 3881 3881 3879 
51 3987 3993 3982 
50 4107 4107 4107 
 
To solidify whether SPPL2a cleavage sites in the context of non-canonical shedding 
and RIP differed, an internal Flag-tag followed by a TEV cleavage site was inserted into 
TNFα FL (Figure 4.7A). The TEV cleavage site enabled removal of the large TNFα ECD just 
before subjecting the samples to mass spectrometry and thus allowed detection of the 





acids C-terminal of the ADAM cleavage site to ensure also detection of peptides generated 
by canonical shedding.  
It was confirmed that TNFα FlagTEV was similarly processed as TNFα wt (Figure 
4.7B). Both proteins were shedded by ADAM10/17 and SPPL2a resulting in the release of 
sTNFα and sTNFα(L2) respectively. Due to the insertion of the Flag-tag and the TEV site, 
TNFα FlagTEV, as well as its soluble peptides, are slightly larger. The NTF, which results 
from canonical shedding, was detectable and further processed into TNFα ICDs (TICD) in 
both TNFα proteins. Intracellular sTNFα/ sTNFα(L2) has continuously been observed in 
other experiments (data not shown). Here it was visualised only in the TNFα FlagTEV trans-
fected cells due to the internal Flag-tag. Using flow cytometry, it was confirmed that TNFα 
FlagTEV was expressed on the cell surface in equal amounts as TNFα wt (Figure 4.7C).  
 
Figure 4.7 Processing of TNFα FlagTEV. (A) Schematic representation of TNFα FlagTEV. (B) Processing of TNFα wt and 
TNFα FlagTEV is essentially similar. Membranes of HEK 293 cells co-expressing (ex.) SPPL2a and the indicated TNFα variant 
were analysed on WB using the monoclonal FlagM2 antibody to detect intracellular TNFα N-terminal fragment (NTF) and 
TNFα intracellular domain (TICD). The respective conditioned media were visualised with the monoclonal V5 antibody to 
detect secreted TNFα ECD variants. (C) Surface expression of TNFα wt and TNFα FlagTEV is similar. Cells transiently trans-
fected with the respective TNFα variants were surface stained with V5 mono antibody and then analysed by flow cytometry. 
GFP positive cells were gated from a single cell population. wt n=8, TEV n=3. Data are represented as mean +/- SD (Spitz et 
al., 2020). 
 
To analyse the cleavage sites of SPPL2a in TNFα FlagTEV, cleavage products were 
isolated from conditioned media by immunoprecipitation utilizing the Flag-tag. The          
isolated protein fragments were enzymatically digested with TEV-protease and peptide 
fragments containing a Flag-tag were again immunoprecipitated and subjected to MALDI-
TOF mass spectrometry. The results revealed two groups of peptides, one reflecting   





peptides one matching the known ADAM10/17 cleavage sites at position V77 (Figure 4.8) 
(Mohan et al., 2002). Other minor cleavage sites were detected at L73, L79 and D66. To 
ensure the larger peptides were indeed generated by SPPL2a cleavage, cells were treated 
with the SPP/SPPL inhibitor (Z-LL)2-ketone prior to analysis. This treatment abolished the 
secretion of all peptides ranging from 4 - 6 kDa, while the secretion of the smaller peptides 
resulting from ADAM10/17 cleavage remained unchanged (Figure 4.8). This indicates that 
non-canonical shedding by SPPL2a occurred at the same positions as cleavage in the       
context of RIP and thus demonstrates that shortened TNFα variants display a valid         
technique of investigating the C-terminal cleavage sites generated by SPPL2 proteases. 
Interestingly however, the most dominant cleavage site of SPPL2a-mediated non-                
canonical shedding mapped to cleavage at V55, while the dominant cleavage sites of RIP-
related processing were detected at L50 and H52 (Figure 4.6). Moreover, this result              
indicates that SPPL2 proteases are able to cleave TNFα at the luminal-membrane border. 
However, even though unlikely, it cannot be fully excluded that an unrelated exopeptidase 
present in the conditioned media partakes in the cleavage of TNFα or the released           
peptides. Table 4.2 lists the exact masses of the measured and calculated peptides.  
 
Figure 4.8 C-terminal cleavage sites in TNFα FlagTEV. HEK293 cells co-expressing (ex.) SPPL2a and TNFα FlagTEV were 
treated with 50µM (Z-LL)2 or DMSO and secreted ECDs were isolated. Numbers indicate the position of the most N-terminal 
amino acid of the respective cleavage product. Peaks from 66-77 reflect cleavage of TNFα by ADAM proteases. Peaks from 
50-55 reflect cleavage of TNFα by SPPL2a. x marks peak of unknown identity. Cleavage sites are indicated in the TNFα 





Table 4.2 Masses of C-terminally cleaved TNFα FlagTEV products measured by MALDI-TOF compared to calculated 







77 2237 2233 
73 2620 2616 
69 3031 3027 
66 3346 3343 
55 4595 4594 
52 4937 4936 
50 5163 5163 
 
 
4.2.3. SHEDDING OF MOUSE TNFα  
So far, non-canonical shedding of TNFα was observed only in vitro. However, sTNFα 
is a strong upstream regulator of many cellular signalling pathways (Tseng et al., 2018). 
To establish a physiological relevance of non-canonical shedding, mouse BMDCs were  
isolated and analysed for sTNFα and sTNFα(L2) secretion.  
While in previous experiments, sTNFα was detected via a C-terminal V5-tag, endo-
genous mouse TNFα antibodies recognizing both sTNFα and sTNFα(L2) had to be                 
established. Several commercially available antibodies against mouse sTNFα were tested 
with the Abcam antibody ab9739 recognising both soluble TNFα peptides in vitro the best. 
However, comparing in vitro shedding from ectopically expressed mouse and human 
TNFα, already revealed a different shedding process of mouse TNFα (Figure 4.9A).              
Detection of soluble peptides with ab9739 resulted in the identification of several           
mouse TNFα peptides (#1-3, Figure 4.9). In addition to this, the detection of C-terminally 
V5-tagged mouse TNFα with the V5 mono antibody was inefficient compared to human 
TNFα. It can only be speculated that mouse TNFα ECD might fold differently impeding 
accessibility of the tag for the antibody. Moreover, treatment with the SPPL-inhibitor did 
not diminish the release of any of the soluble peptides (+(Z-LL)2 Figure 4.9A) and they were 
also detectable in SPPL2a/b-deficient cells. However, fragments were absent when ADAM 





processed differently. Even though several soluble ECDs are released, they all seemed to 
originate from canonical shedding by ADAM proteases.  
 
Figure 4.9 Shedding of mouse TNFα is different from human TNFα. (A) ECDs of human (hTNFα) and mouse TNFα 
(mTNFα) were isolated from HEK293 cells co-expressing (ex.) human SPPL2a. Cells were treated with either 5µM GI 254023X 
and 1µM BMS-561395 (AI), 50µM (ZLL)2, 1µM PMA, or DMSO as control. Samples were analysed with the V5-mono antibody 
and with an antibody directed against mouse TNFα ECD (ab9739). sTNFα(L2) is indicated with red arrows. (B) The ECDs of 
TNFα were isolated from conditioned media of cells co-expressing SPPL2a or cells deficient for SPPL2a/b (ko). Cells were 
treated with either 50µM (ZLL)2 or 1µM PMA and detected as in (A). 
 
These results were confirmed by experiments in BMDCs derived from wt and 
SPPL2a-deficient mice. Breeding of the mice, as well as isolation of the cells and treatment 
with or without LPS and ADAM inhibitors, was conducted by collaborators at Dr. Bernd 
Schröder’s Lab. Conditioned media was analysed for the secretion of soluble TNFα          
peptides. After 24h of LPS stimulation, which induces the secretion of sTNFα, several       
soluble fragments were detectable (Figure 4.10). However, the secretion of all fragments 
was reduced when the cells were treated with ADAM inhibitors (Figure 4.10; + AI) and no 
fragment was notably absent in SPPL2a-deficient mice. These results indicate that SPPL2a 
does not shed mouse TNFα and that processing of mouse TNFα is generally different    
compared to human TNFα. 
 
Figure 4.10 TNFα shedding in mice is only facilitated by ADAM proteases. BMDCs of wt (mSPPL2a wt) or SPPL2a-defi-
cient (mSPPL2a ko) mice were isolated and treated for the indicated period with LPS and 20µM marimastat (AI) or DMSO as 





4.2.4. NON-CANONICAL TNFα SHEDDING CAN BE MODULATED BY TM MUTATIONS 
Earlier experiments suggested that cleavage capacity of aspartyl-IMPs is affected 
by the conformational flexibility of the substrate TMD (Fluhrer et al., 2012, Götz et al., 
2019, Langosch et al., 2015, Langosch and Steiner, 2017). The domains of the protein that 
are embedded in the lipid membrane are usually compacted as α–helix. Amino acids that 
can affect helix properties in TMDs are asparagine, cysteine, glycine, histidine, proline and 
serine (Li and Deber, 1994). Amino acids with polar side chains are able to form stabilizing 
hydrogen bonds with upstream residues (Gray and Matthews, 1984, Scharnagl et al., 
2014), while glycine facilitates local helix bending and changes the TMD dynamics (Högel 
et al., 2018). The positive charge of histidine influences back-bone stability, thus disturbing 
the helix (Armstrong and Baldwin, 1993). Analysis of the TNFα TMD revealed five of these 
structurally important residues: S34, S37, G43, C49 and H52. Each residue was substituted 
by alanine, leucine or proline to specifically alter the TMD dynamics. Alanine but even 
more leucine have stabilising effects by enabling a rigid helical structure (Quint et al., 
2010). In contrast, proline is a strong helix-destabilizer enhancing flexibility of the                      
substrate’s TMD (Cordes et al., 2002). All TNFα mutants were co-expressed at similar 
amounts with SPPL2a in HEK293 cells (Figure 4.11A). Substitutions of S34, S37, G43 and 
C49 by proline significantly enhanced non-canonical TNFα shedding, while an H52P         
mutation had no effect. On the contrary, leucine substitutions in all positions decreased 
non-canonical TNFα shedding, with C49L and H52L having the strongest effect (Figure 
4.11C). Alanine substitutions in all positions had only a minor impact on non-canonical 
shedding. Interestingly, substitution with a proline at G43 had the most pronounced effect 
of all proline variants on non-canonical shedding, but substitution with leucine in this        
position barely reduced non-canonical shedding. However, additional substitutions of the 
flanking alanines with leucines (AGA42,43,44LLL) resulted in an almost complete loss of 






Figure 4.11 Modulating non-canonical TNFα shedding by mutations in the TMD. In the TMD of TNFα, leucine substitu-
tions reduce and proline mutations increase non-canonical shedding significantly. (A) Secreted TNFα from media of cells 
co-expressing (ex.) SPPL2a and the respective TNFα mutant was analysed using the V5-mono antibody. Detection of TNFα 
FL from membranes served as transfection and calnexin as loading control. (B) Representative WB of the AGA/LLL mutant.            
(C) Quantification of (A) and (B). sTNFα(L2) was quantified relative to sTNFα from respective WB by densiometric analysis 
and normalized to TNFα wt, n=3. Data are represented as mean +/- SD. Statistical significance was calculated applying an 
unpaired two-sided Student’s t-test. *: p<0.05 (Spitz et al., 2020). 
 
Although SPPL2b did not act as a non-canonical sheddase on TNFα wt (Figure 4.4), 
proline substitutions at positions S34, S37 and again most pronounced at position G43 
allowed non-canonical shedding also by SPPL2b (Figure 4.12).  
These data demonstrate that the dynamics of the TNFα TMD affect its non-               
canonical shedding. While increased dynamics and less contact with neighbouring                
residues induced by proline enhanced non-canonical shedding, tight packing of TMD     
residues caused by leucines had the opposite effect. Interestingly, leucine substitutions 
had the strongest impact in the C-terminal part of the TMD, whereas the increase of non-






Figure 4.12 Non-canonical shedding of TNFα mutants by SPPL2b. Mutations in the TMD of TNFα induce shedding by 
SPPL2b. In the media of cells co-expressing (ex.) SPPL2b and the respective TNFα variant secreted TNFα was detected with 
the V5-mono antibody. Detection of TNFα FL in the membranes served as transfection and calnexin as loading control (Spitz 
et al., 2020).  
 
To elucidate whether increased non-canonical shedding induced by proline           
substitutions also altered the SPPL2a cleavage sites, TNFα variants were analysed by 
mass-spectrometry. Proline substitutions that significantly increased non-canonical        
shedding (S34P, S37P, G43P and C49P) did not change SPPL2a cleavage sites (Figure 4.13). 
Interestingly, H52P substitution, which had no effect on non-canonical shedding, resulted 
in an almost complete loss of the major cleavages close to the substitution site. In             
contrast, exchange at position C49, which also locates close to an SPPL2a cleavage site, 
did not result in loss of any specific cleavage product. Proline substitutions at S34 and S37 
relatively increased cleavage at H52 and G43P cleavage at R60. The triple leucine               
substitution enabled an additional cleavage site at I56, but overall position L50 remained 
the major cleavage site.  
These data may indicate that cleavage by SPPL2a is to a certain degree dependent 
on primary sequence requirements as the cleavage at H52 is disrupted by a proline                
substitution. However, the secondary structure and charges of amino acids close to the 
cleavage site seem to be more important since amino acids that introduced disruptions 
or tightened the TMD helix as well as the change of the charges significantly changed          
cleavage efficiency. By altering the TMD structure substitutions were able to exert effects 
on cleavage even if not placed at a cleavage site directly. Table 4.3 lists the exact masses 






Figure 4.13 C-terminal cleavage sites in TNFα TMD mutants largely remain unchanged. Secreted ECD from HEK293 
cells co-expressing (ex.) SPPL2a and the indicated TNFα variants were isolated with the FlagM2 antibody. Numbers indicate 
the position of the most N-terminal amino acid of the respective cleavage product. Cleavage sites are indicated with arrows. 
Substituted amino acids are indicated in pink, the TMD in grey and the FlagAP-tag in green (Spitz et al., 2020). 
 
Table 4.3 Masses of TNFα variant C-peptides measured by MALDI-TOF compared to calculated masses. Measured 
values are normalised to the calculated mass of the peptide resulting from cleavage at position 50. 







60 3045 3044 
55 3540 3539 
52 3881 3881 
51 3994 3994 
50 4107 4107 
S37P 
60 3045 3044 
55 3540 3539 






4.2.4.1. SUBSTRATES WITH NATURALLY OCCURRING PROLINE IN THE TMD 
Since proline substitutions drastically increased non-canonical TNFα shedding to 
levels comparable with canonical shedding, it is tempting to speculate whether further 
substrates exist that are efficiently shed by SPPL2a. The previous experiments showed 
that a proline especially in the N-terminal half of the TNFα TMD improved non-canonical 
shedding. Thus, TNFα characteristics such as the length of the TMD of around 22 amino 
acids, a cysteine close to the TMD/ ICD border plus at least one proline in the N-terminal 
half of the TMD provided the basis for a tailored prediction algorithm identifying potential 
substrates. The analysis, performed by Stephan Beilmann, resulted in 26 type II TM         
proteins matching these criteria. Due to their localisation and function, five potential        
substrates, SACA3, ENTPD6, GOLM1, TNFSF15 and NKG2D were chosen for a more in-
depth investigation (Table 4.4). The cDNAs were fused to an N-terminal Flag-tag and a        




51 3994 3993 
50 4107 4107 
G43P 
60 3045 3045 
55 3540 3539 
52 3881 3881 
50 4107 4107 
C49P 
60 3045 3045 
55 3540 3540 
52 3881 3880 
50 4107 4107 
H52P 
60 3045 3045 
55 3540 3540 
50 4067 4067 
AGA/LLL 
60 3045 3041 
56 3441 3435 
55 3540 3537 
52 3881 3880 





Table 4.4 Overview of type II TM proteins with at least one naturally occurring proline in the TMD. Unknown and 
therefore suggested functions are quoted from www.uniprot.org. PM: plasma membrane 






SACA3 WCPAGIMLLALVCLLSCLLPS 25.8 PM of 
sperm 
o Sperm-egg plasma mem-
brane adhesion and       
fusion during fertilization 
o Receptor for the egg      
oligosaccharide residue 
N-acetylglucosamine 
(Mandal et al., 2003) 
ENTPD6 VAKVAYPLGLCVGVFIYVAYI 55.6 PM and 
Golgi 
o Unknown (Support of gly-
cosylation reactions,     
catalyses the hydrolysis 
of extracellular nucleo-
tides) 
GOLM1 SPPLVLAALVACIIVLGFNYWIA 47.7 Golgi o Unknown (Cellular        
response protein to viral 
infection) 
TNFSF15 ALTCCLVLLPFLAGLTTYLLV 30.5 PM / se-
creted 
o Activation of NF-kB.  
o Inhibition of vascular        
endothelial growth and 
angiogenesis (in vitro).  
o Activation of caspases 
and apoptosis (Valatas et 
al., 2019) 
NKG2D PFFFCCFIAVAMGIRFIIMVA 27.6 PM o Immunosurveillance by 
scavenging various          
cellular stress-inducible 
ligands  
o Activation of NK cells, 
leading to cytotoxic          
activity (Lanier, 2015) 
 
Secretion of soluble peptides from the potential substrates was investigated in 
HEK293 cells and HEK293 cells ectopically expressing either SPPL2a or SPPL2b. SACA3, 
ENTPD6 and GOLM1 secreted only a single fragment, which was also detected in 
SPPL2a/b-deficient cells. Since no change in the secretion pattern was detected when 
comparing cells ectopically expressing SPPL2 proteases with cells deficient for them, it 
suggests that non-canonical shedding did not occur in these proteins (Figure 4.14). Since 





canonical vs. non-canonical shedding might have been missed. However, de-glycosylation 
assays did not reveal multiple fragments (data not shown), concluding that a proline        
residue in the N-terminal half of the substrate’s TMD is not the only determinant for non-
canonical shedding by SPPL2a. TNFSF15 ECDs could not be detected at all. Several             
detection methods did not yield any results, which suggests a very rapid degradation of 
the sECD or generally a low expression/ transfection efficiency in HEK293 cells. 
 
Figure 4.14 An N-terminal proline in the substrate’s TMD is not the only determinant for non-canonical shedding 
by SPPL2a. HEK293 cells, cells ectopically expressing (ex.) either SPPL2a or SPPL2b or HEK293 cells deficient for SPPL2a/b 
(ko) were transiently transfected with the indicated proteins. Soluble ECDs of the proteins were detected with the mono-
clonal V5 antibody. Isolation of the FL protein (red arrows) from cell lysates serves as transfection and calnexin as loading 
control. SACA FL was not unambiguously identified and thus is not marked.  
 
 
4.2.5. MODULATION OF SHEDDING BY INSERTION OF NON-SUBSTRATE DOMAINS 
From accompanying studies on biophysical properties of the TNFα TMD, it is known 
that single amino acids influence the dynamics of the TMD even over a certain distance 
from the cleavage sites (Section 4.2.4) (Spitz et al., 2020). The data described above 
demonstrated that proline itself is not sufficient to induce non-canonical shedding in 
type II TM proteins generally. To unravel other important determinants for non-canonical 
shedding subdomains of TNFα were substituted with the corresponding subdomains of 





In the context of Leonie Wittmann’s bachelor thesis, the TMDs of TNFα, Bri2 and 
Bri3 were validated to reassure correct exchange of the protein’s subdomains (Wittmann, 
2017). Molecular dynamics simulations in 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho- 
choline (POPC) bilayers and multiple prediction algorithms confirmed the annotated 
TMDs for TNFα and Bri2. For Bri3 the analysis indicated that the TMD is not correctly        
annotated but rather assigns five amino acids further C-terminal (Figure 4.15). TNFα/Bri3 
chimeras were designed according to these results. However, previously the processing 
and recognition of Bri2 by SPPL2b was investigated via the same method using Bri2/Bri3 
chimeras solely based on the annotated TMDs (Martin et al., 2009). However, comparing 
processing of published Bri2/Bri3 chimeras with TMD-adjusted Bri2/Bri3 chimeras 
showed only very little changes (data not shown).  
 
 
Figure 4.15 Sequence of Bri3. The annotated TMD according to www.uniprot.org is underlined, the newly predicted TMD 
according to Wittmann, 2017 is highlighted in grey.  
 
Bri proteins contain an additional pro-peptide, which is removed by Furin-             
mediated cleavage. As this cleavage does not affect further processing (Section 1.3.3) the 
pro-peptide was removed. Throughout the study, those proteins are referred to as full-
length (FL). 
 Since Bri3 is not canonically shedded by ADAM10/17 and also not cleaved by 
SPPL2a, the TICD and/ or TMD were fused to the Bri3 ECD, to evaluate whether this allows 
non-canonical shedding by SPPL2a (Figure 4.16). To test whether Bri3 exhibits inhibitory 
functions on non-canonical shedding, the Bri3 ICD and/ or TMD were fused to the TNFα 







Figure 4.16 Schematic representation of the TNFα/Bri3 chimeras. TMD, ECD and ICD of TNFα and Bri3 were exchanged. 
The amino acid sequence displays the exact transition between the individual domains. TNFα is depicted in pink, Bri3 in 
purple. The TMDs are indicated in grey. 
 
To allow comparison of processing, surface expression of all chimeras was tested 
via flow cytometry (Figure 4.17). Except 3T3, all chimeras were expressed in similar 
amounts on the cell surface compared to TNFα. 3T3 was expressed less and its detection 






As established in this study, cleavage of the TNFα ECD results in the release of two 
fragments, sTNFα (Figure 4.18; #4) and sTNFα(L2) (Figure 4.18; #1). Chimeras comprising 
Figure 4.17 All TNFα/Bri3 chimeras are 
expressed on the cell surface. HEK293 
cells were transiently transfected with the 
indicated chimera and surface stained 
with the V5-mono antibody prior to analy-
sis by flow cytometry. GFP positive cells 
were gated from a single cell population. 






the Bri3 ECD are not shedded by ADAM10/17. Interestingly, non-canonical shedding by 
SPPL2a was also not detected in these chimeras. Conversely, chimeras with a TNFα ECD 
and a Bri3 TMD were shedded by SPPL2a, ADAM10/17 and even additional intermediate 
fragments were observed (Figure 4.18; #2, #3). Of note, substitution of only the TICD with 
Bri3 (3TT) resulted in reduced non-canonical shedding compared to the control and also 
canonical shedding seemed to be reduced slightly (see also Figure 4.19) whereas                      
substitution of TICD and TNFα TMD (33T) increased non-canonical shedding by SPPL2a 
and even allowed SPPL2b non-canonical shedding.  
 
Figure 4.18 Non-canonical shedding does not occur in chimeras comprising Bri3 ECD. HEK293 cell lines co-expressing 
(ex.) SPPL2a or SPPL2b were transiently transfected with the indicated TNFα/Bri3 chimera. Soluble ECDs were isolated using 
the monoclonal V5 antibody. Detection of the FL proteins isolated from membranes was used as transfection and calnexin 
as loading control.  
 
To ensure secreted fragments were generated by ADAM10/17 and SPPL2a        
cleavage, chimeras were expressed in SPPL2a/b-deficient cells and treated with ADAM         
inhibitors. As expected, canonical shedding of TNFα wt was inhibited by application of 
ADAM inhibitors (+AI) and non-canonical shedding was abolished in SPPL2a/b-deficient 
cells (Figure 4.19). 3TT and T3T chimeras behaved similarly; however, Bri3 ICD and TMD 
seem to exhibit impeding effects on non-canonical shedding when present individually. 
Surprisingly, the substitution of both domains at the same time did not enhance the           
reducing effect of Bri3 but in contrast, increased non-canonical shedding. In addition, 33T 
chimera displayed intermediate fragments (Figure 4.19; #2, #3). Fragment #2 was               
diminished in ADAM inhibitor-treated cells and fragment #3 absent in SPPL2a/b-deficient 
cells. This indicates that the Bri3 TMD can be cleaved by SPPL2a generally and non-                 
canonical shedding sites exist. Furthermore, the presence of Bri3 TMD generates                  
additional canonical cleavage sites for ADAM10/17. However, secretion of sTNFα(L2) was 





additionally secreted intermediate fragments in T3T were also not diminished by the                  
inhibition of ADAM activity or SPPL2a/b deficiency (Figure 4.19; #3). This may suggest that 
an unrelated protease is contributing to the cleavage and the generation of sTNFα(L2) in 
chimeric proteins with a Bri3 TMD (Figure 4.19; #1).  
 
Figure 4.19 Bri3 ICD and TMD display inhibitory effects on non-canonical shedding individually but not synergisti-
cally. Cells ectopically expressing SPPL2a (ex.) and SPPL2a/b-deficient cells (ko) were transfected with the respective 
TNFα/Bri3 chimera. Where indicated, cells were treated with 5µM GI 254023X and 1µM BMS-561395 (+AI) or DMSO as               
control (-). Soluble ECDs were isolated using the monoclonal V5 antibody. Detection of the FL protein isolated from                 
membranes was used as transfection and calnexin as loading control.  
 
4.2.5.1. INSERTION OF A PROLINE INTO TMD OF CHIMERIC PROTEINS 
To unravel the reason for the strong inhibitory effect of the Bri3 ECD on non-           
canonical shedding even in the presence of a substrate’s TMD, a proline was introduced 
in the TMD of 3T3. As shown above, S37P and G43P substitutions strongly increased non-
canonical TNFα shedding. Therefore, S66 and G72 of 3T3 were substituted by proline and 
shedding was investigated. 
Chimeric proteins substituted with prolines did not show any release of soluble 
peptides by neither ADAM10/17 nor SPPL2a/b (Figure 4.20). Substitution of the central 
glycine with proline (G73P) even led to premature degradation of the protein as no FL 
protein was detected. Even if non-canonical shedding in this mutant was theoretically       
enabled, the lack of successful surface transport hindered analysis and final conclusions. 
Nevertheless, technical problems like reduced transfection or blotting efficiency and             
decreased viability of SPPL2a/b-deficient cells might need to be considered additionally     






Figure 4.20 Proline in the TMD of 3T3 does not enable non-canonical shedding. SPPL2a or SPPL2b overexpressing and 
SPPL2a/b-deficient cells were transfected with the respective TNFα/Bri3 chimera. Soluble ECDs were isolated using the 
monoclonal V5 antibody. Detection of the FL protein isolated from membranes was used as transfection and calnexin as 
loading control. The TMD of 3T3 is highlighted in grey and the position of the substituted amino acids in pink. 
 
 
4.2.6. SHEDDING CAN BE MODULATED BY JMD MUTATIONS 
4.2.6.1. DISTINCT JMD SEGMENTS INFLUENCE SHEDDING DIFFERENTLY 
Since the presence of the Bri3 ECD abolished both canonical and non-canonical 
shedding, changes in the luminal JMD were introduced to evaluate their impact on            
processing. The ADAM10/17 cleavage site in TNFα is located 24 amino acids C-terminal of 
the luminal border of the TMD at position A76. The JMD was split into three sections, each 
substituted with the corresponding section of the Bri3 JMD to investigate whether these 
parts have an inhibitory effect on shedding.  
Whereas the substitution of the entire TNFα ECD with Bri3 diminished both types 
of shedding (Figure 4.18), exchanges of smaller JMD sections still enabled the release of 
the TNFα ECD (Figure 4.21). Substitution of the second or third TNFα JMD section with Bri3 
abolished canonical shedding (almost) completely (Figure 4.21A; juxBri3_2, juxBri3_3) 
while substitution of the first section selectively diminished non-canonical shedding         
(Figure 4.21A; juxBri3_1). Interestingly, non-canonical shedding was not affected by        
substitution of the second and only slightly reduced by substitution of the third section. 
This not only suggests that it is possible to inhibit canonical TNFα shedding and only          
enable non-canonical shedding by SPPL2a but also corroborates that both cleavage    
mechanisms are not co-dependent. Additionally, the Bri3 JMD seems to comprise a certain       





cleavage site inhibited corresponding peptide release. However, it was interesting to see 
that the second section of the Bri3 JMD displayed inhibitory effects on ADAM10/17-            
mediated shedding even though several amino acids distant from the actual cleavage site. 
This suggests that this section comprises certain characteristics important for TNFα        
processing by ADAM10/17.   
Again, several intermediate fragments were detected (Figure 4.21; #2-4). These          
intermediate peptides that were released upon substitution of the first JMD section were        
partially insensitive to ADAM inhibition and did not decrease in SPPL2a/b-deficient cells 
(Figure 4.21B). Thus, cleavage by an unrelated protease might not only interfere with 
shedding of chimeric proteins when the TMD is substituted (Figure 4.19) but also sections 
close to the TNFα TMD.  
 
Figure 4.21 Bri3 substitutions in the TNFα JMD affect shedding. (A) Cells ectopically expressing SPPL2a or SPPL2b (ex.) 
were transiently transfected with the respective TNFα mutants. Soluble ECDs were isolated using the monoclonal V5 anti-
body. Detection of the FL proteins isolated from membranes was used as transfection and calnexin as loading control.                
(B) Indicated cell lines were treated with 5µM GI 254023X and 1µM BMS-561395 (+ AI) to inhibit ADAM proteases. Soluble 
ECDs and controls were isolated as in (A). The TNFα TMDs of the juxBri3 mutants are highlighted in grey and substituted 
amino acids in blue.  
 
4.2.6.2. REMOVAL OF NEGATIVELY CHARGED RESIDUES FROM TNFα JMD AFFECTS 
SHEDDING 
To pinpoint the inhibitory effect of the Bri3 JMD on shedding the primary sequence 
of both TNFα and Bri3 was analysed in more detail. A study on the cleavage mechanism 
of SPP showed that positively charged residues in the JMD have an inhibitory effect on 
substrate processing (Lemberg and Martoglio, 2002). When comparing the JMD of TNFα 
with that of Bri3 the distribution of the charged residues stands out. In the TNFα JMD the 





the Bri3 JMD are more spread (R90, D91, R95, E101). As both JMDs contain two positively 
charged residues in similar positions, the effect of the negatively charged residues was 
analysed. Thus, residues E61, E62 and D66 of the TNFα JMD were mutated into asparagine 
or glutamine (E61Q, E62Q, D66N; QQN) to eliminate the charge but keep structural 
changes to a minimum. However, substitution of D66N generated a glycosylation site that 
was indeed glycosylated (Figure 4.22). Therefore, D66 was substituted by alanine (E61Q, 
E62Q, D66A; QQA). Additionally, a mutant with all three positions substituted by alanine 
was generated (E61A, E62A, D66A; AAA). 
 
Figure 4.22 Removal of negative charges from the JMD abolishes non-canonical shedding. (A) Cells ectopically ex-
pressing SPPL2a (ex.) were transiently transfected with the respective TNFα variants. Soluble ECDs were isolated using the 
monoclonal V5 antibody. Detection of the FL proteins isolated from membranes was used as transfection and calnexin as 
loading control. The generation of a glycosylation motif by substitution of D66N in the TNFα JMD is indicated in blue.                    
(B) The removal of charges from the JMD shifts the usage of the ADAM cleavage site (#3) more N-terminally (#2) and abol-
ishes sTNFα(L2) release (#1). Cells ectopically expressing SPPL2a and SPPL2a/b-deficient cells (ko) were transiently trans-
fected with the indicated TNFα variant. Indicated cell lines were treated with 5µM GI 254023X and 1µM BMS-561395 (+ AI) 
to inhibit ADAM proteases or DMSO as a control. Soluble ECDs and controls were isolated as in (A).  
 
The removal of charges from the JMD with minimal changes in the structural             
integrity resulted in reduced canonical shedding at the major cleavage site (Figure 4.22B; 
#3). In addition, a second soluble fragment was detected but depleted when treated with 
an ADAM inhibitor (Figure 4.22B; #2). Thus, removal of the negative charges shifted the 
primary cleavage site of canonical cleavage by ADAM10/17 a few amino acids further                
N-terminal. It was established previously that ADAM10/17 mainly cleaves at position A76. 
Nevertheless, other cleavages sites such as position P73, L69 and D66 were observed           
(Figure 4.8) and are likely to be used in the TNFα QQN and QQA mutants. Since the       
cleavage shift was not as prominent in the QQN mutant, it might be speculated that the 





in reduced shedding by ADAM10/17. However, as the shift of canonical shedding also            
occurred in the QQA mutant, which was not artificially glycosylated, the effect on shedding 
may be attributed to the removal of the negative charges. Interestingly, replacement of 
all three charged residues by alanines resulted in reduced surface expression, thus no 
analysis of this mutant was possible. These results conclude that ADAM10/17-mediated 
cleavage is not only abolished when negatively charged residues are inserted close to the 
cleavage site (Figure 4.21; juxBri3_3) but is also reduced when negatively charged residues 
distant from the cleavage site are reduced (Figure 4.21; juxBri3_2) or removed (Figure 
4.22; QQN/QQA).  
Interestingly, non-canonical shedding was completely abolished in the charge           
mutants. Even though SPPL2a-mediated cleavage seemed not to be affected by the            
reduction of charges (Figure 4.21; juxBri3_2), their removal abolished non-canonical         
shedding. These results support the conclusion that negatively charged residues in the 
TNFα JMD seem to play a crucial role not only for canonical but also non-canonical           
shedding. Furthermore, the effect is conducted over the distance of several α-helical 
turns, as the modifications of the second section of the TNFα JMD are distant from the 
actual SPPL2a and ADAM10/17 cleavage sites in contrast to substitutions of the first and 
second section of the TNFα JMD.  
 
 
4.2.7. SHEDDING CAN BE MODULATED BY PALMITOYLATION OF THE TICD 
The previous results indicate that substitution of TICD with Bri3 ICD reduced non-
canonical shedding (Figure 4.18). One characteristic of the TICD is a palmitoylated cysteine 
at position 30 that affects the processing of TNFα by SPPL2b (Poggi et al., 2013, Utsumi et 
al., 2001). Therefore, the effect of lipid modification on non-canonical shedding was            
investigated in more detail. To confirm lipid modification of the cysteine, TNFα wt and two 
cysteine mutants (C30S, C30A) were treated with hydroxylamine to remove a possible              
palmitoylation. Depletion of the palmitoylation resulted in free thiol groups at the            





a fragment bound to the beads confirms palmitoylation of TNFα wt (Figure 4.23). As both 
mutants were not palmitoylated, peptides were not isolated.  
 
After validating that TNFα undergoes palmitoylation in the cellular system used for 
the analysis, shedding of the non-palmitoylated C30S and C30A mutants was compared 
to that of palmitoylated TNFα wt. The results showed that non-canonical shedding by 
SPPL2a increased in non-palmitoylated mutants compared to the wt (Figure 4.24). Since 
the increased effect was not as pronounced as in the proline TMD mutants (Section 4.2.4) 
it is not surprising that non-canonical shedding by SPPL2b was not enabled.  
 
Figure 4.24 Non-canonical shedding increases when palmitoylation is abolished. Soluble TNFα species were isolated 
from conditioned media of the indicated cell lines and quantified relative to sTNFα from respective WB by densitometric 
analysis and normalized to the wt, n=3. Data are represented as mean +/- SD. Statistical significance was calculated applying 
an unpaired, two-sided Student‘s t-test. *: p<0.05. The WB shows one representative experiment. TNFα FL was used as 
transfection and calnexin as loading control.  
 
 
4.2.8. NON-CANONICAL SHEDDING OF OTHER SPPL2 SUBSTRATES 
The results on non-canonical TNFα shedding raised the question whether this 
shedding is a general feature of SPPL2a and if other substrates are processed similarly. In 
order to confirm a general shedding capacity of SPPL2a, the known substrates Bri2, FasL, 
TMEM106b and CD74 were analysed for the release of sECDs into the conditioned media. 
Figure 4.23 TNFα is palmitoylated at C30. TNFα wt 
and the indicated variants were isolated from cells 
endo- genously (en.) expressing SPPL2a/b. Free thiol 
groups were quenched before palmitate was removed 
via hydroxylamine treatment (+NH2OH). Release of pal-
mitate resulted in accessible thiol groups that were 
used to immunoprecipitate the proteins using thiopro-
pyl beads. Isolation of the FL protein using the FlagM2          





All proteins except TMEM106b were successfully expressed on the cell surface. Despite 
successful expression, no sFasL was detected (Figure 4.25A). Multiple secreted fragments 
were generated from Bri2 and CD74. In CD74 however, the secreted fragments probably 
represent differently matured peptides, as the CD74 ECD is glycosylated multiple times 
(Table 1.1). 
 
Figure 4.25 SPPL2a-mediated non-canonical shedding is probably an exclusive characteristic of TNFα. ECDs from 
conditioned media of HEK293 cell lines co-expressing the indicated substrates and SPPL2a, SPPL2b or none of the proteases 
(ko) were isolated and detected with the V5-mono antibody. (A) Cells were treated with 1µM PMA to activated ADAM            
cleavage. (B) Cells were treated with either 1µM PMA to activated ADAM cleavage, 50µM Z-LL2-ketone (+ (ZLL)2) to inhibit 
SPPL2 catalytic activity or with 5µM GI 254023X and 1µM BMS-561395 (+ AI) to inhibit ADAM proteases. Controls were 
treated with DMSO (-). (C) sBri2 secreted from the indicated mutant was isolated as in (A). The expression of the FL protein 
was used as transfection and calnexin as loading control. 
 
Even though Bri2 secreted several soluble fragments as well, no fragment was     
decreased in SPPL2a/b-deficient cells or by the application of the SPPL2 inhibitor (+(ZLL)2) 
(Figure 4.25B). Not all of the secreted ECDs were inhibited by the treatment with an 
ADAM10/17 inhibitor, thus, Bri2 might be shedded in several positions by more than just 
the ADAM-proteases. Even insertion of a proline in the centre of the TMD did not induce 
non-canonical shedding; it rather even decreased canonical shedding in SPPL2b-                





non-canonical shedding and substitutions of the central TMD glycine by either leucine or 
proline even negatively affect canonical shedding. The secreted sBri2 peptides might as 
well result from the release of differently matured Bri2 ECD, as Bri2 just as CD74 is glyco-
sylated at several sites (Table 1.1). To conclude, it appears that SPPL2a mediated non-
canonical shedding exclusively occurs in TNFα and the other so far known SPPL2               





4.3. SUBSTRATE RECOGNITION AND INITIAL CLEAVAGE 
So far it was assumed that most SPPL2 substrates are shedded by a accompanying 
(metallo-) protease, then recognised by SPPL2 and subsequently processed. However, the 
previous data showed that TNFα is shedded as FL protein by SPPL2a, which indicates that 
the protease is able to recognise not only the NTF but already the FL protein. Indeed, 
previous studies have shown that SPPL2 proteases are able to bind FL proteins, but yet 
binding does not necessarily result in the cleavage of the protein (Bri3) (Martin et al., 2008, 
Fluhrer et al., 2006). Thus, it seems that binding is rather unspecific and further protein 
features determine which proteins are cleaved by SPPL2. Therefore, assuming that SPPL2 
proteases are capable of binding most type II TM proteins, other substrate criteria                 




In the context of RIP, the shedded substrate NTFs are cleaved by SPPL2 releasing 
a small C-peptide into the conditioned media. This first cleavage is referred to as initial 
cleavage. To investigate initial cleavage of TNFα by SPPL2a and SPPL2b, a TNFα variant 
Figure 4.26 Secretion of C-peptide by SPPL2. C-peptides were isolated 
from conditioned media of HEK293 cell lines expressing exogenous (ex.) 
levels of SPPL2a, SPPL2b or none of the proteases (ko) and ectopically        
expressing TNFα NTF using the polyclonal V5 antibody. For visualization 
on WB, the monoclonal V5 antibody was employed. Calnexin served as 






lacking the ECD (TNFα NTF) was established. TNFα NTF was C-terminally V5-tagged to         
enable detection of the C-peptide. Co-expression of TNFα NTF and SPPL2b resulted in             
secretion of TNFα C-peptides (Figure 4.26), which confirmed previously published results 
(Fluhrer et al., 2006). SPPL2a triggered the secretion of comparable amounts of TNFα         
C-peptide, suggesting that the initial endoproteolytic processing step by both protease, 
which follows canonical shedding, occurs with similar efficiency. As a result of SPPL2a/b-
depletion, TNFα NTF accumulated within the cell and no C-peptide was released. TNFα 
NTF also accumulated in cells co-expressing SPPL2a, which was probably due to a higher 
transfection efficiency and higher cell desity as indicated by the detection of calnexin. 
 
 
4.3.1. INITIAL CLEAVAGE IN TNFα/ BRI3 CHIMERAS 
To identify determinants that enable initial cleavage in the context of RIP TNFα/Bri3 
chimeras lacking the ECD were established. Confirming earlier results, co-expression of 
SPPL2a or SPPL2b with Bri3 NTF did not result in release of a C-peptide (Figure 4.27) 
(Martin et al., 2008).  
Release of a C-peptide by SPPL2a or SPPL2b was detected in all chimeras                    
comprising a TNFα JMD. However, initial cleavage and therefore release of a C-peptide in 
3TT and 33T NTF was reduced, indicating that Bri3 ICD has an inhibitory effect on the initial             
cleavage by SPPL2. Bri3 TMD seemed not to affect initial cleavage, as C-peptide release 
from T3T was as efficient as in TNFα wt. In line with this, the TNFα TMD did not enable 
cleavage by SPPL2 in the context of Bri3 (Figure 4.27; 3T3). Since 3TT and TT3 were still 
cleaved by SPPL2, Bri3 ICD and JMD seemed to both comprise a certain inhibitory effect 
which when combined abolished initial cleavage of TNFα by SPPL2. Interestingly, while the 
addition of the whole Bri3 ECD inhibited shedding and subsequent processing (Figure 
4.18), Bri3 JMD in short chimeras was not able to abolish release of the C-peptide com-
pletely but reduced the cleavage slightly. Surprisingly, even if the TMD seemed not to        
influence initial cleavage by SPPL2 in 33T, it was able to reduce/ abolish cleavage by SPPL2 





are able to reduce TNFα cleavage by SPPL2 and that the TMD does not play a role in the 









Further analysis of the SPPL2a cleavage sites in TNFα/Bri3 chimeras revealed 
changes of cleavage sites induced by the respective Bri3 segments. While Bri3 ICD did 
affect the general cleavage capacity of SPPL2 (Figure 4.27), it did not alter cleavage sites 
(Figure 4.28; 3TT). Bri3 TMD influenced initial cleavage capacity rather less in WB analysis; 
however, it did induce additional cleavage sites in the TNFα JMD (33T, T3T). Furthermore, 
detection of secreted peptides in SPPL2a/b-deficient cells was used to ensure specificity 
of SPPL2a-mediaited cleavage. Interestingly, cleavages in 33T and T3T were not or only 
partially reduced in SPPL2a/b-deficient cells indicating that an unrelated protease is           
indeed cleaving TNFα/Bri3 chimeras. Even though mass spectrometry results supported 
the hypothesis that the Bri3 TMD can actually be cleaved by SPPL2 (Figure 4.28; 33T, T3T, 
T33) it also showed that a so far unidentified protease is partaking in the cleavage at the 
same positions as SPPL2 proteases.  
Even though Bri3 JMD was not sufficient to inhibit cleavage by SPPL2a completely 
it abolished (TT3) or reduced (3T3) cleavage at specific sites in the TNFα TMD. Additionally, 
the combination of TNFα TMD and Bri3 JMD (TT3, 3T3) increased the amount of cleavage 
Figure 4.27 Initial cleavage by 
SPPL2 is reduced in chimeras 
comprising Bri3 ICD and/ or Bri3 
JMD. C-peptides were isolated 
from conditioned media of 
HEK293 cell lines expressing exo-
genous (ex.) levels of SPPL2a, 
SPPL2b or none of the proteases 
(ko) using the poly-clonal V5 anti-
body. For visualization on WB, the 
monoclonal V5 antibody was          







sites in the Bri3 JMD. However, when combined with the Bri3 TMD (T33) cleavage sites in 
the Bri3 JMD were reduced, while presence of TNFα ICD induced cleavage by SPPL2 in the 
Bri3 TMD. Surprisingly, while 3T3 cleavage was not observed in WB analysis, cleavage sites 
in mass spectrometry were detectable. The soluble fragment might have been missed in 
WB analysis as peptide properties such as hydrophobicity enabled better detectability in 
mass spectrometry then on WB. Table 4.5 lists the exact masses of the measured and 
calculated chimeric peptides. 
 
Figure 4.28 Identification of C-terminal cleavage sites in TNFα/Bri3 chimeras by mass spectrometry. Secreted ECDs 
from HEK293 cells co-expressing SPPL2a (ex.) or deficient for SPPL2a/b (ko) and indicated chimeras were isolated using the 
FlagM2 antibody and were analysed via mass spectrometry. Black arrows indicate the position of SPPL2a cleavage. Grey 
arrows indicate cleavage by an unknown protease. The TMD is highlighted in grey, TNFα in pink and Bri3 in blue. x marks 





Table 4.5 Masses of TNFα/Bri3 chimeric cleavage products measured by MALDI-TOF compared to calculated masses.              
Measured values of samples with a TNFα TMD are normalised to the calculated mass of the peptide resulting from cleavage 
at position H52/ H81. Measured values of samples with a Bri3 TMD are normalised to the calculated mass of the peptide 













89 3044 3041 
84 3539 3537 
81 3880 3879 
79 4106 4106 
33T 
89 3044 3043 
88 3172 3168 
85 3440 3434 
84 3539 3539 
79 4176 4176 
77 4469 4471 
T3T 
60 3044 3043 
59 3172 3165 
56 3440 3444 
55 3539 3539 
50 4176 4176 
48 4438 4440 
3T3 
95 2551 2553 
88 3396 3389 
87 3467 3469 
86 3580 3585 
85 3728 3732 
81 4288 4288 
TT3 
65 2551 2552 
58 3396 3393 
57 3467 3473 
56 3580 3584 
55 3728 3732 
54 3875 3875 
T33 
65 2551 2554 
58 3396 3385 





4.3.2. INITIAL CLEAVAGE IN JMD CHIMERAS 
The results shown above demonstrated that the Bri3 JMD decreases the initial 
cleavage but increases cleavage sites especially in the section close to the TNFα TMD. 
Thus, sectional JMD substitutions (Section 4.2.6.1) lacking the majority of the TNFα ECD 
were investigated for their influence on the initial cleavage by SPPL2.  
The analysis of the short Bri3 JMD chimeras suggests that especially the second 
section of the JMD is crucial for initial cleavage by SPPL2 (Figure 4.29). Release of the             
C-peptide was abolished when the second and reduced when the first section of the TNFα 
JMD was substituted with the respective Bri3 sequence. Even though increased initial 
cleavage and subsequent C-peptide release would suggest a reduction of NTF and              
reduced C-peptide release implies an accumulation of the NTF, this did not correlate in 
WB analysis. This phenomenon has also been observed for other RIP substrates such as 
APP (Sastre et al., 2001). It might be caused by an accelerated processing of the short 
compared to the FL protein. Nevertheless, these results imply that the second and - to a 
lesser extent - also the first part of the TNFα JMD is crucial for initial cleavage by SPPL2 in 
the context of RIP.  
 
To investigate whether SPPL2a-mediated cleavage sites in JMD chimeras differed 
compared to TNFα wt and whether a certain section of the Bri3 JMD induced the before 
mentioned cleavage by an unknown protease, JMD mutants were investigated by mass 
spectrometry. Cleavage sites in TNFα with the third section of the JMD substituted with 
Bri3 were not changed (Figure 4.30; juxBri3_3). The substitution of the second section of 
the TNFα JMD with the corresponding Bri3 section resulted in the loss of the most                  
C-terminal cleavage site at position 60 and shifted the most N-terminal cleavage site at 
Figure 4.29 The first and second 
part of the TNFα JMD are                        
important for initial cleavage. (A-
B) C-peptides of the indicated TNFα 
JMD chimeras were isolated from 
conditioned media of HEK293 cell 
lines using the polyclonal V5 anti-
body. Cells expressed either exoge-
nous (ex.) levels of SPPL2a, SPPL2b 
or none of the proteases (ko). For 
visualization on WB, the monoclonal 
V5 antibody was employed. Calnexin 





position 50 one amino acid further N-terminal. In addition, two major peaks that did not 
correlate with any possible secreted peptide were detected in SPPL2a-expressing cells 
and absent in SPPL2a/b-deficient cells, which indicates that - even though unidentified - 
these peptides are probably specific for an SPPL2a-mediated cleavage. The peptides 
might originate from smaller peptides (#55, #52) that became modified. Both unidentified 
peaks are ≈ 80 Da larger than the corresponding peptide. However, it seems puzzling that 
the peptides become modified only in this chimera and not in TNFα wt or juxBri3_1.          
Furthermore, small, unidentified peaks were detected in juxBri3_3; however, these         
peptides were ≈ 55 Da larger.  
Besides the major SPPL2 cleavage positions 50 and 55, juxBri3_1 displayed                
additional cleavage sites in the area of substitution that were not abolished in SPPL2a/b-
deficient cells. This indicates that besides SPPL2a an unrelated protease is cleaving the 
chimeric protein. Moreover, it seems that the unknown protease cleaves the TNFα             
chimera at the same positions as SPPL2a, as cleavages at positions 55 and 50 were only 
reduced and not abolished in SPPL2a/b-deficient cells. Table 4.6 lists the exact masses of 
the measured and calculated peptides.  
 
Figure 4.30 Identification of cleavage sites in JMD chimeras by mass spectrometry. Secreted ECDs from HEK293 cells 
co-expressing SPPL2a (ex.) or deficient for SPPL2a/b (ko) and the indicated TNFα variants were isolated using the FlagM2 
antibody. Numbers indicate the position of the most N-terminal amino acid of the respective cleavage product. x marks 
peaks of unknown identity. Cleavage positions in the sequence are indicated with arrows. The TMD is highlighted in grey 





Table 4.6 Masses of TNFα JMD variant C-peptides measured by MALDI-TOF compared to calculated masses.             






4.4. CONSECUTIVE SUBSTRATE PROCESSING 
4.4.1. CONSECUTIVE CLEAVAGE OF TNFα  BY SPPL2A 
After initial cleavage, the TNFα counterpart that remains in the membrane after     
C-peptide release is further processed by SPPL2. The conversion of TNFα NTF into TICDs 
is best visualised when the FL protein is co-expressed with exogenous levels of SPPL2 
(Fluhrer et al., 2008, Fluhrer et al., 2006). Consecutive cleavage of TNFα in HEK293 cells 
endogenously expressing SPPL2a/b is barely detectable (Figure 4.31) and co-expression 
of TNFα NTF and SPPL2 accelerate turnover to the point where TICDs cannot be observed 
on WB anymore. Therefore, to monitor TICD production, N-terminally Flag-tagged TNFα 
FL was co-expressed with either SPPL2a or SPPL2b, which resulted in the reduction of 
TNFα NTF and the release of several TICDs (Figure 4.31). Turnover of TNFα NTF provides 








59 3073 3070 
58 3201 3193 
56 3385 3378 
55 3532 3532 
53 3843 3844 
50 4206 4209 
juxBri3_2 
55 3622 3622 
52 3963 3967 
49 4292 4286 
juxBri3_3 
60 3158 3156 
55 3652 3652 
52 3994 4995 





their turnover hints towards the efficiency of the consecutive cleavage. Co-expression of 
TNFα wt with SPPL2a or SPPL2b confirms previous findings on SPPL2b (Fluhrer et al., 2006, 
Fluhrer et al., 2008) and supports evidence that SPPL2a is able to consecutively cleavage 
TNFα as well. Both initial cleavage and consecutive cleavage were eradicated when 





To address whether SPPL2a utilizes processive cleavages within the TMD similar to 
SPPL2b, an in vitro conversion assay was performed (Fluhrer et al., 2008). Membrane         
preparations from cells co-expressing either SPPL2a or SPPL2b and TNFα were incubated 
at 37°C for different time intervals. The efficiency of the consecutive cleavage is defined 
by the number and amount of detected fragments and their size. Hence, the detection of 
less or smaller fragments hints towards an increase and accumulation or larger fragments 
hints towards a decrease in consecutive cleavage efficiency. Similar to SPPL2b, SPPL2a 
evinced processive activity, converting longer TICD species into shorter ones (Figure 4.32).             
However, SPPL2b was more efficient in the turnover since the decrease of TNFα NTF was 
much faster and TICD conversion more efficient. Generally, less and smaller TICDs were 
detected when TNFα was co-expressed with SPPL2b while co-expression of TNFα with 
SPPL2a resulted in accumulation of larger TICDs. While SPPL2b converted the largest TICD 
(Figure 4.32; #1) within two hours into three smaller TICDs (Figure 4.32; #2-4), SPPL2a only 
showed two cleavages (Figure 4.32; #2, #3) within five hours.  
 
Figure 4.31 Consecutive TICD generation by SPPL2a and 
SPPL2b. Membranes of the indicated HEK293 cell lines ectopically 
expressing TNFα FL were isolated. Intracellular TNFα species were 
visualised by the monoclonal FlagM2 antibody. Isolation of TNFα FL 







Due to the differences of both SPPL2 proteases in the kinetic of consecutive        
cleavage, MADLI-TOF mass spectrometry was used to determine whether the N-terminal 
cleavage sites generated during sequential cleavage also differ. Analysis of TICDs                      
produced by SPPL2b cleavage confirmed previously reported cleavage sites in the TMD 
after amino acids S34 and L39 (Fluhrer et al., 2006) and the release of additional smaller 
peptides resulting from the cleavages after position P18, G26 and R28 (Figure 4.33). The 
most prominent cleavage at position R28 displayed a modification of the cleavage site in 
SPPL2b-expressing cells. To this end, it can only be speculated whether it originates from 
a C-terminal modification of the arginine or whether the peptide is modified at a more            
N-terminal residue. The ≈40 Da mass difference between the peaks could correlate to an 
acetylation of either Lys19 or Lys20. However, the second peak could also result from the 
formation of sodium adducts (Zhu and Papayannopoulos, 2003). The reason why this 
modification primarily occurred in SPPL2b-expressing cells could not be identified. 
In addition to the earlier study (Fluhrer et al., 2006), a new consecutive cleavage 
site at S37 was identified. Even though SPPL2a appeared less efficient in the consecutive 
cleavage on WB analysis, more cleavage sites and smaller TICDs compared to SPPL2b 
were identified by mass spectrometry. While the most dominant cleavage of SPPL2a in 
the TMD was at S34, SPPL2b main cleavage occurred at L39. Additionally, to the SPPL2b 
cleavage sites, SPPL2a cleaved the TNFα TMD at L35 and L31 and at position K20 in the 
TICD. The exact masses measured in mass spectrometry are compared to the calculated 
masses in Table 4.7.  
Figure 4.32 Processive turnover of 
TNFα by SPPL2 proteases. Membranes 
of HEK293 cell lines co-expressing either 
SPPL2a or SPPL2b and TNFα FL were       
incubated for the indicated time periods. 
ICD conversion was monitored using WB 
and the Flag M2 antibody for detection. 
TNFα FL served as transfection and        
calnexin served as a loading control.     
(Experiments displayed in this figure 
were conducted by Martina Haug-







Figure 4.33 N-terminal cleavage sites in TNFα. Mass spectrometric analysis of the TICD generated from SPPL2a or 
SPPL2b, respectively. Numbers indicate the position of the most C-terminal amino acid of the respective cleavage product. 
Lysates of untransfected controls were included to decipher unspecific peaks (*). A modification of a cleavage product is 
indicated with a #. Arrows indicate the cleavage sites in the TNFα sequence. The TMD is indicated in grey and the Flag-tag 
in green (Spitz et al., 2020).  
 
Table 4.7 Masses of TICDs measured by MALDI-TOF compared to calculated masses. Measured values are normalised 





Measured mass  
(in Da) 
SPPL2a SPPL2b 
18 3058 3059 3058 
20 3314 3315  
26 3811 3810 3312 
28 4055 4056 4050 
#   4090 
31 4427 4429  
34 4774 4776 4775 
35 4888 4892  
37 5122 5126 5124 
39 5383 5383 5383 
 
 
4.4.2. PROCESSIVITY CAN BE MODULATED BY TMD MUTATIONS 
The consecutive cleavage of IMPs is also termed processivity. Since the exchange 





shedding of TNFα (Section 4.2.4), the effect of these mutations on processivity was                
investigated. The most prominent effects were again observed when amino acids were 
substituted by leucine and proline, while as expected alanine substitutions mainly              
displayed similar effects as leucine substitutions but less prominent. Leucine and alanine 
in positions S34, S37 and H52 increased the amount of TICD, pointing to a reduced              
processivity. In contrast, proline induced the opposite effect in all positions tested, except 
at C49 and H52 (Figure 4.34). NTF and TICD in these mutants were barely detectable, 
providing evidence for a faster turnover. SPPL2a/b-deficient cells served as a control 
demonstrating that decrease of NTF and therefore the generation of TICD was specific for 
SPPL2a activity.  
 
Figure 4.34 Mutations in TMD affect the processivity of SPPL2a. Membranes of HEK293 cell lines either co-expressing 
SPPL2a (ex.) or neither of the SPPL2a/ SPPL2b proteases (ko) with the indicated TNFα variant were isolated. TNFα cleavage 
products were monitored using WB analysis and FlagM2 antibody for detection. Detection of the FL protein served as trans-
fection and calnexin as a loading control. 
 
To better monitor consecutive cleavage of the TNFα variants over time, an in vitro 
conversion assays was performed as described above (Section 4.4.1) (Fluhrer et al., 2008). 
The accumulation of TICD compared to the respective wt control supported the evidence 
that single leucine mutants in position S34, S37, H52 but also G43 and the triple leucine 
substitution (AGA/LLL) slowed down consecutive cleavage by SPPL2a (Figure 4.35). It 





AGA/LLL, as the NTF was not processed as quickly as in the corresponding wt. To no            
surprise also over a longer period of time no fragments were detectable in proline          
substituted TNFα variants, further supporting an improved processivity by increased TMD 
dynamics. Similar effects were observed for SPPL2b (data not shown).  
 
Figure 4.35 Substitutions in the TMD affect processivity of SPPL2a. Membranes of HEK293 cell lines co-expressing 
SPPL2a (ex.) and the indicated TNFα variant were incubated for the indicated time periods. TICD conversion was monitored 






Figure 4.36 Use of N-terminal cleavage sites in the TNFα TMD proline variants is changed. TICDs were isolated from 
membranes of cells ectopically expressing SPPL2a (ex.) and the indicated TNFα variant and isolated using the FlagM2 anti-
body. Numbers indicate the position of the most C-terminal amino acid of the respective cleavage product. The TMD is 
highlighted in grey, the Flag-tag in green and the substituted amino acid in pink.   
 
To elucidate whether the altered processivity induced by proline substitutions also 
affected the SPPL2a cleavage sites, TNFα variants were analysed by mass spectrometry. 
Positions of the cleavage sites in TNFα variants did not change; however, the overall       
number of cleavage sites was strongly reduced upon proline substitution (Figure 4.36). 
Whereas in TNFα wt S34 was the major cleavage site within the TMD, all mutants displayed 
a most prominent cleavage at L39. Except for TNFα variants S37P and C49P that were also 
cleaved at L35 within the membrane, cleavage sites in all other variants within the TMD 
were diminished. R28 remained the most prominent N-terminal cleavage site. Therefore, 





cleavage kinetics or the reduction of cleavage sites compared to the wt. Proline in the 
TNFα TMD might have triggered a structural rearrangement, which resulted in an earlier 
release of the TICD from the membrane and thus these mutants display a reduced            
consecutive cleavage and subsequent release of TICDs in WB analysis. Exact masses of 
calculated and measured ICD peptide masses are displayed in Table 4.8.  
 
Table 4.8 Masses of N-terminally cleaved TNFα variants measured by MALDI-TOF compared to calculated masses.            
Measured values are normalised to the calculated value of cleavage position 39. 




Measured mass  
(in Da) 
S34P 
18 3058 3059 
28 4055 4056 
39 5393 5393 
S37P 
18 3058 3058 
28 4055 4055 
35 4888 4893 
39 5393 5393 
G43P 
18 3058 3057 
26 3811 3808 
28 4055 4050 
39 5382 5382 
C49P 
18 3058 3051 
28 4055 4047 
35 4888 4888 
39 5382 5382 
H52P 
18 3058 3051 
26 3811 3806 
28 4055 4048 
39 5382 5382 
 
 
4.4.3. PROCESSIVITY CAN BE MODULATED BY INSERTION OF NON-SUBSTRATE   
DOMAINS 
Since Bri3 ICD exhibited strong inhibitory effects on the initial cleavage (Figure 4.27) 
the impact of the ICD but also TMD and ECD on the processivity of SPPL2 proteases were 





SPPL2b. As already established, the Bri3 ECD abolished shedding by ADAM10/17 or 
SPPL2a (Figure 4.18), thus no consecutive cleavage could be monitored in chimeras with 
a Bri3 ECD (Figure 4.37A). In line with the results described above, Bri3 ICD also slowed 
down consecutive cleavage, as ICDs of 3TT and 33T accumulated compared to TNFα wt 
ICD. While Bri3 TMD in the context of TNFα did not affect initial cleavage, it seemed to 
increase consecutive cleavage drastically. However, as already observed in the context of 
initial cleavage, opposing effects of Bri3 ICD and TMD were not additive, as the consecu-
tive cleavage of 33T was not restored to TNFα wt processing. To ensure that all cleavages        
resulted from SPPL2 processing TNFα/Bri3 FL chimeras were expressed in SPPL2a/b-       
deficient cells. Elimination of ICD production and accumulation of chimera NTFs in these 
cells demonstrates that consecutive cleavage of the mutants is mediated by SPPL2          
proteases and is indeed accelerated by the substitution of the TNFα TMD with Bri3 (Figure 
4.37B). This shows that even if the TMD has rather a low impact on shedding and initial 
cleavage it becomes important for consecutive cleavage. However, while Bri3 exhibited 
an inhibitory effect on initial cleavage by SPPL2 it increased consecutive cleavage. 
 
Figure 4.37 SPPL2 processing of TNFα/Bri3 chimeras is reduced by the Bri3 ICD. HEK293 cell lines co-expressing either 
SPPL2a or SPPL2b were transfected with the indicated TNFα/Bri3 chimera. ICD conversion was monitored using WB and 






Intramembrane proteases are involved in a wide variety of processes that range 
from transcriptional control over cellular signalling to prevention of parasitic and bacterial 
invasion. They act in the context of RIP. RIP of TM proteins can either activate or terminate 
a signalling process or remove membrane-resident protein fragments (Figure 5.1). The 
regulation of this cleavage mechanism can occur on many levels, e.g., the activity of the 
enzyme can be controlled by expression, co-factors or localisation. If the enzyme is          
constitutively active, the regulation of cleavage can be modulated by substrate                              
determinants such as consensus cleavage site or substrate enzyme affinity. This ensures 
that the enzyme cleaves specific proteins and not, for instance, all membrane proteins. 
However, even though for some IMPs no specific cleavage sequence has been identified, 
their substrate selection and processing mechanism seem to be highly specific. The             
question of what characteristics determine a substrate of a specific protease is still               
pending. Thus, in the context of this thesis, features of the SPPL2 substrate TNFα were 
exploited in order to increase the understanding of substrate selection and cleavage 
mechanism of SPPL2 proteases. The following sections will discuss these findings and 
identify commonalities and differences between the SPPL2 substrates and substrate 
recognition by other (aspartyl-) IMPs. 
 
Figure 5.1 Functions of intramembrane proteases (IMPs). By cleaving a TM protein, the intramembrane protease (IMP)        
releases an intracellular and extracellular peptide. The IMP can terminate a signal by cleaving a TM protein that is active in 









5.1. IDENTIFICATION OF NON-CANONICAL SHEDDING BY SPPL2 PROTEASES 
Shedding of proteins is one of the key mechanisms within a cell that contributes to 
the termination or activation of a protein’s function. Signalling between cells is often           
facilitated via soluble peptides that originate from the release of a TM protein’s ECD. For 
TNFα, ADAM17 is the major sheddase that releases sTNFα to signal to recipient cells to 
induce their survival or death (Coeshott et al., 1999, Kalliolias and Ivashkiv, 2016). The 
remaining membrane-bound NTF is subsequently processed by the aspartyl-IMPs SPPL2a 
and SPPL2b (Fluhrer et al., 2006). This study showed that SPPL2a besides ADAM17           
contributes to the release of the TNFα ECD by directly cleaving the FL protein (Figure 4.3). 
This direct cleavage by SPPL2a generated a slightly larger fragment termed sTNFα(L2). 
Overexpression of either SPPL2a or SPPL2b indicates that non-canonical shedding of 
TNFα wt is only efficiently catalysed by SPPL2a and not SPPL2b (Figure 4.4). These results 
go in line with previous studies showing that SPPL2b does not accept Bri2 FL as substrate 
but needs a preceding shortening of the Bri2 ECD by ADAM10 (Martin et al., 2009).  
SPPL2a-mediated non-canonical shedding was sensitive to an SPPL-specific              
inhibitor and abolished in SPPL2a/b-deficient cells. Thus and in line with the definition of 
shedding (Lichtenthaler et al., 2018), SPPL2a qualifies as a part-time sheddase for TNFα. 
In addition, non-canonical shedding occurred independently of canonical shedding, as the 
inhibition of ADAM17 did not affect shedding by SPPL2a (Figure 4.5).  
Because sTNFα(L2) is slightly larger than regular sTNFα, it is not surprising that the 
SPPL2a shedding sites mapped to cleavage sites within or close to the TMD while the         
canonical shedding site of ADAM17 located more N-terminal (Figure 5.2). Direct analysis 
of SPPL2a non-canonical shedding sites in TNFα is not possible, as large fragments are 
not reliably distinguished by MALDI-TOF mass spectrometry. Therefore, a TEV cleavage 
site was introduced into the ECD of TNFα. Comparing the surface expression and SPPL2 
processing of TNFαTEV to TNFα wt showed that the insertion of the FlagTEV did not affect 
processing. Thus, both canonical and non-canonical shedding most likely occurred on the 
physiological cleavage sites. Cleavage of TNFα FlagTEV by SPPL2a mainly mapped to              
position V55. Of note, cleavage sites of SPPL2a in the context of RIP have previously not 
been determined. Therefore, it was interesting to see that even though different in their 





context of RIP (R60, V55, H52 and L50), although with different intensities (Figure 4.6). 
Comparing the cleavage sites generated from RIP (Figure 4.6) with the ones from non-
canonical shedding (Figure 4.8), showed that the major cleavage site in RIP (L50) occurred 
five amino acids more N-terminally and within the TMD. This may suggest that either            
binding of TNFα FL and TNFα NTF to SPPL2a occurs differently or that the ADAM-shedded 
TNFα NTF is positioned differently within the membrane due to the lack of its ECD. In 
addition, a possible effect of the FlagTEV introduction cannot be fully excluded even 
though it seems unlikely, as the overall quality of cleavage sites in TNFα FlagTEV was          
essentially similar as in TNFα NTF. Therefore, these results further solidify previously 
found cleavage sites in TNFα and show that non-canonical shedding and cleavage in the 
context of RIP occur at similar positions.  
 
Figure 5.2 TNFα can be shedded by ADAM17 and SPPL2a but not by SPPL2b. The canonical shedding by ADAM17 gen-
erates a soluble ECD (sTNFα) and a membrane-bound N-terminal fragment (NTF). The non-canonical shedding by SPPL2a 
generates a slightly larger ECD (sTNFα(L2)) and directly a TNFα intracellular domain (TICD). SPPL2b is not able to cleave 
TNFα FL.  
 
Other members of the aspartyl-IMP family have been investigated for their             
shedding function showing that γ–secretase, SPP and SPPL3 can act as non-canonical 
sheddases that directly cleave most or at least some of their substrates without any prior 
shedding.  
So far, Nicastrin was suggested as the gatekeeper of γ-secretase ensuring adequate 
shortening of the substrate’s ECD. The APP-homolog APLP1 however, has a large ECD of 
several hundred amino acids. Nevertheless, in addition to its canonical shedding by 





2018). While the exact mechanism of how APLP1 bypasses the strict short ECD length      
requirement imposed by nicastrin is unknown, the mechanism of non-canonical shedding 
by SPP has been investigated more precisely. Generally, SPP is not able to process FL         
proteins and needs preceding shortening of the ECD by signal peptidases. Nevertheless, 
with the help of the inactive rhomboid protease derlin1 SPP cleaves Xbp1u without prior 
shedding (Figure 1.11) (Chen et al., 2014a). Shedding capacity of SPPL3 has been described 
for several substrates (Voss et al., 2014) and it exceeds that of SPPL2a, as the FVenv          
protein is processed by SPPL2a, SPPL2b and SPPL3 but only SPPL3 is also capable of    
shedding this substrate (Voss et al., 2012).  
As so far only one substrate for each SPP, SPPL2a and γ-secretase has been             
described, which is non-canonically shedded by the respective protease, they qualify as 
non-canonical part-time sheddases while SPPL3 might be considered a non-canonical full-





5.2. PROCESSING OF TNFα BY SPPL2A IS AFFECTED BY DETERMINANTS… 
5.2.1. …IN THE TMD 
The TNFα TMD was investigated, in order to determine specific characteristics that 
enable non-canonical shedding and subsequent processing by SPPL2. As expected,           
exchanging the TNFα TMD with the non-substrate Bri3 TMD did not affect canonical            
shedding. Nonetheless, the Bri3 TMD in the context of TNFα still enabled non-canonical 
shedding by SPPL2a (Figure 4.19) and initial cleavage in the context of RIP (Figure 4.27). 
Vice versa, the substrate TNFα TMD in the context of Bri3 did not result in cleavage of 3T3 
by ADAM10/17 or SPPL2a on WB analysis. However, investigation of the cleavage sites by 
MALDI-TOF mass spectrometry showed that T3T and 3T3 are both processed by SPPL2a. 
Additionally, T3T was not only processed by SPPL2 proteases but also by an unrelated and 
unidentified protease. In contrast, 3T3 displayed cleavages only generated by SPPL2. Since 





soluble fragments was generally aggravated. Consecutive cleavage was strongly increased 
when TNFα TMD was substituted with Bri3 (Figure 4.37), which indicates that the                     
individual amino acid composition and therefore the secondary structure of the TMD can 
affect the processivity of SPPL2. The effects of all TNFα TMD alterations on shedding and 
subsequent processing are summarized in Table 5.1. 
Taken together, results from TNFα/Bri3 TMD chimeras indicate that the TMD itself 
is neither sufficient to generate a substrate from a non-substrate nor able to inhibit cleav-
age of a substrate. These results go in line with observations on γ-secretase. A substrate 
TMD (TNR12) is not cleaved in the context of a non-substrate (Itgβ/DAP12), whereas the 
non-substrate TMD is cleaved in the context of the substrate (Güner, unpublished data). 
While results on TNFα/Bri3 TMD exchange and TMD exchange in γ–secretase substrates 
are consistent, Bri2/Bri3 TMD exchange experiments reveal contradictory results. While 
the substitution of the Bri2 TMD with Bri3 consistently increased processing, vice versa 
insertion of the Bri2 TMD in Bri3 still enabled processing (Martin et al., 2008). It rather 
seemed as if the Bri3 TMD even accelerated cleavage. Additionally, non-canonical                  
shedding could not be identified in these substrates. This strengthens the hypothesis that 
the cleavage mechanism is defined by substrate rather than protease properties.  
Studies in the context of other aspartyl-IMPs such as presenilins and SPPL2b            
suggested that intramembrane proteolysis is indeed influenced by the conformational               
flexibility of the substrate TM helix (Fluhrer et al., 2012, Götz et al., 2019, Langosch et al., 
2015, Langosch and Steiner, 2017). In line with these observations, proline substitutions 
especially in the N-terminal half of the TNFα TMD increased non-canonical shedding         
(Figure 4.11) and overall processivity of SPPL2a (Figure 4.34). Structural analysis of proline- 
substituted TNFα revealed the destabilisation of the N-terminal TM helix and shift of the 
hinge bending as cause for the increase in non-canonical shedding (Spitz et al., 2020). The 
reduced capacity of prolines to form amide hydrogen bonds and its cyclic side chain           
encounter the N-terminal neighbours, therefore disturbing stabilising interactions 
(Cordes et al., 2002). Furthermore, proline substitutions in TNFα lead to an increase in the 
tilt angle of the helix, thus repositioning the protein within a lipid bilayer. In conclusion, 
proline substitutions affected helix flexibility and positioning, which may explain their 





SPPL2a-mediated shedding and processivity but also enabled non-canonical shedding 
and increased processing of TNFα by SPPL2b.  
Conversely, leucine, especially a triple leucine motif in the centre of the TMD 
(AGA/LLL) stabilised the TM helix reducing non-canonical shedding (Figure 4.11) and            
slowing down processivity of SPPL2a (Figure 4.34, Figure 4.35). The central motif mimics a            
glycine hinge that upon leucine substitution reduced flexibility and thus cleavage by 
SPPL2. Such a glycine hinge can also be found in the APP TMD and reduces cleavage by      
γ-secretase upon substitution with leucine (Götz et al., 2018). Similar to TNFα, the APP 
glycine hinge is distant from the initial cleavage sites of γ-secretase.  
Even though certain TNFα TMD mutations were placed at cleavage positions of 
SPPL2a (S34, C49, H52), a shift of the cleavage sites, and thus alternative product lines as 
in APP were not observed. Furthermore, even though N-terminal proline and the                         
C-terminal leucine mutations significantly changed the efficiency of non-canonical                 
shedding, they did not affect the cleavage position (Figure 4.13). However, cleavage sites 
were abolished when proline was inserted C-terminally next to the cleavage position            
(Figure 4.13, Figure 4.36), which suggests that SPPL2a might not accept any amino acid at 
the site of cleavage.  
 
Table 5.1 Effect of TMD mutations in TNFα on shedding and processing. Shedding was measured by the release of the 
proteins ECD into the conditioned media. Initial cleavage was measured by the release of C-peptide from a short chimera 
while consecutive cleavage was measured by ICD detection in FL chimeras. TMD: transmembrane domain. =: levels of                
shedding/ processing were not changed. x: no cleavage was detected. v: reduction of shedding/processing. ^ : increase of 
shedding/ processing. 
Mutation ADAM17              
shedding 








A = =  v 
L = =  v 
P = ^  ^ 
S37 
A = =  v 
L = =  v 
P = ^  ^ 
G43 
A = =  v 
L = =  v 
P = ^  ^ 
C49 
A = =  v 
L = x  v 
P ^ ^  ^ 





L v x  v 
P = =  v 
AGA/LLL  v x  v 
TMD 




3T3 x x x x 
 
Similar to TNFα, several other aspartyl-IMP substrates exhibit flexible hinge regions 
in the TMD that upon substitution with leucines (or alanines) significantly reduce the            
processing (Götz et al., 2019). Cleavage of Xbp1u by SPP and APP by γ-secretase were 
shown to be reduced upon leucine insertions in the respective TMD (Yucel et al., 2019). 
Interestingly, removal of an N-terminal but not C-terminal glycine in the TMD of Bri2           
reduced cleavage by SPPL2b (Fluhrer et al., 2008). In contrast, reduction of CD74                
processing was only observed when all three helix-destabilizing glycine residues were                 
substituted. However, the individual roles of the three glycines were not tested (Hüttl et 
al., 2016). Nevertheless, a helix-break-helix structure in the substrate’s TMD might be one 
of the key features affecting the processing mechanism of aspartyl-IMP substrates, even 
though it does not necessarily have to be located in the centre of the TMD (Lemberg and 
Martoglio, 2002).  
A model explaining how increased TMD flexibility possibly affects the cleavage is 
depicted in Figure 5.3. The substrate is recognised at one or more exosites in the protease, 
which is followed by translocation to the active site. While the N-terminal part of the helix 
already occupies its final binding sites, the C-terminal is able to bypass the extra-cellular 
loop due to the flexible hinge in the TMD (Hitzenberger et al., 2020). The glycosylation of 
this loop spanning TMD 6 and 7 in SPPL2b might display an additional structural                       
hindrance that cannot be bypassed by TNFα wt. Thus, SPPL2b is not able to non-                    
canonically shed TNFα wt; however, increased TMD flexibility by proline substitutions can 
enable this mechanism. In contrast, leucine mutations reduce the TM flexibility and there-






Figure 5.3 Hypothetical mechanism of how proline mutations increase non-canonical shedding by SPPL2a and             
enable shedding by SPPL2b. TNFα wt even though recognised by both proteases is only shedded by SPPL2a but not 
SPPL2b. It can be speculated whether the glycosylation of the extracellular loop spanning TMD 6 and 7 inhibits transport to 
the active site. However, destabilisation of the TM helix by proline substitutions increases the shedding by SPPL2a and even 
enables shedding by SPPL2b. The proline might induce a structural change in TNFα that enables bypassing the structural 
hindrance. However, the question whether the accessibility of the TMD is the cleavage-determining factor or the rearrange-
ment of the ECD is necessary as well cannot be answered so far. Furthermore, a specific exosite in SPPL2 proteases that is 
responsible for recognition has not been described so far.  
 
This model however, only provides information on the shedding mechanism. To 
explain the changed processivity of the SPPL2 proteases, it is speculated that besides         
rearranging itself within the protease, the substrate needs local unfolding of the helix at 
the cleavage sites to allow hydrolysis. Local helix destabilization by proline facilitates         
access of the helix backbone to the catalytic residues of the protease (Langosch et al., 
2015). Due to its strong interactions with neighbouring residues, leucine in contrast may 





actually due to their influence on the flexibility of the helix or direct interaction with the 
residues of the protease is still debated.  
While results on TMD exchange of SPPL2 and γ–secretase substrates were             
consistent, differences emerge regarding the substitution of single amino acids in the 
TMD. While leucine substitutions in the APP TMD consistently reduce non-canonical      
shedding and processivity by γ-secretase, proline substitutions reduce cleavage even 
stronger (Werner, unpublished data). Hence, it is possible that the degree of helix            
flexibility would need to match the flexibility of the protease and the extent of steric         
hindrance presented by the enzyme. Besides bypassing structural hindrances, affecting 
the TMD flexibility might affect transport within the enzyme to the active site. Therefore,          
increased flexibility reduces transport, which results in decreased processivity of the          
substrate. However, structural data of a substrate-enzyme complex have only been           
resolved for γ-secretase and its substrates (Bai et al., 2015, Cai and Tomita, 2020, 
Osenkowski et al., 2009). As the required substrate-flexibility will most likely depend on 
the type of protease, information on SPPL2 substrate interaction cannot be drawn from 
γ–secretase models and 3D structures of SPPL2 proteases would be of great help to            
support the SPPL2 cleavage model.  
Nevertheless, the flexibility of the TMD seemed to be one key element for non-
canonical shedding in TNFα. However, increasing flexibility with a proline substitution of 
an in principle cleavable TMD in the context of a non-substrate did not enable shedding 
(Figure 4.20). Substitution of the central glycine with proline in the 3T3 chimera abolished 
cell surface expression and thus no conclusion about possible effects on shedding or 
cleavage can be drawn. Inhibition of the proteasome showed that this protein was           
prematurely degraded, which accounts for the tight control mechanisms of the cell                
controlling for inappropriate folding of a protein.  
Since the introduction of a proline into a TNFα/Bri3 chimera did not help to answer 
the question if increased TM flexibility generally enables non-canonical shedding by 
SPPL2a, a screen for potential substrates comprising a natural proline within the TMD was 
applied. Out of five proline-containing type II TM proteins, none displayed non-canonical 
shedding by SPPL2a (Figure 4.14). Thus, generating a substrate from a non-substrate by 
solely enhancing the flexibility of the TMD is not possible, indicating that further substrate         





computing approaches might help in the future to narrow down the possible substrates; 
however, in vitro experiments are still needed to verify the results, especially to pinpoint 
actual substrate requirements to increase again the precision of the prediction algorithm. 
 
 
5.2.2. …IN THE LUMINAL JMD/ ECD 
Substitutions of the TNFα TMD with Bri3 did not impact on shedding in particular; 
however, exchange of the TNFα ECD with Bri3 (TT3, T33, 3T3) resulted in a complete loss 
of canonical and non-canonical shedding despite the presence of TNFα ICD and/ or TMD 
(Figure 4.18). Thus, consecutive cleavage by SPPL2 in these chimeras was also not               
observed (Figure 4.37). However, initial cleavage of the short TNFα/Bri3 chimeras                      
comprising the Bri3 JMD (TT3, T33) was not completely abolished but rather reduced when 
TNFα ICD was present (Figure 4.27). Moreover, several cleavage sites were detectable by 
mass spectrometry, which resulted from SPPL2a-mediated cleavage (Figure 4.28). These 
results indicate that the Bri3 JMD is not sufficient to inhibit SPPL2-mediated cleavage and 
that the Bri3 JMD such as the TMD can be cleaved by SPPL2 even though less efficient. The 
effects of all JMD mutations on shedding and subsequent processing are summarized in 
Table 5.2. 
 
Figure 5.4 Negatively charged residues in the JMD of TNFα and Bri3. Known cleavage sites in TNFα by SPPL2a and 
ADAM17 are indicated with arrows. The TMD is indicated in grey and the luminal JMD in green. Negatively charged residues 
in the JMD are highlighted in red and positively charged residues in dark green. JMD sections that were exchanged are 
underlined.  
 
In order to determine in more detail the features of the Bri3 JMD that display the 
impeding effects on shedding and initial cleavage, the TNFα JMD was split into three          
sections that were individually substituted with the corresponding section of the Bri3 JMD 
(Figure 5.4). Exchange of the first part of the JMD with Bri3 reduced non-canonical                 





cleavage site within the TNFα TMD (L50) was still detectable, additional cleavage sites in 
the altered JMD section occurred (Figure 4.30). Since these cleavage sites were still present 
in SPPL2a/b-deficient cells, it is most probable that they were generated by an unrelated 
and so far unidentified protease. In the context of a cellular assay, other proteases may 
interfere with cleavage, as indicated by mass spectrometry results. Interestingly,                
substitution of only the first section of the TNFα TMD with Bri3 did not abolish the                 
cleavages in the Bri3 section in SPPL2a/b-deficient cells, whereas cleavages in chimeras 
with the whole TNFα JMD substituted with Bri3 were generated by SPPL2 as indicated by 
their elimination in SPPL2a/b-deficient cells. Whether these results display a valid effect, 
where Bri3 JMD attracts an unrelated protease for cleavage or whether technical             
problems such as the contamination of the SPPL2a/b-deficient cells interfered with the 
analysis needs to be validated in the future.  
While the substitution of the second JMD section reduced canonical shedding, it 
did not affect non-canonical shedding (Figure 4.21). In contrast, initial cleavage by SPPL2a 
was strongly reduced (Figure 4.29, Figure 4.30). Thus, it seems that this section of the JMD 
is crucial for initial cleavage in the context of RIP but rather less important for non-                
canonical shedding. These results indicate that either non-canonical shedding and             
cleavage in the context of RIP are two independent processes or that the FL protein is 
positioned and processed differently than the short substrates.  
The exchange of the third section of the TNFα JMD, which comprises the ADAM17 
cleavage site, abolished canonical shedding while still keeping a reduced amount of non-
canonical shedding (Figure 4.21). As initial cleavage was not affected by the substitution, 
it seems that this part of the TNFα JMD does not affect the cleavage by SPPL2.  
These results conclude that the first and second section of the TNFα JMD contains 
SPPL2 substrate-defining properties. Generally, the luminal JMD of TNFα is an un-            
structured domain connecting the helical TMD and the β-sheet structured ECD (Eck and 
Sprang, 1989, Idriss, 2000). Analysis of the primary structure revealed that the TNFα JMD 
contains three negatively (E61, E62, D66) and two positively charged residues (R60, R65), 
most of them in the second section of the JMD. The importance of charges on processing 
by an aspartyl-IMP was previously demonstrated by a study on the SPP cleavage                
mechanism, where positively charged residues in the JMD had an inhibitory effect on        





TNFα and Bri3 JMD it becomes apparent that the Bri3 JMD contains also two positively 
(R80, R85) three negatively charged residues (D81, E91, D92). However, whereas the           
positively charged arginines of Bri3 and TNFα are in similar positions, the negatively 
charged residues are distributed differently in the Bri3 JMD (Figure 5.4). Substitution of 
the whole TNFα JMD with Bri3 did not change the balance of the charges but repositioned 
them. Since initial cleavage was still enabled in these chimeric proteins (Figure 4.27) but                 
canonical shedding abolished, these results suggest that SPPL2 is more accepting of           
diverse positions of the charges whereas ADAM10/17 does not accept negatively charged 
residues in the proximity of its cleavage site. This conclusion corresponds with the                 
observations when the third TNFα JMD section was substituted with Bri3. This exchange 
kept the negatively charged residues of the second TNFα JMD section in place and inserted 
two additional negatively charged residues close to the ADAM10/17 cleavage site, which              
eradicated canonical shedding (Figure 4.21).  
The substitution of the second section of the TNFα JMD with the corresponding 
section of Bri3 reduced the negatively charged residues and even added a positively 
charged residue to the chimeric JMD. This modification abrogated initial cleavage            
completely (Figure 4.29); therefore, it can be speculated that negative charged residues 
enable cleavage while positive charges have an inhibitory effect at least for the initial 
cleavage by SPPL2. 
Since these mutations affected the number of negative charges in the substrate 
JMD, the respective residues were substituted with their structurally similar amino acids 
(EED/QQN). This resulted in a shift of canonical shedding but also abolished non-canonical 
shedding completely (Figure 4.22). Thus, it seems that ADAM is dependent on the correct 
localisation of the negatively charged residues to enable proper cleavage. Furthermore, it 
indicates that SPPL2 but also ADAM10/17 need a certain balance of charged residues in 
the middle of the TNFα JMD for processing. 
Because substitution of the charged residues with alanines abolished surface           
expression of the TNFα variant, their importance in maintaining the structure of the TNFα 
protein is further highlighted. As modifications of the TNFα JMD impact on both shedding 
and initial cleavage, it is not surprising that also the consecutive cleavage in the chimeric 





The presented data show that canonical shedding of TNFα is less sensitive to              
modifications in the substrates since amino acid substitutions and thus structural 
changes throughout the protein did not affect canonical shedding unless changes were 
placed close to the actual cleavage site. The removal of the negative charges in the second 
part of the JMD and engrafting charges very close to the cleavage site diminished the 
shedding. How exactly the charges affect the cleavage by ADAM17 remains to be                  
investigated. Possible explanations are electrostatic forces between substrate and             
enzyme or the induction of favourable structures by the charges that are more easily              
recognised by the enzyme. 
 
Table 5.2 Effect of mutations in the luminal JMD of TNFα on shedding and processing. Shedding and consecutive 
cleavage were monitored in FL proteins whereas initial cleavage was measured by the release of C-peptide in proteins 
lacking the ECD. Therefore, initial cleavage might have been detected even though in the FL protein shedding was abolished. 
JMD: juxtamembrane domain. TMD: transmembrane domain. ECD: ectodomain. Shift: A change in fragment size was mon-
itored; however, cleavage was still facilitated by the indicated protease as inhibitors or protease knockout were able to 
diminish the cleavage. =: Levels of shedding/processing were not changed. x: No shedding/processing was detected. v: 
Reduction of shedding/ processing. ^: Increase of shedding/processing. Protease X: Intermediate fragments were detected 
and could not be abrogated with ADAM or SPPL inhibitors/ ko, thus cleavage is most likely facilitated by an unknown pro-
tease. (_) indicates finding from experiments that were conducted but not shown in the result section. 
Mutation ADAM17        
shedding 









QQN v + shift x  (v) 
QQA v + shift x (=) (v) 
AAA   (v)  
juxBri3_1  = v + Protease X v (v) 
juxBri3_2  v = v (v) 
juxBri3_3  v v = (v) 
ECD TT3 x x v x 
ECD+TMD T33 x x v x 
 
 
5.2.3. …IN THE ICD 
Besides ECD/ JMD and TMD, also the ICD affected processing and unexpectedly 
even shedding of TNFα. By exchanging the TICD with Bri3 ICD (3TT), non-canonical               
shedding was abolished and even canonical shedding was slightly reduced (Figure 4.18).         
Surprisingly, the effect was not enhanced but rather reversed by the additional exchange 





canonical shedding (Table 5.1). Consecutive processing (Figure 4.37), as well as initial 
cleavage (Figure 4.27) of 3TT and 33T, were reduced. Since C-terminal cleavage sites in 
these chimeric proteins were not affected (Figure 4.28), this indicates that the ICD is able 
to affect cleavage efficiency even in distant domains. Comparing Bri3 ICD and TICD shows 
an obvious size difference, however previous studies on SPP observed no impact of the 
size of the cytosolic domain on cleavage (Lemberg and Martoglio, 2002). It would be            
interesting to know whether charges also in the ICD affect positioning of the substrate 
within SPPL2 and thus affect the cleavage. In contrast to the negative charges in the JMD 
(Figure 5.4), TNFα ICD comprises two positive charged residues at the cytosolic membrane 
border whereas Bri3 positive charges are shifted towards the N-terminus (Figure 5.5). 
Upon ICD exchange positive charges at this membrane border are eliminated, which 
might be the reason for the reduction of cleavage by SPPL2. Further research will be 
needed on whether negative charges in the JMD and positive charges in the ICD                     
coordinate a balance that is necessary for efficient SPPL2 cleavage. The effects of all ICD               
modifications on shedding and processing are summarised in Table 5.3. 
 
Figure 5.5 Charged residues in the ICD of TNFα and Bri3. The TMD is highlighted in grey and cleavage sites of SPPL2 are 
indicated with arrows. Negatively charged residues are highlighted in red and positive residues in green.  
 
In addition to the differently located charged residues in TNFα and Bri3 ICD, TNFα 
undergoes palmitoylation at C30 (Figure 4.23) (Utsumi et al., 2001). To investigate the         
effect of palmitoylation on SPPL2 cleavage, the cysteine was substituted by serine or            
alanine. Even though this might induce structural changes, this is the most reliable 
method to abolish palmitoylation. Inhibitors such as 2-BP inhibit several enzymes involved 
in lipid metabolism as well as triacylglycerol biosynthesis (Planey and Zacharias, 2010). 
Therefore, it is important to note that the effects observed upon 2-BP treatment are not 
necessarily only due to its effects on protein palmitoylation. The research on lipid                    
modifications of TNFα is further complicated by the fact that the PATs and APTs that add 
and remove palmitoylation are unknown. Thus, specific inhibition of TNFα palmitoylation 





substituting TNFα C30 with serine or alanine enhanced non-canonical shedding (Figure 
4.24) which indicates that palmitoylation of TICD might display a structural hindrance for 
the access of SPPL2 to its substrate. When removed, SPPL2a gains easier access to the 
cleavage sites and thus shedding and processivity are improved. 
 
Table 5.3 Effect of ICD mutations on shedding and processing. ICD: intracellular domain. TMD: transmembrane domain.          
=: Levels of shedding were not changed. x: No shedding was detected. v: Reduction of shedding. ^: Increase of shedding. 
Protease X: Intermediate fragments were detected and could not be abrogated with ADAM or SPPL inhibitors/ ko, thus 
cleavage might be facilitated by an unknown protease. (_) indicates findings from experiments that were conducted but not 
shown in the result section.  
Mutants ADAM17        
shedding 








S = ^  (^) 
A = ^  (^) 
ICD 3TT v x v v 





5.3. CLEAVAGE DETERMINANTS OF SPPL2A AND SPPL2B  
Based on previous results this study provides further information about the              
cleavage mechanism of SPPL2 proteases and their substrate characteristics. The side-by-
side comparison of SPPL2a and SPPL2b showed that the proteases share a common 
mechanism by which they process their substrates but yet are distinct from each other 
regarding the details.  (Figure 5.6).  
The most prominent indication that SPPL2 substrates are not only determined by 
a pure size-exclusion mechanism is the fact that the non-substrate Bri3 that is lacking its 
ECD (Bri3 NTF) is not processed by SPPL2 (Figure 4.28) (Martin et al., 2009). Therefore, 
properties within the ECD, TMD and ICD of TNFα were determined in this study. Further-
more, it was investigated whether the identified TNFα properties also apply to other 
SPPL2 substrates.  
While ADAM10/17-mediated shedding was only affected by changes close to its 





throughout the substrate. It requires the proper positioning of the substrate within the 
enzyme, which may be facilitated by a balance of positive and negative charges in the JMD 
and ICD. Furthermore, a certain flexibility of the TM helix is necessary (Figure 5.6). As 
structural elements distant from the actual cleavage sites affect cleavage efficiency, this 
study supports the hypothesis of SPPL2 proteases comprising an exosite for substrate                
recognition that is spatially different from the active site. Whether substrate properties 
only determine binding to the exosite and subsequent transport to the active site or          
directly influence the cleavage at the active site as well is yet to be determined. 
 
Figure 5.6 Summary of the SPPL2a and SPPL2b cleavage of TNFα. TNFα FL is usually shedded by ADAM17 releasing 
sTNFα. Canonical shedding by ADAM17 is influenced by negative charges in the JMD (-). Besides canonical shedding by 
ADAM17, TNFα FL is also shedded by SPPL2a, a process termed non-canonical shedding releasing sTNFα(L2) into the extra-
cellular space. TNFα non-canonical shedding and processing in the context of RIP are influenced by many substrate prop-
erties. Both proteases most likely need a balance of negatively charged residues in the JMD and positive ones (+) in the ICD 
for correct positioning of the substrate in the protease. Furthermore, palmitoylation (green) is able to reduce non-canonical 
shedding and slow down subsequent consecutive cleavage. Even though both SPPL2 proteases are able to cleave TNFα 
consecutively, it is less pronounced in SPPL2a resulting in longer TNFα ICDs (TICDs) that are quicker released into the cyto-






With these substrate-defining properties, other SPPL2 substrates were                            
investigated to determine whether non-canonical shedding by SPPL2a is a general              
characteristic of the protease. A comparison of the primary sequence of known SPPL2 
substrates with Bri3 did not uncover obvious criteria that distinguish the substrates from 
a non-substrate (Figure 5.7). Furthermore, characteristics such as the distribution of the 
charges are not shared amongst all substrates. Therefore, it is not surprising that             
substrates differed regarding processing in the context of RIP. Already the detection of 
the ECD was highly variable and substrate-specific (Figure 4.25). Several soluble CD74       
fragments of different size were observed. However, they were also present in SPPL2a/b-
deficient cells, arguing against a non-canonical shedding mechanism. As published             
before, these different soluble fragments probably account for differently glycosylated 
peptides. Whether these represent various maturation states or actually fulfil different 
functions is not yet investigated. 
 
Figure 5.7 Alignment of human SPPL2 substrates with the non-substrate Bri3. Common characteristics that decipher 
an SPPL2 substrate from the non-substrate Bri3 are not apparent from the primary sequences. Arrows indicate SPPL2                
cleavage sites in human substrates that have been determined experimentally. Negatively charged residues are highlighted 
in red and positively charged residues in green. The TMD is highlighted in light grey and (potentially) destabilising glycines 
in the TMD in dark grey.  
 
Even though cells secreted several sBri2 fragments, SPPL2a-mediated non-              
canonical shedding of Bri2 was not observed (Figure 4.26) as the secretion of none of the 
fragments was impaired in SPPL2a/b-deficient cells. Even substitution of the central         





processing is generally aggravated, as the exact cleavage sites of neither canonical         
shedding nor subsequent SPPL2 processing are not known. Even though efforts were 
made to identify the cleavage sites of SPPL2b in Bri2, results were not reliable. Further-
more, the question of whether Bri1 is indeed a substrate or at least shedded could not be 
answered to full satisfaction in the context of this thesis.  
Secreted ECDs of the other substrates (FasL, TMEM106b) could not be detected at 
all, which complicated the identification of SPPL2a non-canonical shedding. Even              
stimulation with PMA did not result in the release of soluble peptides. So far, little is known 
about TMEM106b processing and the identification of a sheddase and detection of a           
soluble fragment are pending. Interestingly and in contrast to many other SPPL2               
substrates, ADAMs, MMPs and cathepsins appear not to act as TMEM106b sheddases 
(Brady et al., 2014). The release of sFasL however, is additionally to ADAM10/17 induced 
by MMP7. MMP7 as well as ADAM17 are not constitutively active and need transcriptional 
activation (Craig et al., 2015). The fact that even with PMA stimulation no sFasL was             
detected suggests that ADAM17 might not be the major sheddase in the model used. 
Thus, further experiments with specific activation of MMP7 shedding or a change of the 
expression system would be needed to gain insight into FasL processing.  
These results indicate that SPPL2a-mediated non-canonical shedding is a          
mechanism unique to TNFα. Nevertheless, it is intriguing to speculate that the SPPL2     
substrate-specific cleavage capabilities might change throughout different physiological 
conditions of the cell. It is imaginable that the cleavage capacity of SPPL2 proteases might 
change under cellular stress such as starvation or apoptosis. Additionally, the proteases 
differ in their sub-cellular localisation. SPPL2a is mainly expressed in lysosomes and 
SPPL2b most likely on the cell surface (Kuhnle et al., 2019) and different conditions, such 
as the pH, could affect the protease function and selectivity. For instance, the acidic pH in 
the lysosome might cause a structural rearrangement in the substrate allowing easier    
access of the cleavage sites for SPPL2a.  
Furthermore, cells throughout the body are equipped differently so that in the  
context of a different cellular system non-canonical shedding might be enabled with the 
help of cell type-specific adaptor proteins. Based on the discovery that ADAM17 is part of 
a complex with iRhom and FRMD8, it is possible that the sheddase itself or its co-factors 





ADAM17 could not be validated. Thus, it would be of interest to see whether ADAM17 
adaptor proteins specifically interact with TNFα and adaptor proteins of different         
sheddases with other SPPL2 substrates. In other words, a basic mode of action for SPPL2 
proteases might exist, that is then modified by the specific interaction of additional cell/ 
organ-specific adaptor proteins. This would also allow different processing mechanisms 
of the same protein throughout the body by the interaction of varying adaptor proteins. 
In contrast, if co-factors actually contribute to the SPPL2 cleavage mechanism it might be 
the lack of these in certain subcellular locations that enable shedding whereas the inter-
action inhibits non-canonical shedding.  
Even though it might be intriguing to speculate that co-factors are responsible for 
substrate selection such as iRhom for ADAM17 (Maretzky et al., 2013), it appears more 
likely that the differences in function are to find in the protease itself. The SPPL proteases 
differ significantly in regard to size and glycosylation of their N-termini (Figure 1.9). While 
the full-time non-canonical sheddase SPPL3 exhibits a rather small N-terminus without 
glycosylation, part-time non-canonical sheddase SPPL2a carries the largest N-terminus of 
all SPP/ SPPL-family members and additionally multiple glycosylation sites (Voss et al., 
2013). Since SPPL2b comprises an intermediate-sized N-terminus with only three glyco-
sylation sites it seems unlikely that size and modification of the N-terminus enable the 
shedding function. However, only SPPL2b carries an additional glycosidic chain in the       
extracellular loop connecting the active site containing TMDs 6 and 7 (Friedmann et al., 
2004). This steric hindrance close to the active site may act as gatekeeper in SPPL2b to 
exclude binding of proteins with a large ECD (Figure 5.3) (Spitz et al., 2020).  
While non-canonical shedding seems to have rather strict requirements, initial 
cleavage seems to occur more promiscuous, as indicated by both SPPL2 proteases                    
preferring substrates with a short ECD. Generally, SPPL2a accepts more changes within 
the substrate suggesting a lesser specificity towards substrate determinants. While              
modifications of the area around the C-terminal cleavage site reduced initial cleavage by 
SPPL2b, SPPL2a cleavage was less affected (Figure 4.29). Furthermore, the distribution of 
charged residues in luminal and probably also the cytosolic JMD greatly influenced the 
initial cleavage by both proteases. 
The subsequent processing that follows the initial cleavage of TNFα occurs in a 





SPPL2b is more efficient in consecutive cleavage. While SPPL2a and SPPL2b cleave TICD 
in the same major positions, additional SPPL2a cleavage sites were detected (Figure 4.33). 
It has not been determined whether this resulted from slower proteolytic cleavage or 
whether a stronger attachment of TNFα NTF to SPPL2a allows more cleavages to occur 
while SPPL2b releases TICD species more easily.  
As for the shedding, consecutive cleavage seems to be substrate-dependent, since 
the analysis of Bri2 cleavage did not result in several ICD peptides (Figure 4.25). Instead 
of indicating a consecutive turnover the detection of several NTF fragments rather            
suggests that many maturation and dimerization states of Bri2 cleavage products exist 
(Tsachaki et al., 2008). 
Whether variations of substrate processing are determined by structural                  
differences in the protease or deviation of localisation and thus diverging environmental 
factors is so far unknown. The results only account for the processing of TNFα as similar 
processing mechanism so far could not be observed for other SPPL2 substrates. In            
contrast to γ-secretase, which seems to process at least some substrates similarly (Okochi 
et al., 2006), SPPL2 proteases seem to process each substrate slightly different. However, 
as the consecutive cleavage of APP by γ-secretase is a central mechanism in the                      
development of Alzheimer’s disease it remains an open question to what extent                  
consecutive cleavage and non-canonical shedding of TNFα by SPPL2a contribute to the 





5.4. PHYSIOLOGICAL RELEVANCE… 
5.4.1. …OF NON-CANONICAL SHEDDING IN TNFα  
Since SPPL2a accepts TNFα for non-canonical shedding, but SPPL2b does not, this 
might indicate that sTNFα(L2) generation is not just a general by-product. This hypothesis 
is supported by the detection of non-canonical shedding in cell lines with endogenous 





shedding BMDCs of wt and SPPL2a-deficient mice were investigated for the release of 
sTNFα(L2). Unfortunately, non-canonical shedding of TNFα could not be detected since 
TNFα processing appeared to be fundamentally different in mice (Figure 4.10). Even 
though several different soluble fragments were secreted into the conditioned media of 
cultured mouse BMDCs, release of all fragments was inhibited by a broad-spectrum MMP 
inhibitor. This indicates that in mice, either ADAM10 and ADAM17 are less specific                
regarding their cleavage sites or other MMPs contribute to a larger extent to the secretion 
of mouse sTNFα. Comparing rodent and human TNFα, the primary sequence shows a high 
level of conservation, especially within the TMD (Figure 5.8). The ECD contains several   
conserved stretches of ≈10 amino acids, interrupted by less conserved regions. The              
residues that facilitate binding of human TNFα to the receptor (Van Ostade et al., 1991) 
are also conserved throughout the species (Figure 5.8, highlighted red). Interestingly, the 
JMD and the region of ADAM17 cleavage are much less conserved. This might explain also 
the less conserved mechanism of ECD shedding in rodents compared to humans even 
though the binding to and activation of the receptor might be similar.   
 
Figure 5.8 Alignment of mammalian TNFα. The protein sequence of human (HS), chimpanzee (chimp), mouse (MM) and 
rat (RN) display high levels of homology. The TMD is highlighted in grey, the JMD in green and residues mediating binding 
to the receptor in TNFα HS in red. The arrow indicates the major shedding site in human TNFα by ADAM17. 
 
In order to analyse the specific role of ADAM17 cleavage in mouse vs. human                 
processing, a knockout of the protease would foster the interpretation of the                            
experimental results. However, due to its promiscuity and large set of substrates,                 
investigating the effects of ADAM17 is difficult, as the huge amount of off-target effects 
would impede a conclusive analysis. Moreover, ADAM17-deficient mice are not viable and 
also cell lines are affected majorly in their growth behaviour (Peschon et al., 1998). To 
enable the analysis of ADAM17-mediated shedding nonetheless, it either is knocked out 
conditionally or cell type-specific. For example, irradiated mice reconstituted with 





2007), which indicates that up to a fifth of the sTNFα production is resumed by other              
proteases. In mouse models, for instance, MMP7 contributes to a great extent to the            
secretion of sTNFα (Haro et al., 2000). Studies on the participation of other sheddases in 
humans show that in vivo contributions of ADAM9, 10 and 19 are rather low (Zheng et al., 
2004). However, during acute local inflammation sTNFα secretion is enhanced by the          
serine protease proteinase 3 (Coeshott et al., 1999). Thus, even though ADAM17 is the 
major sheddase of TNFα, many other proteases are able to partake in this cleavage,              
depending on the protease expression profile and activation status of the cell. Neverthe-
less, most of these sheddases cleave human TNFα in a similar position as ADAM17,           
generating soluble peptides of similar sizes (Table 5.4) and so far, the release and mode 
of action of a ≈20-25 amino acid longer peptides has not been described. Furthermore, it 
can be speculated whether the larger mouse sTNFα peptides are differently matured and 
glycosylated fragments or actually originate from a cleavage within the TNFα TMD.                   
Nevertheless, as the human and mouse TNFα TMD is highly conserved it is surprising to 
see that the proteins are processed differently. This might be due to the fact that other 
sheddases contribute to the release of sTNFα, therefore SPPL2a does not encounter TNFα 
FL. As SPPL2 cleavage sites are conserved between the two species the difference in        
cleavage might be due to differences in human and mouse SPPL2a. To determine which 
peptide is released by which protease, mass spectrometry analysis of mouse TNFα in 
mouse cell lines would be needed. However, it was beyond the scope of this study to 
scrutinize the cleavage sites of ADAM proteases and SPPL2 in mice. 
 
Table 5.4 Cleavage position of several sheddases in TNFα (Spitz et al., 2020, Zheng et al., 2004).  













The different proteases releasing sTNFα account for the importance of the soluble 
peptide in general and commend for a fine-tuned regulatory mechanism. Based on this, 
the cell/ organ-specific expression of different sheddases may not only allow a local               
regulation of the amount of secretion but the different peptides of TNFα may also exert 
different functions. This hypothesis is further supported by data indicating that                   
approximately up to a third of the patients that receive treatment with anti-TNFα drugs 
do not respond to the treatment (Parameswaran, 2010). The lack of responsiveness and 
the mechanisms behind it are still unclear.  
sTNFα exerts central immunological functions by inducing cell survival or death 
(Kalliolias and Ivashkiv, 2016, Tartaglia et al., 1991). Misregulated cleavage of TNFα               
accounts for or exacerbates many autoimmune diseases such as rheumatoid arthritis, 
chronic bowel diseases (Crohn’s disease) and skin diseases like psoriasis (Parameswaran, 
2010). Usually, the release of sTNFα via cleavage of ADAM17 leads to interaction with            
either one of the two TNFα receptors (TNFR1, TNFR2). The crystal structure suggests that 
sTNFα consists of several β-sheets that associate in homotrimers resembling a pyramidal 
shape (Figure 5.9A) (Eck and Sprang, 1989, Mukai et al., 2010), which binds to the receptor 
with the tip facing the membrane. Based on the crystal structure of sTNFα resolved               
already in 1989, the residues responsible for binding to the receptor have been deter-
mined by amino acid exchange. They cluster in two regions at 108/112 and 160/162/167 
(Figure 5.9B) (Van Ostade et al., 1991). Interestingly, the more N-terminal cluster facilitates 
binding mostly to TNFR1, while the more C-terminal one facilitates binding to TNFR2 
(Mukai et al., 2009). Since TNFR1 binds sTNFα and TNFR2 binds membrane-bound TNFα 
(Tartaglia et al., 1993b, Grell et al., 1995), sTNFα is probably able to dip deeper into the 
binding groove of TNFR1 utilising the more N-terminal residues for interaction and                  
binding of membrane-bound TNFα may display a steric hindrance. However, another                
explanation for utilisation of different binding motifs might be a different folding of the 
membrane-bound TNFα ECD compared to sTNFα. Additionally, binding kinetics vary 
greatly between the receptors as binding of sTNFα to TNFR1 is considered irreversibly 
while the interaction of TNFα with TNFR2 displays rapid on and off dynamics (Tartaglia et 
al., 1993a). Even though many crystal structures of TNFα without or in combination with 
the receptor are available, the model of membrane-bound TNFα with TNFR2 does not fully 





anchoring domain to allow crystallisation (Mukai et al., 2010). Nevertheless, subtle             
differences in folding of TNFR2 were detected compared to TNFR1. Even though receptors 
differ in interaction dynamics and the form of TNFα they bind, so far little is known about 
the correlation of ligand binding and subsequent intracellular complex formation. Upon 
binding of sTNFα to TNFR1, formation of either complex I, which induces the NFκB path-
way and thus cell survival or complex II, which activates caspase 8 and consequently cell 
death decide the fate of the receptor cell. As these are two very different functions, the 
question emerges whether sTNFα variants of different sizes might affect the activation 
status of the receptor and thus signalling capacity. Modelling of sTNFα(L2) shows that the 
longer N-termini of the trimerised peptide are facing the extracellular space and not the 
binding sites of the receptor. However, the additional 20-25 amino acids of sTNFα(L2) 
might be able to widen the bottom of the pyramidal structure thus affecting binding to 
the receptor as it is not able to bring interacting residues close to each other. This might 
weaken the activation of the receptor. If the elongated N-terminus interferes with the       
correct folding or trimerisation of sTNFα, interacting residues might not become exposed 
in the direction of the receptor. Again, these changes would weaken the binding of 
sTNFα(L2) to the receptor or even induce a shift of preference towards one of the TNFRs.  
 
Figure 5.9 sTNFα(L2) structure. (A) 3D structure of sTNFα(L2) binding to the soluble TNFR. sTNFα (green) trimerises in a 
pyramidal shape. It binds to the receptor (blue) with the tip of the pyramid facing the membrane. In the top view, binding 
of each sTNFα(L2) monomer to a trimerised TNFR is indicated. The interacting residues are shown in red. The elongated    
N-terminus of sTNFα(L2) is highlighted in pink (PyMol ID: 3alq, the modelling was kindly conducted by Dr. Sabine Höppner). 
(B) Cleavage sites and receptor interaction sites in the TNFα primary sequence. Shedding sites of SPPL2a and ADAM17 are 






Addition of several amino acids on the N-terminus of sTNFα could induce                   
aggregation similar to Aβ. The shift of γ-secretase cleavage in APP generates peptides that 
are just a few amino acids longer but display a strongly increased capacity of aggregation 
(Cukalevski et al., 2015, Moore et al., 2017). Even though the binding of sTNFα(L2) to its 
receptor might not be influenced directly, the longer fragments could affect trimerisation 
by aggregation into larger multimers. If these aggregates accumulated in the extracellular 
space and form plaques, this would subsequently result in reduced receptor binding, thus 
altering signalling. Consistently, in Bri2 the duplication of 10/11 amino acids leads to a 
severe form of dementia due to the aggregation of the altered Bri2 pro-peptide (Tsachaki 
et al., 2008). Therefore, additional of ≈25 amino acids in sTNFα(L2) could have severe            
effects on the fragment’s characteristics.  
Considering the localisation of SPPL2a on the cell surface but also in lysosomes, 
non-canonical TNFα shedding would release the soluble peptides into the extracellular 
space but also to the inside of the lysosome. Both, sTNFα and sTNFα(L2) were detected 
within the cell (Figure 4.7). Thus, it might be speculated that sTNFα(L2) is especially                 
generated by lysosomal SPPL2a to cleave surface-escaped TNFα FL. If this cleavage only 
served a degradational purpose for misfolded or dysfunctional proteins, SPPL2a would 
have been expected to cleave other substrates in a similar manner and not only                         
specifically TNFα. Therefore, it is conjectured that intracellular sTNFα/ sTNFα(L2) may have         
additional functions within the cell. Whether intracellularly generated sTNFα(L2) can be 
secreted from lysosomes to the extracellular space was not determined within this study.  
 
 
5.4.2. …OF CONSECUTIVE CLEAVAGE 
Mechanistically, the consecutive cleavage may be explained by TNFα passing 
through the hydrophilic, pore-like active site of SPPL2. While TNFα is moving along the 
enzymatic domain, SPPL2 remains locked within the membrane. Such a “sliding” along the 
enzyme would be supported by dynamics of the substrate TMD (Fluhrer et al., 2008). Local 
unfolding and stretching of the substrate’s α-helix enable access of the cleavage sites by 
the catalytic residues. It is tempting to speculate that physiological reasons for this                   





ICD. This lipid modification of the cytosolic cysteine enables modulation of the                     
consecutive cleavage by anchoring the ICD to the membrane. Since palmitoylation is a 
reversible modification, the cell might be able to increase TNFα palmitoylation guiding the 
membrane-associated proteins to lipid rafts (Poggi et al., 2013) but also enabling a               
consecutive cleavage upon interaction with SPPL2. In contrast, removal of the                       
palmitoylation would decrease lipid raft association and either accelerate consecutive               
cleavage or reduce it to fewer cleavages. Thus, consecutive cleavage could serve merely a 
degradational purpose, as a slower turnover would result in less ICD release, which                
reduces the intracellular signalling. Conversely, the removal of the palmitoylation may            
result in a fast release of the ICD to induce intracellular signalling. On the contrary, a slow            
consecutive cleavage might keep the TICD in close proximity to the membrane enabling 
recruitment of other proteins to the site of action and a fast release from the membrane 






6. OUTLOOK AND FUTURE IMPLICATIONS 
The results of this study have provided insights into the cleavage mechanism of 
SPPL2a and SPPL2b. Besides the identification of a non-canonical shedding function of 
SPPL2a, substrate determinants of TNFα such as the flexibility of the TMD but also charges 
in the luminal JMD have been identified. However, in a cellular context modifications of 
the substrates seemed to enable cleavage by proteases other than SPPL2 or ADAM10/17. 
Thus, the development of an in vitro assay in which purified substrate and protease              
encounter each other under specific, controlled conditions would be crucial. This would 
help to conclude more certainly if and to what extent modifications affect SPPL2 cleavage 
and thus substrate properties can be deducted more easily. Therefore, future work will 
be needed to pinpoint additional characteristics that distinguish random proteins form 
SPPL2 substrates. 
Even though results showed that negative charges affect shedding by ADAM10/17 
and SPPL2 as well as initial cleavage, the role of positive charges and charges in the TICD 
was so far not investigated. Indications that positive charges in both cytosolic and luminal 
JMD are important for TNFα processing by SPPL2 proteases would need to be addressed 
in experiments substituting these residues. As charges in the luminal TNFα JMD that were 
distant from the actual cleavage site affected the cleavage efficiency of SPPL2 it would be 
interesting to see whether a similar effect for the cytosolic JMD residues can be observed. 
Substitutions of these residues would yield insights into whether also the positive charges 
affect processing. To verify the results, which indicated that an increased amount of               
positive charges in the luminal JMD inhibited initial cleavage, targeted insertions of              
positively charged residues, for instance by substituting the negative residues at E61, E62 
and D66 with positively charged residues would be required.   
In the context of ICD modifications, it was established that the removal of                            
palmitoylation increases on non-canonical shedding and consecutive cleavage. It has 
been shown that for peripheral membrane proteins mutations distal to the sites of                
palmitoylation can strongly impact the likelihood of lipidation (Ko and Dixon, 2018). There-
fore, it would be interesting to test whether proline substitutions in the membrane              
effected the palmitoylation status of TNFα. If proline substitutions in the TNFα TMD             




actually reduce ICD palmitoylation, increased processivity of these mutants by SPPL2 
might also be induced by the lack of lipidation.   
The SPPL2 substrate TNFα is a cytokine, crucial for initiating and regulating many 
essential signalling pathways and thus to be fundamental for inflammatory processes and 
host defence. Therefore, investigating its lifecycle and the physiological role of its cleavage 
products might be essential in improving the treatment of TNFα-related diseases.  
Even though in this study endogenous levels of SPPL2a displayed non-canonical 
release of sTNFα(L2) from transfected TNFα, in this experimental setup levels of soluble 
TNFα peptides are much higher as under physiological conditions. Thus, in the future, it 
would be of interest to investigate the amount of non-canonical shedding in the context 
of physiological TNFα levels. These experiments would require a cell line with detectable        
endogenous amounts of SPPL2a and TNFα. A cell line probably most suitable for                  
experimental use would be HMC-1 that displays relative high levels of both proteins            
(Figure 6.1). HMC-1 is a mast-cell cell line derived from a patient with leukaemia. Although 
secretion of TNFα could be further enhanced by LPS stimulation, an HMC-1 SPPL2a/b-          
deficient clone would need to be established to conclude about the specificity of the                
possibly generated fragments. Furthermore, the investigation of whether adaptor              




Besides the amount of physiologically released sTNFα(L2), its fate and function 
within the cell might be of interest. Design of sTNFα(L2) peptides that can be used in                 
cellular assays could give insights about their signalling capacity. Cells with detectable 
amounts of TNFR such as HeLa cells could be analysed for changes in the intracellular 
Figure 6.1 Immortalised cell lines that express TNFα 
and SPPL2a endogenously. Generally, myeloid cell 
lines express the highest levels of TNFα. Especially NB-
4 cells that are derived from bone marrow of a patient 
with progressive leukaemia. Also, solid tumours upreg-
ulate TNFα, therefore, medium levels can be found in 
the lymphoid cell line HDLM-2. SPPL2a is ubiquitously 
expressed and can be found in myeloid and lymphoid 
cell lines. Highest levels are found in HMC-1 mast cells 
and Karpas-707 cells originated from myeloma cells 
(www.proteinatlas.org). 
 




signalling pathways. Analysis of mRNA levels using qPCR or on protein level using WB 
might yield interesting results of whether sTNFα(L2) alters signalling of sTNFα. To explore 
whether sTNFα(L2) is able to aggregate such as Aβ peptides, aggregation capacity could 
be investigated by MD simulations or by SEC-MALS (size exclusion chromatography with 
multiple-angle light scattering analysis). In addition, mouse models overexpressing 
SPPL2a could give a hint towards a phenotype generated by the longer TNFα fragment.  
Anti-TNFα antibodies that antagonise the receptor or neutralize soluble TNFα are 
the gold standard in the treatment of TNFα-related diseases and among the most sold 
drugs worldwide. Other approaches such as to inhibit ADAM17 to reduce sTNFα failed to 
reach clinical trials as the broad substrate spectrum elicits severe side effects (López-Otín 
et al., 2009, Vandenbroucke and Libert, 2014). However, as specifically long-term             
treatments increase the risk of developing autoantibodies or decrease the physiological          
response (Tack et al., 2009, Tseng et al., 2018) other strategies that make use TNFα             
variants are being pursued. Soluble TNFα variants are developed that compared to the 
antibodies are less likely to be recognised as foreign. Non-naturally occurring sTNFα               
monomers would interact with endogenous sTNFα wt monomers resulting in mixed               
trimers incapable of activating the TNFR. This regulates the activation of the TNFRs and 
therefore adjusts the host immune response. These sTNFα variants could be used for 
(short-term) treatment of patients as an alternative for classical treatment (Dahiyat and 
Filikov, 2006). Depending on the outcome of how sTNFα(L2) behaves in physiological              
conditions it might be of interest to increase non-canonical shedding by SPPL2a.                  
Additionally, it might be of interest to investigate whether gene or protein variations of 
SPPL2a affect physiological cleavage of TNFα and thus sTNFα(L2) release, especially in the 
context of patients with TNFα-related diseases that do not respond to classical treatment 
approaches.  
  




In summary, the processing of TNFα is more diverse than previously thought, and 
SPPL2a and SPPL2b differ in their processing capacity of this substrate. Instead of the 
conventional process of RIP with a preceding removal of the ECD by an accompanying full-
time sheddase such as ADAM10/17 and subsequent processing by SPPL2, TNFα can               
directly be shedded in a non-canonical fashion by SPPL2a but not SPPL2b. The subsequent 
consecutive cleavage however, is more efficiently facilitated by SPPL2b whereas SPPL2a 
displays most likely slower cleavage kinetics. The cleavage of TNFα by SPPL2a and SPPL2b 
is not enabled by a consensus sequence but rather by structural properties throughout 
domains close to the membrane. Nevertheless, the substrate determinants in TNFα did 
not apply for other SPPL2 substrates. Thus, it would be of interest to analyse other             
physiologically relevant substrates of SPPL2a and SPPL2bin more detail to finally conclude 
about the recognition and cleavage process. Nevertheless, the implication of SPPL2a in 
the processing of important proteins such as TNFα and CD74 emphasises an essential 
role of the protease in a functioning host defence mechanism. Even if not as a single         
trigger for disease, increased as well as decreased SPPL2a expression might affect the 
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